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Die biologische Bestrahlungsplanung in der Partikeltherapie erfordert eine zuverlässige 
Abschätzung der relativen biologischen Wirksamkeit (RBW) im bestrahlten Gewebe. Für 
das Pilotprojekt an der GSI Helmholtzzentrum für Schwerionenforschung GmbH in 
Darmstadt und in den bisherigen europäischen Partikeltherapiezentren basiert die RBW-
Vorhersage auf einem biophysikalischen Modell, dem Local Effect Model (LEM). 
Die derzeit verwendete erste Version des Modells (LEM I) ist auf die Beschreibung der 
Wirkung von Kohlenstoffstrahlen im Zielvolumen optimiert. Es zeigt jedoch für den 
Eintrittsbereich der Kohlenstoffionen als auch generell für leichtere Ionen systematische 
Abweichungen der RBW. Aus diesem Grunde wurde das LEM kontinuierlich 
weiterentwickelt. Die aktuelle Version (LEM IV) zeigt eine bessere Übereinstimmung der 
Modellrechnung mit den Ergebnissen aus in-vitro Zellexperimenten. Für die Anwendung 
des LEM IV in der Bestrahlungsplanung ist daher die Untersuchung der möglichen 
Unterschiede zu LEM I unter klinisch relevanten Bestrahlungsbedingungen von Interesse. 
Die in dieser Arbeit präsentierten Analysen haben das Ziel, die aus verschiedenen 
Verfahren und Modellvarianten resultierenden RBW-gewichteten Dosen für Protonen und 
Kohlenstoffionen zu vergleichen. Dadurch sollen mögliche Auswirkungen von 
Unterschieden auf die klinische Anwendung herausgestellt und die Interpretation von 
klinischen Ergebnissen verschiedener Institute ermöglicht werden. 
In der vorliegenden Arbeit konnte gezeigt werden, dass sich für typische 
Bestrahlungssituationen mit Kohlenstoffstrahlen von Chordomen der Schädelbasis die aus 
Anwendung des LEM I und LEM IV resultierenden RBW-gewichteten Dosen im Mittel um 
weniger als 10 % unterscheiden und damit die Anwendung des LEM IV ebenfalls eine 
konsistente Interpretation der klinischen Daten erlaubt. In den japanischen Zentren wird die 
RBW aus der klinischen Erfahrung mit Neutronenstrahlung und in-vitro Zellexperimenten 
mit Kohlenstoffionen abgeschätzt (HIMAC Ansatz). Die in der Arbeit vorgestellten 
Methoden ermöglichen einen direkten Vergleich des HIMAC Ansatzes mit dem LEM und 
damit auch der erzielten klinischen Ergebnisse. Eine Sensitivitätsanalyse der RBW 
bezüglich der Modellparameter stellte die Charakterisierung der Photonen-Dosiseffektkurve 
als eine besonders relevante Kenngröße heraus. Die Anwendung des LEM IV für 
Protonenstrahlen gibt die experimentell beobachtete Erhöhung der RBW im Vergleich zu 
dem klinisch verwendeten Wert von 1.1 am distalen Ende des Bestrahlungsfeldes genauer 
wieder. Sie erlaubt darüber hinaus eine bessere systematische Charakterisierung der 
Erhöhung der effektiven Reichweite von Protonenstrahlen, die eine Folge der RBW-
Erhöhung am distalen Ende des Bestrahlungsfeldes ist. 
Die Ergebnisse dieser Arbeit unterstreichen damit den Stellenwert der RBW Modellierung 
für eine langfristige Verbesserung der Bestrahlungsplanung in der Partikeltherapie und die 
damit verbundene bessere Ausnutzung der Vorteile dieser Bestrahlungsmodalität. 
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Treatment planning in ion beam therapy requires a reliable estimation of the relative 
biological effectiveness (RBE) of the irradiated tissue. For the pilot project at GSI 
Helmholtzzentrum für Schwerionenforschung GmbH and at other European ion beam 
therapy centers RBE prediction is based on a biophysical model, the Local Effect Model 
(LEM). 
The model version in use, LEM I, is optimized to give a reliable estimation of RBE in the 
target volume for carbon ion irradiation. However, systematic deviations are observed for 
the entrance channel of carbon ions and in general for lighter ions. Thus, the LEM has 
been continuously developed to improve accuracy. The recent version LEM IV has proven 
to better describe in-vitro cell experiments. Thus, for the clinical application of LEM IV it is 
of interest to analyze potential differences compared to LEM I under treatment-like 
conditions. 
The systematic analysis presented in this work is aiming at the comparison of RBE-
weighted doses resulting from different approaches and model versions for protons and 
carbon ions. This will facilitate the assessment of consequences for clinical application and 
the interpretation of clinical results from different institutions. 
In the course of this thesis it has been shown that the RBE-weighted doses predicted on 
the basis of LEM IV for typical situations representing chordoma treatments differ on 
average by less than 10 % to those based on LEM I and thus also allow a consistent 
interpretation of the clinical results. At Japanese ion beam therapy centers the RBE is 
estimated using their clinical experience from neutron therapy in combination with in-vitro 
measurements for carbon ions (HIMAC approach). The methods presented in this work 
allow direct comparison of the HIMAC approach and the LEM and thus of the clinical 
results obtained at Japanese and European ion beam therapy centers. Furthermore, the 
sensitivity of the RBE on the model parameters was evaluated. Among all parameters the 
characterization of the photon dose-response curve has been found to be of particular 
importance for the determination of RBE. The application of the LEM IV for proton beams 
more correctly represents the experimentally observed increase of RBE towards the distal 
end of the irradiation field compared to the clinically considered constant value of 1.1. It 
further allowed a better systematic characterization of the increased effective range of 
proton beams that is a consequence of the RBE enhancement at the distal edge of the 
treatment field. 
The results of this work underline the importance of detailed RBE modeling for a long-term 
improvement of treatment planning in particle therapy and the better exploitation of 
advantages inherent to this radiation modality. 
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I. Introduction  
With 7.6 million deaths (around 13 %), cancer is one of the leading causes of death 
worldwide in 2008 (WHO 2013) and the second most frequent cause of death in 
Germany after diseases of the circulatory system in 2010 (DKFZ 2013). Cancer is most 
commonly treated with surgery, chemotherapy, radiotherapy or a combination of these 
treatment methods. The aim is a curative or palliative treatment of the patient, i.e., to 
cure the patient or improve quality of life. To cure the patient from cancer the tumor 
needs to be removed or at least hindered from growth and spread. In radiotherapy, 
mostly high energetic photon radiation is used to achieve this goal. Common methods 
of radiotherapy are brachytherapy and external radiotherapy. For the latter primarily 
accelerators are used to deliver the desired dose to the tumor volume. 
External radiotherapy with conventional photon irradiation is steadily improved and 
nowadays offers advanced technologies to achieve highly conformal dose delivery to 
the tumor and a lower dose to surrounding tissue. A common method is intensity-
modulated radiotherapy (IMRT); the intensity of the photon beam is varied in a large 
number of fields from different angles. However, for this radiation modality normal 
tissue is burdened with a high integral dose (Pirzkall et al. 2000). 
Radiotherapy with ion beams is a promising alternative treatment method to 
conventionally used photons (Wilson 1946; Castro et al. 1982; Kraft 2000; Tsujii et al. 
2007; Schardt et al. 2010). The advantage of ion beams is the inverse depth dose 
distribution with the Bragg peak at the end of their range, maximizing the dose to the 
cancer region and sparing normal tissue as much as possible. The dose to the 
surrounding tissue can be reduced by around 60 % comparing proton radiotherapy with 
IMRT (Roelofs et al. 2011; Loeffler & Durante 2013). 
In addition to physical advantages, ion beams show an increased effectiveness 
particularly in the Bragg peak region. This includes the increased response of hypoxic 
cells or tissue, in terms of a decreased oxygen enhancement ratio (OER), and of 
cancer stem cells (CSC) mainly for heavier ions like carbon or oxygen (Pignalosa & 
Durante 2012; Scifoni et al. 2013). Recently, the diverse genetic response in terms of 
different gene expressions has gained interest regarding ion beam compared to photon 
irradiation (Fokas et al. 2009; Ding et al. 2013). 
The treatment with ion beams has a long history and started in 1954 in Berkeley with 
the application of protons. Later during phase I-II clinical trials different ion species 
were used ranging from protons to argon ions (Castro et al. 1982). In 1994 the first 
patient was treated with carbon ions at the Heavy-Ion Medical Accelerator (HIMAC) at 
the National Institute of Radiological Science (NIRS) in Chiba (Japan; Tsujii et al. 2004). 
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A pilot study at the GSI Helmholtzzentrum für Schwerionenforschung GmbH (GSI) in 
Darmstadt has been performed in cooperation with the radiological hospital in 
Heidelberg, the research institute Rossendorf FZR in Dresden and the German Cancer 
Research Center DKFZ from 1997 to 2008. Within that project over 400 patients were 
treated successfully with carbon ions. The excellent clinical results motivated the 
installation of dedicated facilities for daily patient treatment like the Heidelberg Ion-
Beam Therapy Center (HIT; Combs et al. 2010) and the Centro Nazionale di 
Adroterapia (CNAO) in Pavia (Italy) (Rossi 2011), a facility at the University Medical 
Center Marburg has been installed and in principle is ready to start patient treatments. 
Protons are more commonly used compared to heavier ions since they are favorable 
from an economic and logistic point of view. More than 100.000 patients have been 
treated with protons compared to around 10.000 treated with carbon ions and around 
2.500 with other ions (PTCOG 2013). Nevertheless, a drawback of protons compared 
to heavier ions is their high lateral and range straggling, which is rather similar to that of 
IMRT methods. However, typically in IMRT a higher number of fields is needed making 
results not directly comparable (DeLaney & Kooy 2007). 
Up to now patients at HIT are treated only with carbon ions and protons but the use of 
other ions like helium or oxygen is considered for the future. Because of the increasing 
interest in ion beam therapy the biological based treatment planning with heavy ions 
plays an important role to fully exploit the advantage of therapy relevant ions (Krämer & 
Durante 2010). For the biological treatment planning the relative biological 
effectiveness (RBE) of the ions in tissue needs to be considered. To predict the RBE 
for the irradiated tissue the local effect model (LEM) was developed and implemented 
in the pilot project (Scholz et al. 1997). Further, it is applied in treatment planning at 
HIT. The LEM derives the biological effectiveness of ions from the effectiveness of a 
reference irradiation, typically using conventional photon irradiation, taking advantage 
of the long experience with this radiation modality. The model has been continuously 
improved and is now capable of predicting the RBE for all therapy relevant ions from 
protons to carbon with similar accuracy, based on a unique, consistent set of input 
parameters (Elsässer et al. 2010). To introduce the recent model version LEM IV to 
clinical routine intensive analysis and comparison with measurements and clinical 
results are required. The following sections focus on relevant physical and biological 
aspects, contributing to the benefits and challenges of ion beam radiotherapy. 
I.I. Depth dose distribution of photons and ion beams 
The interaction of ionizing irradiation with atoms and molecules is used in radiotherapy 
to treat cancer cells. Photons and ions show different mechanisms of interaction with 
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matter that lead to substantial different dose distributions. The relevant photon 
interactions are the photoelectric absorption and the Compton scattering transferring 
the total or partial energy of the photon to the electrons of the atom. On the contrary ion 
beams give continuously small fractions of energy to the target atoms via coloumb 
interaction (ionization and excitation) and can also undergo nuclear reactions leading to 
projectile or target fragmentation. A detailed description of the processes can be found 
in Podgorsak (2005). 
In radiotherapy and biology often the measure linear energy transfer (LET) is used to 
describe the average energy deposited per unit length (in keV/µm) in an absorber 
material like a cell or tissue. The energy deposition of ions as a function of the depth in 
matter is characterized by the Bragg curve (fig. 1). The LET is increasing when 
particles slow down in the absorber material up to a maximum at the end of their path 
with the highest energy loss at the so called Bragg peak. The position of the 
Bragg peak depends on ion type and initial energy. This can be exploited in ion beam 
therapy since the Bragg peak can be shifted in depth by means of energy variation. 
Figure 1 illustrates the advantage of ion beams compared to photons regarding the 
depth dose distributions.  
 
Figure 1: Relative depth dose distribution of photons, protons and 12C-ions with different initial 
energies in water. The Bragg peak position can be shifted in depth by varying the initial 
energy of the ions. (Courtesy of Wilma Kraft-Weyrather, GSI Darmstadt, Germany) 
After an initial build-up region that is caused by the range of the secondary electrons, 
photons show an exponential decrease of the dose with depth. In contrast, ion beams 
show an inverse depth dose distribution compared to photons with the maximum dose 
deposition at the end of their range. The depth dose distribution of 12C-ions shows a 
sharp decrease beyond the Bragg Peak but exhibits a tail, which consists of fragments 
lighter than 12C, thus having a higher penetration depth. Protons do not show a 
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fragment tail, but compared to 12C-ions show a broader Bragg Peak since they are 
lighter and thus scattering effects are more pronounced when they interact with matter. 
I.II. Biological effectiveness of ionizing radiation 
So far, most of the knowledge about the response of cells or tissues to ionizing 
irradiation is based on the experience with photon irradiation, i.e., low-LET irradiation. 
Thus, most of the radio-oncological principles and radiobiological models invented 
were developed to describe the dose response of photon irradiation rather than the 
response to ion beam irradiation. The following section deals with biological 
effectiveness of ionizing radiation and a remedy to transfer the knowledge about the 
effectiveness of photon irradiation to ion beams. 
 
Ionizing radiation causes damage to cells and tissues primarily as a consequence of 
damage to the DNA. The ability to repair damage strongly depends on the cell type and 
is reflected in the sensitivity to irradiation. In general, the radiosensitivity of a cell type is 
related to its proliferation capacity. For example, cells with a high mitotic activity, i.e., a 
high division rate, tend to be more sensitive to irradiation, whereas slow or non-
proliferating cells are more radioresistant. Regarding in-vivo systems this can explain 
why for example cells of the hematopoietic system which are replaced continuously 
belong to the most radiosensitive cells whereas neurons which are highly differentiated 
and do not reproduce are very resistant to irradiation (Rubin & Casarett 1968). 
Description of cell- and tissue sensitivity with the linear-quadratic (LQ)-model  
From the response of cell or tissue types to irradiation dose-effect relationships can be 
established. The shouldered form of the dose-response curve observed for in-vitro cell 
survival experiments can be described by the linear-quadratic (LQ)-model 
𝑆(𝐷) = eି(ఈ∙஽ାఉ∙஽
మ) 
with the cell survival S as the function of the dose D described by the parameters α and 
β (Sinclair 1966; Kellerer & Rossi 1971; Douglas & Fowler 1976). The interpretation 
often used for the parameters α and β is the relation of hits to the induced lethal events. 
The   parameter   α   characterizes   a   linear   relationship,   resulting   from   a   single   hit  
mechanism,   and   the   parameter   β   a  quadratic   relationship,  which   is   caused  by   lethal  
events resulting from multiple hits. The α/β-ratio describes the dose where the linear 
and quadratic components are equally contributing to the cell survival. For conventional 
irradiation with photons a high  α/β-ratio (>6 Gy) is common in radiosensitive cells and 
early responding tissues including many tumors. A   low   α/β-ratio (1-6 Gy) is often 
observed for radioresistant cells or late responding tissue types (Hall & Giaccia 2011). 
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The sigmoid shaped dose-response curve characteristic for clinical endpoints, i.e., local 
tumor control or normal tissue complication can be derived from the clonogenic cell 
survival curve assuming a certain number of functional cells which need to be 
inactivated in order to have a response of the tumor or organ regarded (McNally & 
Sheldon 1977; Dawson & Hillen 2006). 
A common method in radiotherapy is the fractionation of the total prescribed dose to 
the tumor volume in order to enhance the differential effect between tumor and normal 
tissue response, i.e., to decrease side effects while keeping the effect to the tumor 
constant. Advantage is taken here from the difference of early and late responding 
tissues to the same fractionation pattern. For dose response curves with a pronounced 
shoulder as observed for rather late responding normal tissues, the effect is more 
sensitive to a change in the dose per fraction. In this case more severe effects for a 
higher dose per fraction are expected with respect to the same prescribed total dose. In 
contrast, the dose response curves of early responding tissues or most tumors are 
typically characterized by only a slight shoulder, the linear component is dominating 
and indicates a less pronounced dependence on the fraction dose (Thames et al. 
1982). Thus the optimal fractionation schedule is mainly determined by the late 
responding normal tissue (Hall & Giaccia 2011: 395). 
The isoeffective dose DIsoE is an appropriate measure to compare the outcome of 
different fractionation regimens. It describes the total dose needed in a reference 
fractionation regimen to end up with the same effectiveness as the fractionation 
regimen with the total dose D and the fraction dose d (Wambersie et al. 2006). 
𝐷ூ௦௢ா =
𝐷(1 + 𝑑 ∙ 𝛽/𝛼)
1 + 𝑑௥௘௙ ∙ 𝛽/𝛼
 
Here, dref describes the fraction dose of the reference fractionation regimen. Another 
measure of effectiveness based on the assumptions of the LQ-model is the equivalent 
uniform dose (EUD) which is useful to estimate the effect of a defined spatial dose 
distribution (Niemierko 1997). 
𝐸𝑈𝐷 = −൬
𝛼
2𝛽
൰ + ඨ−
𝑙𝑛𝐸ത
𝛽
+ (𝛼/2𝛽)ଶ 
The EUD is corresponding to the dose leading to the mean radiobiological effect 𝐸ത in a 
defined volume (target) and is useful to describe the impact of a heterogeneous dose 
distribution as it occurs especially in the normal tissue surrounding the tumor volume.  
The LQ-parameters α  and  β or at least the α/β-ratio of the photon dose-response curve 
are needed to calculate the EUD and the isoeffective dose.  
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Enhanced biological effectiveness of ion beams  
Ion radiation induces increased radiation damage in cells compared to photons, In 
general, the higher effectiveness becomes visible in dose response curves as an 
increased linear coefficient α of the LQ-model whereas the change in the quadratic 
component, i.e., the coefficient β, is less pronounced and is observed only for very 
high-LET values. The relative biological effectiveness (RBE) is defined as the dose 
ratio of a reference irradiation like photons to ions resulting in the same biological effect. 
RBE =
𝐷௥௘௙
𝐷௜௢௡
ฬ
ூ௦௢ா
 
The increased effectiveness can be explained by the different microscopic energy 
deposition patterns of photons and ions, respectively. On the level of the cell nucleus, 
photons show a rather sparsely, but homogenous energy distribution. Ions on the 
contrary show a concentrated energy distribution along the ion trajectory. The 
correspondingly higher ionization density in the track center induces damage, which is 
believed to be more difficult to repair for the cell, resulting in a higher effectiveness of 
high-LET irradiation like, e.g., carbon ions in the Bragg peak region. 
The RBE is a complex quantity and depends on several variables such as the LET of 
the ion, which is the reason for a higher RBE in the Bragg peak region than in the 
entrance channel. This differential behavior of the RBE in the Bragg peak and entrance 
channel region poses the biological advantage of high-LET irradiation such as heavier 
ions, compared to low-LET irradiation like photons. The extent of it though depends on 
the radiosensitivity of the cells or tissues irradiated (Fokas et al. 2009). A cell or tissue 
type with a rather small α/β-ratio for photon irradiation shows a more distinctive 
response to high-LET compared to low-LET irradiation. For a high α/β-ratio a smaller 
difference between low-LET and high-LET irradiation can be observed. Weyrather et al. 
(1999) and Friedrich et al. (2013a) have shown that there is an empirical linear 
relationship of β/α to the RBE, i.e., the RBE increases with the inverse of the α/β-ratio. 
The RBE also depends on the ion type since ionization densities are different for the 
same range in water. Furthermore, RBE depends on the effect level regarded, which is 
dependent on the applied dose. Thus, the RBE is dependent on the fractionation 
schedule, i.e., on the dose per fraction. 
I.III. Treatment planning in radiotherapy 
Dose optimization in treatment planning for photon and ion beam radiotherapy requires 
delineation of the tumor volume and relevant organs at risk (OAR). The definition of the 
planning target volume (PTV) is based on the macroscopic tumor extension, i.e., the 
gross target volume (GTV) and the subclinical spread of the tumor accounted for by an 
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extra margin, i.e., the clinical target volume (CTV) (ICRU 1999a and 1999b). The 
localization of the PTV and relevant OARs is assessed by computer tomography (CT) 
and magnetic resonance (MR) images. The optimization is performed for a prescribed 
fraction dose to the tumor volume and thereby takes into account the tolerance doses 
of the surrounding normal tissues. The number of fields contributing to the prescribed 
dose and the corresponding beam direction is defined by the aim to spare the OAR as 
much as possible. 
Treatment planning objective in radiotherapy  
In conventional radiotherapy with photons the treatment planning is concentrated on 
the delivery of a prescribed physical absorbed dose to the tumor volume. Dosimetry 
procedures ensure the accuracy of the applied dose to the patient. The fractionation 
regimen takes into account the radiosensitivity of the tumor and the surrounding normal 
tissues, which are typically derived from experience and clinical studies. Biological 
modeling approaches in terms of the LQ-model, tumor control probability (TCP)- and 
normal tissue complication probability (NTCP)-modeling and effective dose 
prescriptions can be used to estimate the effectiveness of the applied physical dose 
and the corresponding dose response relationships (Niemierko 1997).  The  α/β-ratio is 
a   widely   used   quantity   for   this   purpose   however   determination   of   the   α/β-ratio for a 
certain   tissue  and  endpoint   is  afflicted  with   large  uncertainties.  To  determine  α/β-ratio 
clinical studies applying different fractionation regimens but resulting in the same 
outcome are needed (Douglas & Fowler 1976).  Otherwise  α/β-ratios can be determined 
from in-vitro or in-vivo experiments and transferred to clinical endpoints, which again 
comprises uncertainties following from the environmental differences. 
At present, the individual patient radiosensitivity is not taken into account for the 
planning procedure and the clinically used fractionation regimens are based on the 
outcome of large patient collectives providing profound knowledge about the dose 
response relationship of the endpoint under consideration. An important aspect of 
planning is the reduction of NTCP that is now possible due to the improved dose 
delivery with IMRT methods, which lead to a high tumor conformity (Pirzkall et al. 2000). 
The focus or future direction is thus to reduce side effects by incorporation of outcome 
predictions instead of only dose values. The difficulty is a largely inhomogeneous dose 
to the surrounding tissues and OARs, which makes the proper assessment of effective 
dose values to evaluate the NTCP increasingly important (Wu et al. 2002). 
The introduction of biological optimization in treatment planning and the consideration 
of the patient specific radiosensitivity to further improve the outcome of radiotherapy 
and reduce side effects is discussed in the literature (Brahme 1995; Wang et al. 1995; 
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Bortfeld et al. 1996; Peacock et al. 1998; Brahme 1999; Stewart & Li 2007). Especially 
in the case of large tumors, which more often comprise a hypoxic region, it is useful 
since the responsiveness of the tumor is dominated by the most radioresistant, i.e. the 
hypoxic, part of it. Commercial treatment planning systems already using biological 
based optimization and including measures like the EUD, TCP and NTCP have shown 
to better spare OAR in comparison to the standard dose-volume method (Semenenko 
et al. 2008; Qi et al. 2009; Li et al. 2012). 
In contrast to conventional radiotherapy with photons, the effectiveness of ions is 
strongly dependent on the position in the treatment field and the applied physical dose 
is not directly related to the responsiveness of the irradiated tissue. Thus, the 
application of ions, especially heavier ions like carbon, requires the consideration of the 
enhanced biological effectiveness at every position in the irradiated tissue in the 
treatment planning procedure to not harm the normal tissue or underestimate the dose 
in the target volume to the expense of the local tumor control. Due to a lack of clinical 
data allowing to deduce the RBE distribution with the required spatial resolution the 
effectiveness needs to be estimated from experimental data or by means of biophysical 
models. In the clinical application of ion beams different approaches are followed to 
account for the enhanced effectiveness in terms of RBE. In proton beam therapy the 
RBE is considered by multiplying the physical dose distribution with a constant value of 
1.1. In the Japanese ion beam therapy centers the estimation of RBE of carbon ions for 
the irradiated tissue is based on the radiosensitivity of human salivary gland (HSG) 
cells and the clinical experience with neutron irradiation (Kanai et al. 1999). The work 
presented in this thesis focuses on the LEM, which is used to predict the RBE for the 
biological optimization of the prescribed dose. 
Biological based treatment planning with TRIP98 
The treatment planning software TRiP98 (TReatment Planning for Particles, 1998 
edition) was developed at the GSI for radiotherapy with heavy ions, especially with 
carbon ions (Krämer et al. 2000; Krämer & Scholz 2000; Krämer & Durante 2010). It 
was used in the pilot study at GSI and is the basis for the commercially developed 
therapy planning system at the HIT, syngo PT Planning (Siemens Healthcare). It is 
specifically designed for applications using a full active beam delivery system with 
active energy variation to modulate the depth position of the Bragg peak and lateral 
raster scanning by means of horizontal and vertical magnetic deflection of the ion beam 
(Haberer et al. 1993). Further it is the first treatment planning software allowing a full 
biological optimization of the prescribed dose for ion beam therapy (Jäkel et al. 2001). 
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The prescribed dose to the PTV is a RBE-weighted dose and thus reflects a photon 
equivalent dose. For the optimization of the RBE-weighted dose, the PTV is divided for 
each field into iso-energy slices corresponding to a constant initial energy of the ions. 
Slice-by-slice a certain number of ions is prescribed to the vertically and horizontally 
arranged raster spots to achieve a homogeneous RBE-weighted dose distribution. In 
depth, the monoenergetic Bragg curves are overlaid and generate the so-called spread 
out Bragg peak (SOBP; fig. 2). Additionally, the method enables an intensity 
modulation by independently varying the particle number, i.e., dose to each raster spot. 
 
 
 
 
 
Figure 2: The superposition of fluence-weighted Bragg curves (red) forms the SOBP (blue) of 
the prescribed dose in the PTV. The relative weighting of the monoenergetic Bragg curves is 
determined by a dose optimization within the treatment planning system. (Courtesy of Wilma 
Kraft-Weyrather, GSI Darmstadt, Germany) 
The planning procedure requires the 3-dimensional information of the particle 
composition at each position in the field. This includes the energy spectra of the 
primary particles, i.e., the projectile, and all projectile fragments. Information about the 
energy spectra of each particle in the irradiated volume is not only important for the 
calculation of the physical absorbed dose but also for the calculation of the 
corresponding RBE-weighted dose. The RBE is predicted by the LEM, which derives 
the effect of the ion beam from the effect of conventional photon radiation on the 
irradiated tissue. The LEM is described in more detail in the following subsection. 
With TRiP98 it is also possible to perform a simultaneous biological optimization of 
multiple fields, i.e., a multi-field optimization of the prescribed RBE-weighted dose in 
the PTV (Gemmel et al. 2008). The difficulty here is that the RBE must be considered 
for the dose of the superimposed fields and not for each individual field since only the 
final particle composition in the mixed irradiation field and dose-level determines an 
accurate RBE. Thus RBE needs to be considered for every iteration step, which is the 
core of the biological optimization. 
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Prediction of RBE with the Local Effect Model (LEM)  
For the GSI pilot project and currently at the HIT the RBE prediction is based on the 
first version of the LEM (Scholz et al. 1997). The two main components of the model 
are the dose-response of a considered endpoint to photon irradiation and the 
amorphous track structure of the ion beam, i.e., the radial dose distribution of the track. 
The basic assumption of the model is that local damage is fully determined by the local 
energy deposition, but otherwise is independent from the radiation type. In contrast to 
photons, ions produce a rather inhomogeneous dose distribution with a dense energy 
deposition pattern close to the track center and a more sparse, photon like energy 
deposition pattern with increasing distance to the track center. The dose response of 
the photon irradiation that is used as input to the model is described by the LQ-model 
and extended with a transition to a linear relationship for doses exceeding a threshold 
dose Dt. 
The focus in the development of LEM I was to correctly represent the RBE in 
therapeutically relevant carbon ion SOBP. Otherwise, it showed to have certain 
limitations with respect to the accuracy of the RBE predictions in the entrance region 
and for lighter ions. The use of parameters that allow accurate representation of RBE in 
the carbon SOBP lead to an overestimation of RBE in the entrance region and a 
general overestimation for lighter ions, in that case for both the SOBP and the entrance 
region. However, reliable RBE predictions for lighter ions like protons and helium with a 
common input parameter set are desirable to allow direct treatment plan comparisons 
for different ion beams. Therefore, model improvements have been gradually 
implemented (Elsässer & Scholz 2007; Elsässer et al. 2008). With the latest model 
version LEM IV (Elsässer et al. 2010) the RBE can be predicted with similar accuracy 
for all positions in the treatment field and over the whole range of clinically relevant ions 
with a common set of input parameters. 
In the LEM IV a two-step procedure is used to determine the biological effect. In a first 
step the local damage distribution in terms of double strand breaks (DSB) within 
individual ion tracks is determined. In the second step the distribution of these DSB 
within the DNA, specifically within megabase pair chromatin loops is determined 
(Friedrich et al. 2012). Hence, an intermediate step is introduced as compared to the 
LEM I for which the local dose distribution is converted into a spatial distribution of DSB. 
This approach allows a more mechanistic interpretation of the induction of cell death. 
Subsequently, the RBE is calculated and stored in a tissue and endpoint specific RBE-
table which is used in TRiP98 to calculate the RBE in the mixed irradiation field. In the 
RBE-table the RBE is sorted by ion type from protons to neon with energies ranging 
from 0.1 to 1000 MeV/u in 40 logarithmically equidistant energy steps. 
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II. Summary of the published results (cumulative)  
II.I. Proof of consistency and comparison with in-vivo experiments 
The comparison of clinical data for different beam qualities and the construction of 
common dose response curves require the accurate prediction of RBE-weighted and 
isoeffective doses. A compilation of 5-year local control for the treatment of skull base 
chordoma with conventional and ion beam radiotherapy and the resulting dose 
response relationship is published in Schulz-Ertner et al. (2007). The compilation 
includes the local control probability obtained in the GSI pilot project corresponding to 
isoeffective doses based on RBE predictions of the LEM I. The isoeffective dose 
predictions are in accordance with other ion beam studies by Castro et al. (1994) at the 
Lawrence Berkeley Laboratory (LBL) using helium and neon ions with the same local 
tumor control of 63 %. The dose response can be well described by a sigmoid shaped 
curve. At higher doses the curve is mainly determined by the clinical results obtained 
with ion beam therapy. Hence, to establish a common dose response curve one needs 
to consider the RBE, whereby uncertainties and inadequate determination of RBE can 
alter the dose response relationship due to the corresponding shift on the dose axis. 
The question arises whether the LEM IV can describe the dose response relationship 
obtained from clinical data published in the literature as good as the LEM I does. Thus, 
it was of particular interest to analyze consequences of the model improvements from 
LEM I to LEM IV in therapeutic relevant situations to demonstrate the applicability of 
the LEM IV for patient treatment. 
Thus, the main goal of article 1 was to compare the LEM IV against LEM I under 
treatment-like conditions for idealized target geometries. In order to compare the two 
models on the level of RBE prediction the underlying physical dose distribution had to 
be the same. Therefore, the dose distribution as applied in the GSI pilot project was 
used in which the RBE-weighted dose was optimized based on the LEM I. The 
resulting physical dose distribution further served as a reference for the LEM IV 
recalculations. Concerning the tissue specification as represented by the photon input 
parameters of the LEM IV,  rather  small  α/β-ratios of 2 Gy and 2.45 Gy are used (RBE-
table AB2 IV and AB2.45 IV; tab. 1, article 1), in line with the known characteristics of 
central nervous system (CNS) tissue types (Karger et al. 2006; Hall & Giaccia 
2011:396) and  with  the  α/β-ratio of the photon input parameters applied in the GSI pilot 
project (RBE-table AB2 I; tab. 1, article 1). The   assumption   of   a   small   α/β-ratio for 
chordoma is further supported  by  the  α/β-ratio of 2.45 Gy, evaluated for local control of 
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chordoma from clinical studies using hypofractionated photon radiotherapy (Henderson 
et al. 2009). 
Figure 1a in article 1 illustrates that the resulting RBE-weighted dose distribution 
based on LEM IV shows a significant rise within the SOBP using the reference physical 
dose profile. This is due to the fact that the RBE predicted by the LEM IV shows a 
steeper gradient of RBE with LET than compared to LEM I. The LET is highest at the 
distal end of the SOBP due to the pronounced contribution of high-LET ion tracks and 
leads to a sharp increase of the RBE-weighted dose. For the 2-field optimization 
(fig. 1b, article 1) the RBE-weighted dose profile is homogenized but the higher 
sensitivity on LET is still visible. Nevertheless, the similarity of the EUD and the mean 
RBE-weighted dose based on the LEM IV predictions for the same target volume 
dimension showed that the inhomogeneity of the RBE-weighted dose distribution is not 
reflected in the mean effectiveness of the irradiation (fig. 2, article 1). 
We were able to show (fig. 5, article 1) that the higher RBE in the distal part of the 
SOBP predicted by the LEM IV is in better agreement with the RBE obtained in the in-
vivo experiments by Karger et al. (2006). The experiments analyzing the tolerance of 
the rat spinal cord after photon and carbon ion irradiation with different fractionation 
schedules aimed to determine the RBE and revealed that the RBE predicted by the 
LEM I was underestimated by about 25 % in the center of a 1 cm SOBP, whereas for 
LEM IV the deviation are on average less than 10 %. The measurements represent the 
RBE in the distal part of the SOBP independent on the dimension, i.e., the RBE at 
around 5 mm from the distal end in any SOBP. 
The consistency of the LEM IV based RBE-weighted dose prediction was further 
verified by the comparison with the 5-year local control data for chordoma of the skull-
base compiled by Schulz-Ertner et al. (2007). For this purpose, the isoeffective doses 
were calculated for two different endpoints, i.e., for two slightly   different  α/β-ratios of 
2 Gy and 2.45 Gy (RBE-table AB2 IV and AB2.45 IV; tab. 1, article 1). Since the 
discrepancy between LEM I and LEM IV has shown to be strongly depended on the 
tumor dimension (fig. 1 and 2, article 1), the isoeffective doses were calculated for the 
median (80.3 ml), minimal (13.9 ml) and maximal (594.2 ml) tumor volume treated in 
the clinical study respectively. 
Figure 4 in article 1 shows the compilation of the 5-year local control data including 
the dose-response of carbon ion therapy for skull-base chordoma in the GSI pilot 
project with 63 % and 100% local control for two different fractionation regimens 
respectively. The isoeffective doses predicted by the LEM I have shown to be in good 
agreement with the dose prescriptions of other studies leading to a similar outcome 
(Castro et al. 1994; Terahara et al. 1999; Hug et al. 2000). Even though the variability 
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with tumor volume is large, the isoeffective doses for the median tumor volumes based 
on RBE predictions of the LEM I and LEM IV deviate by less than 5 % for the two 
considered  α/β-ratios. This agreement of the isoeffective doses confirms the capability 
of the LEM IV to consistently describe the clinical outcome. 
II.II. Conversion of institutional dependent RBE-weighted doses  
From the comparison with the compiled clinical data of Schulz-Ertner et al. (2007) the 
question arises to what extent the RBE-weighted doses estimated in other institutions 
are comparable if they rely on a different approach. This is the case for protons, when 
a constant RBE is assumed, or for the clinical trials with helium at the LBL where only a 
depth dependent RBE is considered (Castro et al. 1994). For the comparison of clinical 
data though, it is of interest to convert RBE-weighted doses predicted by different 
models for a better understanding and comparison of dose-effect relationships. Since 
the HIMAC approach is applied in patient treatment at the NIRS for a long time and 
many different types of tumors the comparison to the GSI/HIT approach based on the 
LEM is of great interest to compare clinical studies and dose-effect relationships and to 
utilize well-experienced fractionation schedules applied. In article 2 a method is 
introduced to convert and compare RBE-weighted doses based on the HIMAC and 
GSI/HIT approach. In comparison to the LEM the HIMAC approach only gives a depth 
dependent RBE which is based on the LET distribution but neglects the dose 
dependence as well as the tissue type dependence. The comparison was done for both 
the LEM I and LEM IV.  
To compare the two approaches, in a first step the HIMAC depth dose profile based on 
passive beam shaping was reconstructed as described in article 2. The resulting 
physical dose profile served as reference to compare the RBE-weighted dose 
distribution resulting from the application of the LEM I and LEM IV, respectively. Since 
the tissue under consideration influences the RBE-weighted dose, the evaluated 
conversion factors are specific for the RBE-tables based on LEM I and LEM IV used in 
the present comparison. However, the conversion factors can be calculated for any 
kind of tissue and endpoint if the required photon input paramters for the LEM are 
available. 
The resulting RBE-weighted dose distribution based on LEM I and LEM IV are different 
in shape and magnitude as can be seen in fig. 2 of article 2 but the mean and median 
RBE-weighted dose are very similar (fig. 3c and tab. 1, article 2). Since the goal of a 
biological optimization is a homogeneous RBE-weighted target dose not only the shift 
in RBE-weighted dose is being compared to the HIMAC approach but also the 
homogeneity in the target volume expressed with the EUD. Typically, the deviation of 
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the EUD from the median RBE-weighted dose is less than 5 % (tab. 1, article 2), in 
agreement with the results obtained in article 1. 
The conversion factors between HIMAC and LEM turned out to be strongly dependent 
on the fraction dose and can range from 1.76 to 0.46 for prescribed HIMAC doses from 
1 to 60 Gy. At a prescribed HIMAC dose of around 5 Gy (RBE) the conversion factor is 
1 leading to similar LEM based RBE-weighted doses in this dose region (fig. 3 and 4, 
tab. 2, article 2). The bandwidth of conversion factors demonstrates the need for 
approriate mapping with treatment planning studies. 
With the conversion factors it is now possible to compare the outcome of clinical 
studies for common dose prescriptions. For instance, the conversion factor for the 
fractionation schedule of 20 x 3 Gy (RBE) applied for the majority of the patients with 
skull-base chordoma in the GSI pilot project would be approximately 1.2. This 
corresponds to a prescribed HIMAC dose of 20 x 2.5 Gy (RBE) and in terms of an 
isoeffective dose for 2 Gy per fraction to 56.25 Gy (IsoE). The estimated isoeffective 
dose is considerably lower than the 75 Gy (IsoE) and 76.75 Gy (IsoE) resulting from 
LEM I and LEM IV predictions respectively. Regarding the local control curve shown in 
Schulz-Ertner et al. (2007) and article 1 the expected TCP for 56.25 Gy (IsoE) would 
be lower, comparable to what has been observed in conventional radiotherapy with 
photons (IMRT). 
The HIMAC patients are more often treated with low fraction numbers and higher dose 
per fraction, therefore it can be expected that the doses converted to the LEM 
approach are considerably lower and can differ by up to a factor of 2 to the prescribed 
HIMAC dose. This is well seen from the comparison with the HIMAC single fraction 
regime of 48 Gy (RBE) prescribed HIMAC dose for non-small-cell lung cancer 
(NSCLC) (Tsujii & Kamada 2012). To the knowledge from conventional radiotherapy, 
48 Gy (RBE) would exceed the tolerance doses of many normal tissues and OAR but 
converted into a LEM I based median RBE-weighted dose of 23.1 Gy (RBE) the 
fractionation regimen shows to be within the limit of tolerance doses. This predicted 
RBE-weighted  dose  corresponds  to  a  rather  radioresistant  tissue  type  with  an  α/β-ratio 
of 2 Gy. For rather radiosensitive tissue types the predicted dose is expected to be 
even lower than the 23.1 Gy (RBE). 
This examples show that caution is necessary if dose-response relationship are based 
on different biological models and tools to convert prescribed doses are necessary 
especially in the context of heavy ion therapy. 
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II.III. Sensitivity of RBE on the LEM input parameters 
In order to estimate the uncertainty of the RBE the LEM inherent RBE sensitivity to the 
input parameters was assessed. In article 1 the sensitivity of the RBE-weighted dose 
on the photon input parameters was evaluated. A modification of the parameters α,  β  
and Dt by 25 % affected the RBE-weighted dose by less than 10 % (tab. 3, article 1). 
This variation is in the order of the uncertainty inherent to clinical data.  
In article 3 the sensitivity of the RBE and RBE-weighted dose was extensively 
analyzed for the input parameters of the LEM (tab. 1, article 3). For the parameter sets 
two  α/β-ratios were chosen, one describing a rather radioresistant late responding cell -
or  tissue  type  with  the  parameters  α = 0.1 Gy−1,  β = 0.05 Gy−2 and Dt = 8 Gy as design 
parameters  for  α/β = 2 Gy and one rather radiosensitive early responding cell- or tissue 
type   with   α = 0.5 Gy−1,   β = 0.05 Gy−2 and Dt = 14 Gy   for   α/β = 10 Gy (article 3). The 
two  α/β-ratios of 2 and 10 Gy represent the typical range of values for relevant radio-
oncological endpoints, although in some cases values exceeding this range are 
observed. For example, for prostate a very  low  α/β-ratio of 1.5 Gy is reported and for 
liver a very high value of 15 Gy (Suit et al. 2010). The choice of the parameter Dt was 
inspired  by  an  empirical   linear   relationship  between  α/β-ratio and Dt which was found 
by Friedrich et al. (2013a). 
The sensitivity analysis has been carried out for irradiation under track segment 
conditions, i.e. for monoenergetic beams with well-defined energy and LET, and for 
irradiation in a mixed field within a SOBP. For the RBE under track segment conditions 
it can be seen in fig. 1 and 2 of article 3 that for a parameter variation of 25 % the 
RBE in general changes less than 25 %. The RBE at the 10 % effect level (RBE10) is 
typically less sensitive to parameter variations compared to the RBE for the initial slope 
of the effect curve (RBEα). Regarding the RBE10 only for the variation in the nuclear 
radii rn the RBE change is larger than 25 % for high LET values above 200 keV/µm.  
For the case of a mixed field irradiation within a SOBP, due to fragmentation, straggling 
and scattering several particle species, each having an individual energy distribution, 
may contribute to the overall dose deposited. Because of this mixing in the extended 
target volumes the sensitivity of RBE to its input parameters is damped as compared to 
the sensitivity observed for monoenergetic ion beams. Instead of the LET dependence 
for the mixed irradiation field the depth dependence was regarded. In compliance with 
the clinical routine the analysis focused on a 2-field optimization to 3 Gy (RBE) for the 
reference cases as well as for every input parameter variation. Figure 3 and 4 in 
article 3 show the RBE sensitivity for the different input parameters. The results of 
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single field optimizations have also been studied extensively and are briefly discussed 
in the article.  
Regarding the 2-field optimizations the largest variation is observed for the chromatin 
loop size parameter lDSB defining the clustering properties of DSB and thus the lethality 
ascribed to a given pattern of DSB. In general the RBE sensitivity is higher for the low 
reference α/β-ratio, i.e., 2 Gy, but for all parameters the RBE variation is less than 
25 %. This means that the variation of the RBE values depends typically less than 
proportional on the variation of the input parameters. The damping of the RBE 
sensitivity in the mixed irradiation field compared to the monoenergetic beam is a 
consequence of the broader LET distribution within the SOBP. This can be concluded 
from the fact that the RBE in the SOBP center is even damped compared to the RBE of 
a monoenergetic beam with comparable LET of about 50 keV/µm. The RBE in the 
SOBP is in general lower compared to the RBE for a monoenergetic beam with the 
same LET and the damping of RBE sensitivity is a consequence of an overall smaller 
RBE. 
II.IV. Proton RBE and assessment of uncertainty 
The RBE is not only a matter of heavier ions like carbon but also for the lighter ions. 
The study presented in article 2 has shown that differences in the RBE prediction can 
lead to different assumptions of the dose effect relationship, assumed tolerance doses 
for normal tissues and modified local control relationships. Thus it is important to try to 
describe these dependencies as accurate as possible. In current clinical practice the 
RBE of protons is considered to have a constant value of 1.1 independent on the depth 
distribution in the SOBP and general RBE dependencies. Paganetti et al. (2002) 
showed by a large compilation of in-vivo experiments that the biological effectiveness 
of protons in tissue is on average very similar to that of x-rays for in vivo endpoints for 
most of their path. This supports the reasoning to use in clinical practice a constant 
RBE of 1.1. Nevertheless neglecting the variability along the SOBP can lead to errors 
in the interpretation of clinical data and to an unnecessary dose to the surrounding 
tissue, e.g., by an extension of the effective range of the proton beam. The capability of 
LEM IV to predict the RBE for protons up to carbon ions with sufficient accuracy 
(Elsässer et al. 2010), gave rise to a systematic analysis of the proton RBE published 
in article 4. In this analysis, we focus on the RBE and RBE-weighted dose at the distal 
end of the SOBP, since LET values increase towards the distal end and thus RBE 
effects are expected to be particularly pronounced in this region. 
Validation by means of in-vitro data showed that the RBE along a proton SOBP 
predicted by the LEM IV is in accordance with the experimental observed RBE. The 
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measured and predicted RBE values for the two experiments of Tang et al. (1997) and 
Bettega et al. (2000) are shown in fig. 2 of article 4. It was important to show that both 
the dose-level dependence of the RBE (fig. 2a, article 4) and the steep increase of 
RBE due to the high LET at the distal end and in the distal penumbra (fig. 2b, 
article 4) are well represented. 
Furthermore the biological range extension of the proton beam was analysed which 
describes the extension of the SOBP due to the enhanced RBE in the distal penumbra 
compared to the constant RBE of 1.1. The range extension was characterized in 
dependence on physical factors like the dose-level, initial beam energy, tumor 
dimension and depth position as well as on biological factors like the tissue type in 
tumor and normal tissue. For the systematic analysis the photon input paramter sets 
described in the last section with α/β-ratios of 2 and 10 Gy are used. An important 
result of the analysis was that the biological extension is strongly influenced by the 
gradient of the distal dose penumbra, i.e., a flat penumbra leads to a more pronounced 
extension than a steep one, although a steep gradient goes along with a higher distal 
RBE-weighted dose compared to a shallow one. This anti-correlation is shown in fig. 5 
of article 4. The difference in the distal gradient can be caused by several physical 
configurations like the depth modulation system, i.e., if it is a passive or active energy 
variation. The main difference between active and passive variation is the initial energy 
used for irradiation. For a passive modulation normally a fixed and relatively high initial 
energy is used. The resulting depth dose distribution for higher energies has a wider 
distal penumbra due to the enhanced range straggling since the beam passes more 
material until it stops and is subject to more scattering processes. Lower energies as 
they can be used in active depth modulation with flexible initial energy show a sharper 
distal penumbra with a higher maximum LET leading to a higher RBE-weighted dose at 
the distal end of the SOBP. Figure 7 in article 4 schematically explains the influence 
of the gradient on the biological range extension. 
Similar to what is done in carbon ion therapy, the biological range extension can be 
accounted for by a biological optimization, which leads to a decreased physical dose 
towards the distal end of the SOBP. The study showed that a reduction of the physical 
dose at the distal end is also necessary to decrease disagreement in the range and 
RBE-weighted dose prediction. The estimated and actual dose can be largely different 
and due to generous margins in proton beam therapy the maximum difference at the 
edges of the SOBP also affects parts of the surrounding normal tissue. 
The range uncertainties and extensions have also been addressed by Gensheimer et 
al. (2010) using MRI measurements after irradiation of the lumbar spine with protons in 
the course of medulloblastoma treatments. They were able to directly determine the 
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biologically effective range in the patients and reported an average overshoot of the 
proton beam in the lumbar spine of 1.9 mm (0.8–3.1 mm). A small part of the overshoot 
(less than 1mm) was attributed to the increased RBE in the distal penumbra according 
to considerations by Paganetti (1998). Nonetheless, a discrepancy to the actually 
measured overshoot can be observed. The results presented in article 4 may fully 
explain the overshoot they have observed with a predicted biological range extension 
of 1.6–3 mm for 235 MeV and 1.1–1.8 mm for 160 MeV (energies typically used), at the 
50 % isodose considering a prescribed RBE-weighted dose (RBE = 1.1) of 2 Gy (RBE). 
The given bandwidth of biological range extensions describes the dependence on the 
radiosensitivity of the tissue type. 
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III. Aim and contribution 
Ion beam therapy requires the consideration of RBE to estimate a reliable prescribed 
dose to the tumor volume. RBE is a complex quantity and the accuracy of the RBE 
prediction relies on a proper modeling taking all the dependencies of RBE into account. 
The work presented here aims at analyzing the influence of enhancements in the RBE 
model currently used for clinical application to outline the potential uncertainties 
occurring when disregarding the complexity of RBE in treatment planning and the 
consequences for the interpretation of clinical and experimental data. 
 
III.I. Article 1 
Impact of enhancements in the local effect model (LEM) on the predicted RBE-
weighted target dose distribution in carbon ion therapy 
The publication deals with the differences occurring in the RBE-weighted dose 
distribution by the application of the improved version of the LEM. I conducted all the 
treatment planning studies and analyzed the RBE-weighted dose distributions including 
the calculation and comparison of the EUD, the sensitivity analysis of the photon input 
parameters, the comparison with the in-vivo experiment by Dr. Christian Karger et al. 
and the consistency check with the 5-year TCP for chordoma of the skull base. The 
design of the research project was done together with Dr. Michael Scholz. I wrote the 
manuscript with advises from Dr. Michael Scholz and Dr. Thomas Friedrich concerning 
the structure and interpretation of the results. Dr. Michael Krämer assisted me with 
concerns related to the treatment planning software TRiP98. Dr. Christian Karger, 
Prof. Dr. Klemens Zink, Prof. Dr. Marco Durante and Prof. Dr. Engenhart-Cabillic 
contribute with ideas and corrections to the manuscript. 
 
III.II. Article 2 
Mapping of RBE-weighted doses between HIMAC- and LEM-based treatment 
planning systems for carbon ion therapy 
The work of Dr. Olaf Steinsträter in the department of Prof. Dr. Marco Durante and in 
the group of Dr. Michael Scholz is partly based on systematic analyzes which I 
performed in previous work. My preliminary work consisted of the assessment of 
photon input parameters for the LEM and systematic dependencies of RBE. Moreover I 
had advisory functions in the realization of the work concerning the introduction to 
biological based treatment planning with TRiP98 and the interpretation of the results. 
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III.III. Article 3 
Sensitivity analysis of the relative biological effectiveness predicted by the local 
effect model 
I supported the work of Dr. Thomas Friedrich in the department of 
Prof. Dr. Marco Durante and in the group of Dr. Michael Scholz with the sensitivity 
analysis of the RBE for the therapy cases, i.e., within the SOBP representing a mixed 
irradiation field. Moreover I partly wrote the manuscript and was involved in the 
interpretation of the results. 
 
III.IV. Article 4 
Physical and biological factors determining the effective proton range 
I did all the systematic analysis and introduced the biological treatment planning for 
protons. I benchmarked the physical base data needed and compared my results with 
experiments from the literature where two of them are shown in the manuscript. I did 
the analysis of the biological range extension and compared my results to other model 
predictions and clinical data from the literature. I wrote the manuscript and interpreted 
and discussed the results with constructive ideas and improvements of 
Dr. Michael Scholz and Dr. Thomas Friedrich. Dr. Michael Krämer has supported me 
with any questions regarding the treatment planning software TRiP98 and modeling of 
the proton base data. Prof. Dr. Klemens Zink, Prof. Dr. Marco Durante and 
Prof. Dr. Engenhart-Cabillic contribute with ideas, fruitful discussions and corrections to 
the manuscript. 
 
 
 
Hiermit bestätige ich die Richtigkeit der gemachten Angaben bezüglich des 
Eigenanteiles von Rebecca Grün an den aufgeführten Publikationen. 
 
Marburg, Februar 2014 
  
Rebecca Antonia Grün 
(Autorin) 
Prof. Dr. Rita Engenhart-Cabillic 
(Betreuerin) 
  
Prof. Dr. Klemens Zink 
(Betreuer) 
Dr. Michael Scholz 
(Externer Betreuer) 
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IV. Discussion  
IV.I. General aspects of modeling dose response in radiotherapy 
Ion beam therapy is no standard treatment procedure in radiotherapy but especially for 
certain types of malignancies like radioresistant head and neck and CNS tumors a 
promising alternative to conventional radiotherapy with photons (Suit et al. 2010). To 
estimate the expected benefit from ion beam therapy, accurate modeling of the RBE in 
tumor and normal tissue is necessary. The RBE is strongly dependent on the dose 
level, the position in the treatment field and the tumor and normal tissue types involved 
in the field. Within the framework of the LEM the dose response known from 
conventional radiation with photons is used to estimate the RBE for ion beams. 
Whereas for the development of the LEM I the main goal was to accurately predict the 
effectiveness for carbon ions in the target volume, the improvements implemented in 
the LEM IV now enable the exploration of RBE dependencies for the whole set of 
clinically relevant particle beams from protons to carbon ions with similar accuracy. 
Hence, it is possible to assess RBE-weighted dose relationships and the expected 
therapeutic gain more correctly. 
In general, modeling can be an important tool to estimate the potential benefit from 
proton or heavy ion radiotherapy compared to conventional radiotherapy. For example, 
Langendijk et al. (2013) report about the approach followed by the Dutch Health 
Council where they compare toxicity rates for proton and photon treatment with 
validated NTCP models to estimate a patient-specific benefit from the application of 
protons. The approach is used to preselect patients who would have a decisive 
advantage of proton therapy in terms of a drastically reduced NTCP compared to 
conventional radiotherapy with photons. This concept can be transferred to treatment 
planning studies based on RBE modeling approaches to choose the most likely optimal 
ion beam species for a given treatment situation and thus to preselect patients for the 
different options of treatments with protons, helium or carbon ions. It is especially 
favorable for pediatric patients for whom the integral dose needs to be kept as low as 
possible (Johnstone et al. 2013). However, this approach will not replace randomized 
clinical trials since hypotheses need to be proved but rather allows distinguishing those 
patients who would have a clear benefit from a certain radiation modality. 
Although improvements of the LEM IV compared to previous model versions have 
been clearly demonstrated by comparison with in-vitro and in-vivo experimental data, 
before potential application of the LEM IV in clinical routine it was important to 
investigate the consistency with existing clinical data. The compilation of local control 
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rates for chordoma of the skull base by Schulz-Ertner et al. (2007) including the 
outcome of the GSI pilot project was the starting point for this investigation. It was 
shown that for the treatment of radioresistant chordoma of the skull-base the predicted 
RBE-weighted dose of the LEM IV is comparable to that of LEM I with less than 5 % 
difference regarding the median tumor volume. On average the predictions of LEM IV 
and LEM I deviate by less than 10 % for radioresistant tumors with a low α/β-ratio. With 
regard to the comparably low patient statistics of the TCP compilation, i.e., the large 
uncertainty of the clinical data available for treatment of skull-base chordoma, both 
models can describe the clinical outcome with sufficient accuracy (article 1). 
The transition from LEM I to LEM IV in treatment planning does not imply a drastically 
adjustment of the physical absorbed dose. The gradient of the physical depth dose 
distribution though would differ due to the steeper RBE gradient predicted by the 
LEM IV as compared to LEM I. However, the gradient of the physical dose is 
dependent on the field configuration and is largely compensated by the application of 
two opposing fields. With the LEM IV, limitations of the LEM I have been overcome like, 
e.g., the overestimation of RBE in the entrance channel that could lead to an undesired 
restriction of the tumor dose. Furthermore, the input parameter set of the LEM IV is not 
any longer ion specific but a common, consistent set of parameters can be applied for 
all ions from protons to carbon ions. Since the comparison of LEM I and LEM IV was 
performed using idealized target geometries it remains to be elucidated how far these 
results can be transferred to real patient plans. 
Schlampp et al. (2011) analyzed the NTCP for the temporal lobes based on the LEM I 
predictions in the course of the treatment of skull-base chordoma with carbon ions in 
the GSI pilot project and showed that they are consistent with clinical tolerance data 
from photon and proton irradiation. In a study by Gillmann et al. (2014, in press) the 
tolerance doses were recalculated with the LEM IV. The recalculation showed that the 
RBE-weighted dose at the edges is sharply increasing leading to possibly higher 
predicted dose to the temporal lobes that are located close to or even within the tumor 
volume. Since the predicted tolerance doses based on the LEM I have been 
considered consistent with the corresponding clinical photon data, the predicted 
tolerance doses based on LEM IV are consequently higher than those observed in 
conventional photon radiotherapy. However, as will be discussed in a later section, 
actually higher tolerance doses might be expected in the case of ion beam therapy due 
to the specific topological properties of the high-LET and thus high-RBE volume that is 
located as a rim at the distal edges of the individual treatment fields. 
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IV.II. Modeling biological effectiveness in hypofractionated treatment regimens 
Especially with heavier ions like carbon hypofractionation regimens are exploited to 
decrease the overall treatment time. The HIMAC uses carbon ions for hypofractionation 
and even single dose schedules to treat for example NSCLC (Miyamoto et al. 2007) or 
hepatocellular cancer (HCC) (Kato et al. 2004; Imada et al. 2010). Hypofractionation 
schedules are also a future direction for the facilities in Europe although careful 
assessment of the normal tissue sensitivity in the entrance channel is needed. The 
analysis presented in article 2 and Fossati et al. (2012) demonstrated that equally 
prescribed clinical doses (i.e., RBE-weighted doses) do not necessarily lead to the 
same outcome since the underlying RBE model is different and so is the corresponding 
physical absorbed dose. Especially when going to hypofractionation, the results in 
article 2 showed that the prescribed HIMAC dose and the RBE-weighted dose 
predicted by the LEM can deviate by a factor of 2 which means that either the HIMAC 
dose is overestimated or the RBE-weighted dose predicted by the LEM is 
underestimated. 
However, to estimate a proper dose-response relationship and explore fractionation 
regimens from different insitutions, modeling is needed and the responsiveness needs 
to be derived from the predictions of the same biological model. Hypofractionation 
regimens with scanned carbon beams are implemented at the HIT too (Habermehl et al. 
2013). They treated HCC of 6 patients with a fractionation regimen of 4 x 10 Gy (RBE) 
based on the HIMAC approach. Since treatment planning at HIT is based on the LEM I, 
the prescribed dose was converted and resulted in an applied 4 x 8 Gy (RBE) 
optimized RBE-weighted dose to the target volume. In total the conversion resulted in a 
20 % lower RBE-weighted dose to the tumor compared to the prescribed HIMAC dose 
even though the underlying physical dose is similar. Furthermore, in the clinical 
application of the LEM I,  currently  an  α/β-ratio of 2 Gy based on the radioresistant skull 
base chordoma and chondrosarcoma treated in the GSI pilot project is considered. 
However, HCC is a rather radiosensitive tumor type which is estimated with an α/β-
ratio of around 15 Gy (Tai et al. 2008). Thus, the RBE can be even lower than currently 
considered with the LEM I. Therefore, the RBE-weighted dose might be even lower 
than the LEM-based prescribed dose of 8 Gy (RBE) at the HIT or the prescribed 
HIMAC dose of 10 Gy (RBE) per fraction currently used. Hence, regarding dose effect 
relationships for tumor and normal tissues caution is advised to compare clinical 
studies based on different RBE modeling approaches epsecially for hypofractionated 
treatment regimens. 
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IV.III. Proton RBE in treatment planning: gain in conformity 
The variability of the proton RBE is neglected for clinical application with the argument 
that it is rather small with a constant RBE of 1.1 and that critical structures can be 
spared by range margins and field configurations where the distal edge is not pointing 
towards an OAR. But this compromises precision and conformity of the treatment and 
sets some unnecessary restrictions to proton radiotherapy. Recently a treatment 
planning comparison of Tang et al. (2012) for prostate cancer treatment comparing 
anterior fields with the current standard of parallel-opposed lateral fields showed that 
anterior or anterior-oblique fields offer a better solution regarding organ sparing and the 
integral dose, but are not used so far due to the range uncertainty of the proton beam. 
At present in many proton facilities 3.5 % uncertainty of the proton range plus extra 
additional 1-3 mm is considered in treatment planning (Goitein 1985; Paganetti 2012). 
In the case of prostate treatments with proton ranges of approximately 15 cm this 
corresponds to more than a 5 mm extra range and would deliver high dose to the 
anterior rectal wall. One part of the range uncertainty could be attributed to the 
increased RBE at the distal edge. Gensheimer et al. (2010) identified an unexpected 
systematic overshoot of the proton beam in the treatment of medulloplastoma patients, 
which could not be explained on the basis of the expectation values discussed for the 
range extension in the paper. With the comparison of the LEM IV predictions to the 
results obtained by Gensheimer et al. (2010) we could show that the biological range 
extension accompanied by the increased RBE in the distal penumbra was 
underestimated by Gensheimer et al. (2010) and thus could explain the systematic 
overshoot. 
Instead to account for the increased RBE at the distal end of a proton SOBP and 
prevent the risk of high-LET dose contributions close to an OAR, homogenisation of the 
LET is considered (Paganetti 2013). However, the LET can only substantially 
homogenized by the application of parallel opposed fields possibly limiting the scope of 
field configurations and thus the sparing of critical structures as outlined by Tang et al. 
(2012). Taking the variable RBE along the SOBP into account would improve the 
accuracy of the treatment planning with protons and safety margins could be reduced. 
Another aspect why proton RBE should be considered for patient treatment like for the 
heavier ions is the potential false estimation of tolerance doses. For the RBE-weighted 
dose at the distal edge of the SOBP a considerable deviation from the clinically used 
constant RBE of 1.1 is expected in line with the results of in-vitro cell experiments 
(Courdi et al. 1994; Wouters et al. 1996; Tang et al. 1997; Bettega et al. 2000). The 
RBE can be more than twice as high leading to corresponding higher RBE-weighted 
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doses. Surprisingly, the increased proton RBE seems not to lead to severe side effects 
reflected in the NTCP. 
A potential explanation might be that actually tolerance doses are increased due to a 
volume effect related to the specific topology of the high-RBE volumes in ion beam 
therapy. The total high-RBE volume at the distal end of the treatment field is rather 
small and in general not a compact, but rather flat, shell-shaped volume. In order to 
assess potential volume effects, in clinical practice the tissue organization especially 
for OAR is often discussed in terms of serial or parallel organization (Källman et al. 
1992). The parallel organized tissues are supposed to show a rather proportional 
response to dose and volume irradiated whereas serial organized tissues are known to 
show rather a threshold response to irradiation (Withers et al. 1988; ICRU 1999a). 
Contradictory to the clinical dogma are the experiments reported by Bijl et al. with the 
rat spinal cord, a highly serial organized organ, which indicate a significant increase of 
the tolerance dose for very small volumes (Bijl et al. 2002; Bijl et al. 2003; van Luijk et 
al. 2005). A reason for this pronounced volume effect, although observed in serial 
organized tissue, could be the sufficient contact to the unirradiated normal tissue in the 
case of irradiated small volumes. This is also the case for the highly effective but thin 
shell-shaped irradiated volumes as they occur at the distal edge of a proton SOBP. The 
tolerance dose in that case could then be higher as compared to the same total volume 
having a more compact shape. This could also explain the marginal side effects seen 
for the temporal lobes in the pilot study with carbon ions even though higher doses are 
predicted by the LEM IV. Here again, only a small volume with a comparably flat 
topology, receives a very highly effective dose. According to the results reported by Bijl 
et al., the short distance to surrounding healthy tissue might lead to a more pronounced 
recovery and thus correspondingly higher tolerance doses. 
IV.IV. Importance of RBE robustness for clinical routine 
The robustness of treatment plans is an important issue in radiotherapy and for ion 
beam therapy this additionally means to keep RBE uncertainties small. Thus, reliable 
RBE model predictions are needed. Article 3 dealt with the LEM inherent sensitivity of 
the RBE prediction. Separately for each input parameter the RBE sensitivity was 
analyzed by means of a ± 25 % variation. The variation of RBE resulting from the 
parameter alteration turned out to be large but depends still less than proportional on 
the input parameters (article 3). However, in combination all parameters, which are 
independent on the experiment or clinical situation to be modeled, form a consistent 
input parameter set and systematic uncertainties of the LEM are minimized by a fit to 
experimental data taken from Furusawa et al. (2000) and Suzuki et al. (2000). We 
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found out that the uncertainty is mainly originating from the uncertainty of the photon 
input  parameters  α,  β  and  Dt. 
Consequently, this is not a specific problem for ion beam therapy, but a general 
problem of modeling, also in conventional photon therapy, since the description of the 
dose response relationship of cell- or tissue types to radiation relies on the knowledge 
of the LQ-parameters or any equivalent parameterization. Hence, in order to minimize 
the uncertainties accurate estimations of the α/β-ratio for the considered endpoint are 
required. For clinical endpoints also the inter-patient variability of dose response plays 
a role. The variable radiosensitivity can be taken into account by a mean value or by a 
parameter distribution. A parameter distribution implies the flattening of the sigmoid 
local control curve which is in better agreement with the local control probability 
observed in clinical trials with large patient numbers (Daşu   et   al.   2003;;   Kanai   et   al.  
2006). However, as shown in article 1 and article 3 a parameter variation, which also 
reflects an inter-patient variability, has a higher impact on the photon than on the ion 
beam dose response relationship. 
As shown in article 3 the RBE uncertainty is dependent on the absolute RBE. For 
clinical practice this can mean that a high RBE usually observed for heavy ions and 
small  photon  α/β-ratios also has larger uncertainties as compared to low-LET particles 
like   protons   and   tumors  with   a   high   photon   α/β-ratio, showing a small RBE but also 
correspondingly smaller uncertainties in the RBE. Hence, in this respect protons and 
heavier ions both have advantages for the clinical application. Heavier ions like carbon 
offer a beneficial high RBE in the target volume having a better sparing effect to the 
normal tissue but higher RBE uncertainty. In contrast, for protons the RBE is afflicted 
with less uncertainties. A promising method to decrease the RBE uncertainty, proposed 
in the literature, can be the homogenization of LET resulting in an overall reduction of 
the dose-mean LET1 (Krämer & Jäckel 2005; Bassler et al. 2010; Grassberger et al. 
2011; Böhlen et al. 2012). The reduction of the LET gradient within a carbon SOBP and 
thus the homogenization of the RBE-weighted dose comparing a single field iradiation 
to an irradiation with two opposing fields is demonstrated in fig. 1 of article 1. Hence, 
as also mentioned in subchapter IV.III, a homogenization of the LET relies on the 
application of multiple fields, at best, parallel opposed fields, but comprises higher 
integral dose compared to a single field irradiation. 
IV.V. Other RBE models 
The comparison of the LEM to other models potentially applicable in treatment planning, 
as, e.g., the microdosimteric kinetic model (MKM) (Inaniwa et al. 2010; Sato & 
                                               
1 Sum of the LET of each beam component weighted by its relative contribution to the total dose 
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Furusawa 2012) or the reformulation of the LQ-model presented by Carabe and Jones 
(Carabe-Fernandez et al. 2007; Jones et al. 2012) is of great interest. Especially the 
comparison with the MKM is promising since NIRS is now starting to use the MKM for 
the patient treatment together with a scanning system. One difficulty to compare 
different treatment planning approaches is that generally they differ in both the phyiscal 
description of the treatment field and the approach to estimate the RBE. However, the 
detailed comparison of the RBE models requires use of the same physical dose 
distributions. In article 2 a method is presented to compare the HIMAC approach, to 
the LEM approach by using the same physical depth dose profile. The physical dose 
was reconstructed based on TRiP98 with the aim to result in the same shape of the 
SOBP along depth. However, the differences in the beam modulation systems, i.e., 
passive vs. raster scanning system, were neglected. This can involve differences in the 
particle and fragment composition that might additonaly influence the RBE. Thus, it is 
of interest to use really identical physical dose distributions for the comparison of the 
LEM with the HIMAC approach and other RBE models. Steinsträter et al. (GSI project) 
implemented a method to apply other RBE models within the framework of TRiP98 and 
the underlying physical beam model, thus allowing for a direct comparison of the 
different biological modelling approaches. 
The model presented by Carabe and Jones for example, which is only applicable for 
protons, will be worth a comparison. In Carabe et al. (2012) they investigated the 
biological range extension based on this model in terms of tissue type and dose-level, 
similarly to our analysis (article 4). However, the results are qualitatively and 
quantitatively quite different since they even observe negative biological range 
extensions which imply an RBE smaller than 1.1 at the distal edge. In contrast to the 
LEM, the parameterization of RBEmax and RBEmin used by Carabe et al. (2012) can 
even lead to RBE values below 1. 
Furthermore, the dose dependence of RBE according to the model in Carabe et al. 
(2012) is inverted compared to the dose dependence predicted by the LEM. For the 
LEM the RBE is decreasing with increasing dose per fraction, which is in agreement 
with experimental results. This behaviour was demonstrated in article 4 by comparison 
of the LEM predictions with experimental results for different dose-levels as reported by 
Tang et al. (1997). Instead, the parameterization used by Carabe et al. (2012), i.e., 
RBEmin and RBEmax, shows a contradictory behaviour regarding their meaning. The 
parameter RBEmax which represents the RBE in the limit of small doses can be smaller 
than 1 for LET → 0. It can be even smaller than RBEmin, representing the limiting RBE 
value for very high doses, which has a limiting value of 1.09 for LET → 0. 
Consequently, this can lead to an increase of the RBE for increasing dose, and 
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therefore the dose dependence of RBE might be inverted compared to the LEM. Thus, 
further detailed comparison is needed to elucidate the impact of specific model 
properties on the RBE since it has a significant influence on the range extension of 
protons. 
IV.VI. Outlook 
The future direction of ion beam therapy goes towards the exploration of the 
advantages of different ion types. At HIT the application of oxygen and helium ions 
additional to carbon and protons is proposed (Jäkel et al. 2003). Brahme (2004) also 
discussed the flexibility of using different ion species in therapy matching with the 
treatment scenario and proposed the use of two to three different ions with low, 
intermediate and high LET, respectively. Oxygen ions offer the additional advantage of 
a high LET particularly effective to hypoxic tumors because of the reduced OER and to 
cancer stem cells (CSC) and can be an alternative to carbon ions (Durante 2014; 
Scifoni et al. 2013; Bassler et al. 2014). Helium ions are considered to have a RBE 
comparable to that of protons but show less lateral scattering in tissue and thus a 
better dose conformation. When comparing the various ion species the differential 
RBE-weighted dose between SOBP and entrance channel is an important measure 
since it defines the therapeutic window between a high local control of the tumor on the 
one hand and a reasonably small NTCP on the other hand.  
The work presented in this thesis demonstrated that the LEM IV is capable to give 
consistent RBE predictions for the clinical situation. The LEM can thus be used to 
assess the expected differential RBE-weighted doses, reflecting the therapeutic gain of 
a given treatment scenario. The differential effect depends on physical properties like 
depth dose profile or dose-level as well as on biological properties like the combination 
of tumor and surrounding tissue type. 
Protons for example show an overall lower RBE but a beneficial physical depth dose 
profile in terms of peak to entrance channel ratio compared to carbon ions. This is due 
to the fact that no projectile fragments are produced which contribute to the dose 
distribution. In this regard it should be noted that target fragments contribute to the 
dose as well, but are in general not yet considered in treatment planning. Up to now, 
only projectile fragments are considered in ion beam therapy. However, the biological 
effectiveness of these mainly low-energetic target projectiles is worth to investigate 
since especially for protons they may contribute to a slightly enhance RBE even in the 
entrance region.  
In addition to a much lower multiple scattering compared to protons, carbon ions are 
considered to show a high differential RBE. Thus, it needs to be elucidated for which 
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clinical cases the advantage of a high differential carbon ion RBE and of the better 
lateral dose conformation overcompensates the less beneficial longitudinal depth dose 
profile of carbon ions as compared to protons. Accordingly, ongoing work at GSI 
includes biological optimized treatment planning studies to compare therapy relevant 
ion species concerning their physical and biological properties with special regard to 
their therapeutic gain.  
A particular question arising in this framework is to what extent hypofractionation 
regimens influence the differential RBE. In general RBE is decreasing with increasing 
dose per fraction, and thus the differential effects are expected to be diminished for 
hypofractionation regimens. However, if tumor conformity is of primary concern, in any 
case carbon ions are expected to be favourable in particular for radioresistant and 
hypoxic tumors allowing to simultaneously reducing the integral dose and thus the 
burden to the normal tissue.  
A major challenge for the reliable estimation of RBE values at present remains the 
limited knowledge of the tissue characteristics in terms of radiosensitivity as commonly 
described by the photon α/β-ratio. This challenge, however, is not specific to ion beam 
therapy, but also is of relevance for conventional photon therapy. Since for a reliable 
RBE prediction a correct estimation of the photon dose-response parameters is 
essential, all the uncertainties concerning the dose response description inherent to 
conventional photon therapy are automatically transferred to ion beam therapy. Thus, 
RBE prediction can only be as good as the corresponding description of the tissue 
characteristics in terms of the photon dose-response parameters. Fortunately, in 
particular in the framework of stereotactic body radiation therapy (SBRT) a lot of efforts 
is put into studies to better characterize clinical dose-response relationships after 
photon radiation (Park et al. 2008; Wennberg & Lax 2013; Song et al. 2013). These 
studies mainly are motivated by the fact that the linear-quadratic model is not strictly 
valid at high doses, and thus the extrapolations based on the linear-quadratic 
parameters that are derived from lower doses per fraction are not expected to be 
accurate (Kirkpatrick et al. 2008; Otsuka et al. 2011). The better description of dose-
response curves at high doses perfectly fits to the needs for the application of the LEM, 
where also the input photon dose response curve is parameterized in the form of a 
modified linear-quadratic model, characterized by a transition to a purely linear shape 
at high dose. In that respect, further improvements in the estimation of clinical RBE 
values will largely profit from the analysis of clinical data performed in the framework of 
SBRT.  
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Abstract
Biological optimization for treatment planning in carbon ion therapy is
currently based on the first version of the local effect model (LEM I). Further
developments implemented in the latest version (LEM IV) allowed to predict
more accurately the Relative Biological Effectiveness (RBE) in-vitro. The
main goal of this study is to compare the LEM IV against LEM I under
treatment-like conditions for idealized target geometries. Therefore, physical
dose distributions resulting from the biological optimization with LEM I were
used to recalculate the RBE-weighted dose distribution based on LEM IV.
Input parameters representing the clinical endpoints late toxicity in the central
nervous system and the tumor control for chordoma were chosen to investigate
the impact of changes on the predicted isoeffective dose levels. The recalculated
RBE-weighted dose distributions show an increase within the target region,
and the mean RBE-weighted dose values are dependent on the geometry and
decrease with increasing target dimension. The differences between predictions
of LEM IV and LEM I are less than 10% for typical tumor volumes treated in
the pilot project at GSI. Median RBE-weighted doses predicted by LEM IV in
the target region are consistent with clinically observed dose-response behavior
as demonstrated by comparison to the 5-year local control curve for skull base
chordoma.
7 Present address: Siemens AG, Healthcare Sector, Erlangen, Germany.
0031-9155/12/227261+14$33.00 © 2012 Institute of Physics and Engineering in Medicine Printed in the UK & the USA 7261
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1. Introduction
Ion beam therapy requires accurate predictions of the relative biological effectiveness (RBE).
For treatment planning the clinical relevant RBE of ions in cells and tissue has to be considered
to obtain a homogeneous RBE-weighted dose within the target volume. In order to achieve
that goal, different strategies have been developed at Heavy Ion Medical Accelerator Japan
(HIMAC) and for the pilot project performed at the GSI Helmholtz Centre for Heavy Ion
Research (GSI). At HIMAC, an approach based on experimental in-vitro data in combination
with the clinical experience obtained with neutron beams has been implemented (Kanai et al
1997, 1999 and 2006). More recently, this approach has been extended by including biophysical
modeling to adapt the treatment planning to treatments using scanned beams (Kase et al 2006
and 2008, Inaniwa et al 2010).
For the GSI pilot project, the RBE of carbon ions was predicted by the Local Effect Model
(LEM I) in conjunction with the treatment planning software TRiP98 (Treatment Planning
for Particles, 98 edition) (Scholz et al 1997, Kra¨mer et al 2000, Schardt et al 2010). The
LEM can predict the biological effect of ions from the response of cells and tissues to photon
radiation. The analysis of the dose-response curves for local control of skull base chordoma
and normal tissue reactions observed in the pilot project suggest that the clinical results
can be expressed sufficiently accurate by the RBE predictions of the LEM I (Schulz-Ertner
et al 2007, Schlampp et al 2011). Experimental data, however, showed an overestimation of
the RBE-weighted dose for light ions in general and for carbon ions in the entrance channel
(Karger et al 2006, Elsa¨sser et al 2008). These differences were not crucial for treatment
safety, since the actual RBE-weighted dose in the entrance channel was less than predicted by
the model. Nevertheless, a better agreement with the experimental data is important for the
general applicability of the model in treatment planning, particularly also for other entities
like the RBE-weighted dose in the healthy tissue as well as systematic comparisons between
different tumor types and ion species.
Consequently, the LEM has been constantly improved with respect to biological
parameters and mechanisms. The LEM I (Scholz et al 1997) directly links the local dose
deposition pattern in the cell nuclei to the dose-response curve of photons. LEM II (Elsa¨sser
and Scholz 2007) and LEM III (Elsa¨sser et al 2008) keep on pursuing this approach. In the
recent version (LEM IV, Elsa¨sser et al 2010, Friedrich et al 2012) an intermediate step is
introduced: rather than the local dose, the complexity of the radiation damage in terms of
microscopic double-strand break distribution on the DNA is considered (Elsa¨sser et al 2010,
Friedrich et al 2012). This damage distribution pattern is assumed to better represent the
processes leading to the finally observed biological effect, and consequently should lead to a
better prediction of the RBE.
However, despite the changes in the model, predictions of the RBE-weighted dose for
the target regions should not be significantly affected to be consistent with the clinical results
obtained so far, since these have been demonstrated to be in agreement already with the LEM I
(Schulz-Ertner et al 2007, Schlampp et al 2011). The latest version of the model (LEM IV)
has already demonstrated a better description of in-vitro data (Elsa¨sser et al 2010, Friedrich
et al 2012) but has not yet been compared in detail with clinical results. Hence, the agreement
of the RBE predictions based on LEM IV with those of LEM I as well as with clinical data
is investigated. For the comparison with the clinical outcome for the treatment of chordoma
of the skull base with carbon ions in the GSI pilot project (Schulz-Ertner et al 2007) the
clinical endpoints late toxicity in the central nervous system (CNS) evaluated in the rat spinal
cord experiment (Karger et al 2006) and local control of chordoma evaluated from clinical
studies of hypofractionated photon radiotherapy (Henderson et al 2009) were considered for
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the RBE prediction. Idealized target volumes instead of real patient plans were used to point
out the major differences between LEM I and LEM IV. In patient plans other aspects like field
configuration, target geometries, margins and inter-patient heterogeneity could smear out the
difference between LEM I and LEM IV and make a systematic analysis difficult. Therefore
this study concentrates on a systematic analysis with idealized geometries rather than real
patient plans which can be transferred to the clinical situation in a further step. A detailed
analysis of the individual patient plans as well as the comparison of the LEM to other models
of the literature will follow in a separate publication.
2. Materials and methods
2.1. Treatment planning
To compare the predictions of LEM IV against LEM I under treatment-like conditions,
idealized target geometries (spheres and cubes) were used to facilitate the systematic
comparison of the different LEM versions. The cubic volume has a fixed lateral dimension of
50 × 50 mm but varies in its dimension along the beam axis. For the spherical volume, the
diameter varies between 20 to 100 mm (20 mm steps) and the target point along the beam axis
(center of volume) varied from 50 to 200 mm depth (50 mm steps). These target configurations
cover the whole spectrum of clinically relevant situations. Treatment plans consisted of two
directly opposing fields in line with the majority of field arrangements in the pilot project. The
treatment planning system TRiP98 was used to optimize the physical dose distribution with
the RBE predictions based on LEM I to achieve a homogeneous RBE-weighted depth dose
profile (Kra¨mer et al 2000).
For comparison with the previously published dose-response curve for chordoma of
the skull base treated in the GSI clinical trial (Schulz-Ertner et al 2007, Schulz-Ertner
et al 2002), the median (80.3 ml), minimum (13.9 ml) and maximum (594.2 ml) tumor
volumes representing the patient population were considered. For the analysis, volumes
close to the original ones expressed with spheres of 53.5, 29.8 and 104.3 mm diameter
respectively were used. These volumes refer to the subvolume (PTV2) of the initial planning
target volume (PTV1) to account for the macroscopic tumor as well as a safety margin for
localization uncertainty. For this analysis, PTV2 was assumed to cover 65% of PTV1, which
was a representative value for the patient population regarded. Treatments were performed
with 15 fractions to PTV1 and 5 fractions to PTV2. The RBE-weighted dose per fraction was
chosen as 3 Gy (RBE) and 3.5 Gy (RBE), corresponding to the clinically applied values
(Schulz-Ertner et al 2002).
2.2. RBE data
For clinical application, the LEM is used to calculate energy dependent RBE values for all
projectiles from protons to neon which are stored in a so-called ‘RBE-table’ and used as input
for the TRiP98 treatment planning program.
As the LEM derives the biological effect of ions from the dose-response to photon
radiation, the biological input parameters of the LEM are the parameters αγ , βγ and Dt
characterizing the photon dose-response curves according to the linear-quadratic model (LQ
model) and extended by the threshold dose Dt (Astrahan 2008) describing the transition into
a purely exponential shape (Elsa¨sser and Scholz 2007). The transition dose Dt is necessary
because the dose-response curve is needed up to very high doses since the LEM uses instead of
a macroscopic dose scale rather the local dose deposition within individual particle traversals.
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Table 1. Input parameters for the RBE tables.
RBE table LEM version αγ (Gy−1) βγ (Gy−2) αγ/βγ (Gy) Dt (Gy)
aAB2 I I 0.1 0.05 2 30
AB2 IV IV 0.003 0.0015 2 22
AB2.45 IV IV 0.0081 0.0033 2.45 30
a AB is the abbreviation for the photon αγ/βγ -ratio from the linear-quadratic formula with the
number representing the magnitude. The roman number represents the LEM version.
Thus the threshold dose Dt has to be considered even for small fraction sizes, i.e. 3–4 Gy (RBE),
to describe the photon-dose response up to high photon doses potentially needed.
For the analysis three different RBE tables were used (table 1) characterized by their αγ ,
βγ and Dt value. All other parameters of the LEM are kept constant and chosen as described
in Elsa¨sser et al (2010). RBE table AB2 I was used during the clinical trial at GSI. The
αγ/βγ -ratio of 2 Gy was selected as it is characteristic for late toxicity in the CNS (Karger
et al 2006). Since no data were available for photon αγ/βγ -ratios of chordoma tumors at the
beginning of the pilot project, the particular choice of αγ/βγ = 2 Gy also for chordomas has
been based on more general considerations concerning a potential correlation between the
αγ/βγ -ratio and tumor volume doubling times, as suggested e.g. by the clinical data reported
by Battermann et al (1981).
The RBE table AB2 IV calculated with the LEM IV is based on the same biological
endpoint, i.e. the same αγ/βγ -ratio of 2 Gy, but the biological input parameters αγ , βγ as
well as Dt were updated. Lower absolute values of αγ and βγ were chosen in accordance with
recent findings concerning the observed difference of the absolute LQ-parameters between
in-vitro and in-vivo endpoints independent on the tumor type (endpoint), i.e. the αγ/βγ -ratio
(Tai et al 2008, Henderson et al 2009).
Recently, also LQ-parameters for tumor control of chordoma became available from
clinical studies of hypofractionated photon radiotherapy (Henderson et al 2009); as we focus
on the analysis of the clinical results for chordoma of the skull base these are used for the third
RBE table AB2.45 IV, also calculated with the LEM IV. Here, Dt is increased in line with an
analysis of cell survival data suggesting an increase of Dt with increasing photon αγ/βγ -ratio
(Elsa¨sser et al 2008).
2.3. Evaluation of the treatment plans
The impact of the model enhancement was investigated based on a reference physical depth
dose profile obtained from a biological optimization using the LEM I (AB2 I). The resulting
physical depth dose profile is used as input for a recalculation of the RBE-weighted dose
based on the new model (AB2 IV and AB2.45 IV). Thus, the physical dose distributions
were identical for both profiles and differences in the RBE-weighted dose can be uniquely
attributed to the change of the LEM version. We focus here on the analysis of the target volume
because clinical data are available, in contrast to the entrance channel where the clinical data
are not yet available. Considering the dose volume histogram (DVH), the median and mean
RBE-weighted doses were regarded for statistical comparison.
2.4. Local control
To assess the impact of the model enhancement, the dose-response data for 5-year local control
of chordoma as compiled by Schulz-Ertner et al (2007) were reanalyzed by (i) replacing
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the clinical target geometries by the idealized PTV1 and PTV2, and (ii) by recalculating
the LEM I-optimized dose distributions with LEM IV using the RBE tables described in
table 1.
As the recalculated RBE-weighted dose distributions are inhomogeneous, the equivalent
uniform dose (EUD) can be used to further characterize the RBE-weighted dose distribution.
If in the case of tumor tissue the corresponding linear-quadratic parameters describe the cell
survival, the EUD can be determined from the mean or median survival S in the target volume
by
EUD = −(αγ /2βγ )+
√
− ln S/βγ + (αγ /2βγ )2, (1)
where αγ and βγ are the photon parameters of the LQ model (Niemierko 1997). Due to the
nonlinearity of the dose-response curve, dose fluctuations can have an increased impact on cell
survival. This is related to the linear-quadratic dependence of the dose-response curve. Strong
deviations from the planned target dose can therefore lead to a disproportionately higher or
lower survival rate becoming perceivable in the EUD. Also the median RBE-weighted dose
was considered as representative, since it reflects the EUD of the tumor in case of directly
opposing fields (Steinstra¨ter et al 2012).
For comparison with the dose response curve given in Schulz-Ertner et al 2007,
the obtained median RBE-weighted doses were recalculated to isoeffective doses using
a fractionation schedule of 2 Gy (RBE) per fraction (dref) according to Wambersie et al
(2006):
DIsoE = D · (1 + β/α · d)1 + β/α · dref , (2)
where d and D are the actually applied fractional and total RBE-weighted doses, respectively.
For the determination of the EUD and the isoeffective dose an αγ/βγ -ratio describing the
endpoint under consideration is needed; therefore the αγ/βγ -ratios associated with the RBE
tables described in table 1 were used.
3. Results
3.1. Dose analysis of idealized geometries
Using the RBE table AB2 IV for the RBE prediction results in an increase of the RBE-
weighted dose towards the distal end of the target volume as illustrated in figure 1(a). This
increase can be explained by the more detailed consideration of correlated double strand
breaks (DSB) within small subvolumes thus leading to a stronger variation of RBE with LET
and consequently a steeper gradient of RBE with depth compared to the LEM I. Moreover it
is shown that the shapes of the distal parts of the RBE-weighted depth dose profiles are the
same for all investigated target dimensions. This is due to the fact that the composition of
the distal part of the SOBP is not affected by adding Bragg peaks at the proximal part when
increasing the dimension of the SOBP, apart from an obviously minor contribution of lighter
fragments. When two opposing fields are used, as typically applied in the GSI clinical trial, the
gradient of the RBE-weighted dose throughout the target region is substantially diminished,
(figure 1(b)). The degree of RBE homogenization decreases with increasing target dimension.
The configuration with opposing fields leads to the largest LET-homogenization compared
to other field configurations like for example a single field or (right) angled fields. Thus
for the opposing fields also the largest RBE gradient compensation is observed. For non-
opposing field configurations, i.e. angled fields, a less pronounced compensation is expected.
For different depth localizations, only minor differences in the shape of the RBE-weighted
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(a) 
(b) 
Figure 1. (a) Physical and RBE-weighted depth dose profiles resulting from RBE predictions with
the RBE tables AB2 I (100 mm diameter) and AB2 IV. Illustrated is one out of two fields for
different spherical target volumes with 20, 60 and 100 mm diameter and an discounter at 100 mm.
(b) Superposition of two opposing fields for the same geometrical arrangements as in (a).
depth-dose profiles are observed (data not shown). In table 2 RBE-values for the RBE-tables
described in table 1 for an SOBP of 60 mm dimension from 75 to 125 mm depth as shown in
figure 1(a) are tabulated to provide detailed information of the RBE for different dose-levels.
In figure 2, the corresponding mean RBE-weighted doses are plotted as a function of the
target dimension. For RBE predictions with AB2 IV, the mean RBE-weighted dose decreases
with increasing dimension. This can be explained by the underestimation of the RBE-weighted
dose as compared to LEM I in the center of the target volume which is increasingly composed
of dose contributions with photon like efficiency leading to a decreased RBE and thus leading
to an overall decrease in the mean RBE-weighted dose. Consequently, the RBE-weighted dose
variation as expressed by the standard deviation increases with increasing dimension (3–7%).
As suggested before, the shape of the target volume has an impact on the RBE-weighted dose
too. For the spherical volumes a higher RBE-weighted dose is observed as compared to the
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Figure 2. Mean RBE-weighted dose, equivalent uniform dose (EUD) and the corresponding
standard deviations for the different spherical and cubic target dimensions at an discounter depth
of 100 mm.
Table 2. RBE-values for the RBE-tables described in table 1 for an SOBP of 60 mm dimension
from 75 to 125 mm depth as shown in figure 1(a).
AB2 IV AB2.45 IV AB2 I
Prescribed
dose cProximal Distal Mean Proximal Distal Mean Proximal Distal Mean
3 aGy (RBE) 2.13 9.59 4.71 2.11 10.40 4.98 3.047 4.45 3.57
0.5 bGy 2.09 8.61 4.19 1.00 9.18 4.27 3.69 4.99 4.19
1 Gy 1.80 6.45 3.30 1.75 6.92 3.40 2.96 3.86 3.30
2 Gy 1.53 4.75 2.56 1.52 5.13 2.66 2.33 2.93 2.56
5 Gy 1.26 3.13 1.83 1.27 3.40 1.92 1.70 2.011 1.82
10 Gy 1.13 2.28 1.45 1.14 2.48 1.52 1.38 1.52 1.43
aThe unit Gy (RBE) describes an optimized RBE-weighted dose.
bThe unit Gy describes an optimized physical dose.
cRBE-values are shown for the proximal end (75 mm) and the distal end (125 mm) as well as the mean value from
175 to 125 mm depth.
cubic volumes for a given dimension. Besides the mean RBE-weighted dose also the median
is calculated and shows no significant deviation (<3%) from the mean (data not shown).
Apart from the agreement of mean or median RBE-weighted doses as described above,
it is of interest to assess the potential impact of the heterogeneity of the RBE-weighted dose
distribution in individual fields. Hence, also the equivalent uniform dose (EUD) calculated
from the mean cell survival was analyzed (Niemierko 1997). The EUD shows only slight
deviations from the mean and median RBE-weighted dose (figure 2). This suggests that the
heterogeneity of the RBE-weighted dose distribution has no particular impact in terms of
disproportional higher or lower overall effect resulting from an over- or underestimation of
the RBE-weighted dose distribution at the distal and proximal end of the target volume,
respectively.
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Figure 3. Physical and RBE-weighted depth dose profiles resulting from the RBE predictions with
the RBE tables AB2 I and AB2 IV with an optimized RBE-weighted dose of 15 × 3 Gy (RBE)
to PTV1 (Ø 61.8 mm) and additional 5 × 3 Gy (RBE) to PTV2 (Ø 53.52 mm) using AB2 I.
3.2. Local control analysis
Comparison of local control rates with other treatment modalities like e.g. modern photon
techniques or proton treatments requires the accurate estimation of RBE values. For the
clinical evaluation of the LEM IV the consistency of the predicted RBE-weighted dose with
the dose-response curve for local control of skull base chordoma as reported by Schulz-Ertner
et al (2007) is important. For this purpose the isoeffective dose for the reference fractionation
schedule of 2 Gy per fraction was chosen to compare different studies in the literature (Schulz-
Ertner et al 2007).
A RBE-weighted target dose of 60 Gy (RBE) in 15+5 fractions of 3 Gy (RBE) and
the linear quadratic parameters corresponding to the RBE table A2 I lead to an isoeffective
dose of 75 Gy (IsoE) for a fraction size of 2 Gy in PTV2. The corresponding tumor control
probability of 63% has shown to be in good agreement with the results obtained in studies
using photon and proton treatments, thus indicating that the estimation of RBE based on LEM
I was sufficiently accurate.
When analyzing the impact of the transition to LEM IV, the dependence on the target
dimensions as illustrated in figure 2 has to be taken into account. Recalculations of the median
isoeffective dose based on the RBE tables AB2 IV and AB2.45 IV were thus performed
for idealized PTV1 and PTV2 (spheres). Figure 3 illustrates the physical and RBE-weighted
dose distributions as applied in 15 + 5 fractions leading to 60 Gy (RBE) in the idealized
PTV2 of 78.3 ml, representing the median value of the patient population (Schulz-Ertner et al
2007).
Furthermore, the local control rates of the original clinical collective (Schulz-Ertner et al
2007) are plotted against the median isoeffective doses predicted here for the idealized PTV2.
These response data points are then compared with the mentioned dose response curve for
local control of chordoma (figure 4), which also includes the original response data points from
the GSI pilot project (LEM I based doses). Note that the median isoeffective doses attributed
to the local control rates within the other studies refer to the median dose applied in the patient
population whereas the recalculated doses refer to the median isoeffective dose within the
above-described idealized PTV2.
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(b) 
Figure 4. TCP curve published in Schulz-Ertner et al (2007) with reanalyzed data points referring
to the median isoeffective dose achieved with (a) the RBE table AB2 IV and (b) AB2.45 IV for a
idealized PTV2 of 78.3 ml and corresponding PTV1 as well as for a PTV2 of 13.6 ml and 578.9 ml
to show the dependence of the isoeffective dose on the target volume dimension.
3.3. Sensitivity
To assess the uncertainties of the photon input data, the sensitivity on variations of αγ , βγ and
Dt was analyzed (table 3). The RBE-weighted dose was therefore optimized to 3 Gy (RBE)
with the corresponding reference RBE-table.
Changing the parameters by 25% results in variations of the RBE-weighted dose by less
than 10%, which is in the order of the scatter of the clinical data around the adjusted TCP
curve in figure 4. This is thus considered to be sufficiently robust for clinical application.
4. Discussion
To fully exploit the potential advantages of ion beams for therapy requires to prospectively
estimate the RBE as accurately as possible for treatment planning. Biophysical models
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Table 3. Sensitivity analysis for a 60 mm extended Bragg-peak spreaded from 120 to 180 mm.
Reference Mean Photon input
RBE-table (Gy(RBE)) parameters LEM Modification (%) △RBE-weighted dose (%)
AB2 IV 2.99 αγ +25 −4.7
−25 +3.4
βγ +25 +2.4
−25 −4.7
Dt +25 +7.4
−25 −9.4
AB2.45 IV 2.99 αγ +25 −5.2
−25 +5.5
βγ +25 +3.5
−25 −6.1
Dt +25 +5.5
−25 −8.0
represent a powerful tool to achieve this goal and have been demonstrated to allow RBE
predictions with reasonable accuracy for different endpoints in-vitro (Elsa¨sser and Scholz
2007, Inaniwa et al 2010), in-vivo (Karger et al 2006, Debus et al 2003) and for clinical
applications (Schulz-Ertner et al 2007, Schlampp et al 2011). Nevertheless, the first version of
LEM I implemented in the treatment planning for the GSI pilot project has been shown to have
certain limitations with respect to the accuracy of the RBE predictions in the entrance region
and for lighter particles like e.g. protons. Subsequent enhancements of the LEM have been
demonstrated to substantially improve the accuracy of the model in biological experiments
(Elsa¨sser and Scholz 2007, Elsa¨sser et al 2008, Elsa¨sser et al 2010, Friedrich et al 2012).
In agreement with experimental data the latest version, LEM IV, predicts a more
pronounced increase of RBE with LET as compared to the LEM I. This leads to the
inhomogeneity and the rise of the RBE-weighted dose towards the distal end of the target
volume, when the RBE-weighted dose is obtained from the physical dose resulting from the
optimization based on LEM I.
In order to estimate the clinical impact of this more pronounced RBE gradient it is
important to assess the accuracy of the model predictions for clinically relevant endpoints, e.g.
late effects in the CNS. Experiments analyzing the tolerance of the rat spinal cord according
to Karger et al (2006) revealed that the RBE predicted with the LEM I was underestimated by
about 25% in the Bragg-peak region. Using instead the LEMIV-based RBE table AB2 IV with
LQ-parameters describing the dose response behavior in the experiment of Karger et al (2006)
results in a higher RBE which is in much better agreement with the measured values (figure 5).
In line with the in vitro data presented in Elsa¨sser et al (2010), this further demonstrates the
improvement of the LEM IV as compared to the LEM I also for in vivo data.
Consequently, the question arises whether this steeper gradient of the RBE and the
resulting inhomogeneity of the RBE-weighted dose distribution would be clinically significant
when reanalyzing the clinical results obtained in the clinical trial with carbon ions at GSI.
Here it is important to note that large parts of the inhomogeneity are already compensated
when using two opposing fields, representing the typical situation for the chordoma patients
treated at GSI. The remaining inhomogeneity and the corresponding difference of the mean
RBE-weighted dose as compared to the LEM I prediction primarily depend on the shape and
dimension of the target volume.
For typical tumor volumes as treated within the pilot project, the mean values of the
RBE-weighted dose according to LEM IV are very similar compared to those of LEM I
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Figure 5. RBE distribution predicted with (a) the RBE table AB2I and (b) the RBE table AB2
IV for the irradiation of the spinal cord in rats according to Karger et al (2006) compared to the
measured RBE (position uncertainty: ± 2 mm within SOBP). Note that the scales in (a) and (b)
differ.
(table 2, figure 2). When taking into account the distribution of tumor volumes for a typical
patient population, the smaller volumes would get a larger RBE-weighted dose, whereas for
the larger volumes a lower RBE-weighted dose would be expected. This could have an impact
on the local control probability of individual patients. In a population-based clinical analysis,
however, this larger spread would probably not be detectable within the other uncertainties
like e.g. inter-patient heterogeneity of radiation sensitivity, and thus the agreement in the mean
values is most important here.
The reanalysis of the isoeffective dose clearly indicates that the transition from LEM I to
LEM IV would have no significant impact on the TCP dose-response curve. Since the LQ-
parameters αγ and βγ published in Henderson et al (2009) are very low and also the absolute
values published in Tai et al (2008) for liver cancer are lower than comparable in-vitro data we
concluded a trend towards lower absolute values for in-vivo endpoints compared to in-vitro.
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We demonstrated with this study that the dose-response behavior in terms of local control
for chordoma and late effects in the CNS can be well described with lower absolute values
independent on the αγ/βγ -ratio. Therefore, the RBE values predicted with LEM IV and the
RBE tables AB2 IV as well as the AB2.45 IV with updated parameters are consistent with the
available clinical data for local control of chordoma (Schulz-Ertner et al 2007).
Besides comparison of the different LEM model versions, comparison to other models
potentially applicable in treatment planning, as e.g. the MKM (Inaniwa et al 2010) or RMF
(Carlson et al 2008, Frese et al 2012) would be of interest. However, at present a direct
comparison of models on the basis of published results is mainly hindered by the fact that the
different biological models are used in combination with different physical models that are
required to characterize the radiation field. For example, Frese et al (2012) use the RFM in
combination with a simple physics model that completely neglects nuclear interactions and
beam fragmentation. Inaniwa et al (2010) use the MKM in combination with a more realistic
physics model based on Geant4, which might however differ from the approach implemented in
TRiP98. As a consequence, differences in RBE predictions cannot be uniquely attributed to the
different biological models, but might also arise from the differences in the underlying physics
description. We are thus currently implementing an interface to the TRiP98 environment that
will allow to use any biological model that is capable of predicting dose response curves as
a function of the particle species and energy or LET. With that, the different models can be
compared on the basis of exactly the same physical composition of the radiation field.
The analysis presented here is based on idealized volumes (spheres and cubes) and
focuses on a general understanding of the main trends. It remains to be elucidated in how
far the conclusions from these idealized geometries can be transferred to the situation of real
patient treatment plans. Therefore, LEM IV based recalculations of patient treatment plans are
currently performed (Gillmann 2011). Similarly, the impact of the model enhancement on the
analysis of normal tissue complications as reported by Schlampp et al (2011) will be assessed.
As a consequence of the differences between LEM I and LEM IV, biological optimization
in treatment planning based on LEM IV would lead to an increase of the physical dose in the
center of the target volume and a reduction of the physical dose at the border as compared to
an optimization with LEM I. Implementation of the LEM IV and the replacement of LEM I
in treatment planning thus requires a thorough clinical assessment of the balance between the
potentially higher effect in the center and reduction of the effect at the field boarders.
5. Conclusion
The differences in the prediction of RBE-weighted doses and isoeffective doses between
LEM I and LEM IV for typical tumor volumes, i.e. averaged over the patient population
in the GSI pilot project, are less than 10%. Thus, based on the analysis of idealized target
geometries, the transition to LEM IV is not expected to lead to significant differences of the
TCP dose-response relationship for chordoma as compared to the analysis based on LEM I.
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Summary
A method was developed to
convert clinically prescribed
RBE (Relative Biological
Effectiveness)-weighted
doses from the approach used
at the Heavy-Ion Medical
Accelerator facility (HIMAC;
National Institute of Radio-
logical Science, Japan) to the
Local Effect Modelebased
approach used at GSI Helm-
holtzzentrum, Germany, and
other centers. For interpreta-
tion and comparison of clin-
ical trials, this conversion is
of extreme importance
because, given the different
methods to determine the
RBE-weighted dose, similar
dose values might not neces-
sarily be related to similar
clinical outcomes.
Purpose: A method was developed to convert clinically prescribed RBE (Relative Biological
Effectiveness)-weighted doses from the approach used at the Heavy-Ion Medical Accelerator
(HIMAC) at the National Institute of Radiological Science, Chiba, Japan, to the LEM (Local
Effect Model)-based TReatment planning for Particles (TRiP98) approach used in the pilot
project at the GSI Helmholtzzentrum, Darmstadt, and the Heidelberg Ion-Beam Therapy Center
(HIT).
Methods and Materials: The proposed conversion method is based on a simulation of the fixed
spread-out Bragg peak (SOBP) depth dose profiles as used for the irradiation at HIMAC by
LEM/TRiP98 and a recalculation of the resulting RBE-weighted dose distribution. We present
data according to the clinical studies conducted at GSI in the past decade (LEM I), as well as
data used in current studies (refined LEM version: LEM IV).
Results: We found conversion factors (RBE-weighted dose LEM/RBE-weighted dose HIMAC)
reaching from 0.4 to 2.0 for prescribed carbon ion doses from 1 to 60 Gy (RBE) for SOBP exten-
sions ranging from 20 to 120 mm according to the HIMAC approach. A conversion factor of 1.0
was found for approximately 5 Gy (RBE). The conversion factor decreases with increasing
prescribed dose. Slightly smaller values for the LEM IVebased data set compared with LEM I
were found. A significant dependence of the conversion factor from the SOBP width could be
observed in particular for LEM IV, whereas the depth dependence was found to be small.
Conclusions: For the interpretation and comparison of clinical trials performed at HIMAC and
GSI/HIT, it is of extreme importance to consider these conversion factors because according to
the various methods to determine the RBE-weighted dose, similar dose values might not neces-
sarily be related to similar clinical outcomes. ! 2012 Elsevier Inc.
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Introduction
Starting in 1994 and 1997, respectively, extensive clinical studies
on carbon ion radiotherapy have been conducted at the National
Institute of Radiological Science (NIRS), Chiba, Japan (1) and at
the GSI Helmholtzzentrum fu¨r Schwerionenforschung, Darmstadt,
Germany (2). To draw maximal benefit from these studies,
a common basis for the mapping between center-related beam
parameters and clinical outcomes should be established.
Although at both centers the treatment plans were based on the
concept of RBE (Relative Biological Effectiveness)-weighted
doses, the approaches to estimate these doses are quite different,
strongly influenced by the different beam delivery systems. At
HIMAC, the RBE-weighted dose is derived from an empirically
established equivalence between carbon and neutron beams
exploiting experiences with neutron radiation therapy at NIRS (3).
For the pilot project at GSI, a radiobiological model, the Local
Effect Model (LEM) (4e7) has been developed that derives RBE
values from experimental data available for photons.
Because of the different methods to relate RBE-weighted and
physically absorbed dose, the same clinically prescribed RBE-
weighted dose will typically not result in the same depth dose
distribution at the two centers. Clinical outcomes are therefore not
necessarily comparable if the given RBE-weighted doses are identical.
In this study, we provide a method to convert between
a prescribed RBE-weighted dose as realized at NIRS and the dose
specification based on the LEM used for treatment planning at
GSI and other centers (e.g., Heidelberg Ion-Beam Therapy Center
[HIT], Particle Therapy Marburg, NRoCK Kiel, CNAO Pavia,
Shanghai Heavy Ion Therapy Center).
Methods and Materials
Methods to determine the RBE-weighted dose at
NIRS and GSI
The HIMAC irradiation system uses passive beam shaping (3):
starting with a fixed beam energy, shape and depth of the spread-
out Bragg peak (SOBP) are adjusted by a ridge filter designed
to reach a uniform survival fraction of 10% for human salivary
gland tumor (HSG) cells inside its nominal SOBP width.
If Dðz; 10%HSGÞ is the physical depth dose distribution of the
filter design (z the water equivalent depth), the physical dose
Dðz; dHIMACpresc Þ used at HIMAC for irradiation according to the
clinically prescribed RBE-weighted dose, dHIMACpresc , is given by
D
!
z;dHIMACpresc
"
ZlHIMACpresc Dðz;10%HSGÞ; ð1Þ
with a factor lHIMACpresc depending on the prescribed dose d
HIMAC
presc .
The calculation of lHIMACpresc is based on the neutron-equivalent depth
zneutron inside the SOBP, where the carbon beam is biologically
equivalent to the NIRS neutron beam (30 MeV deuteron projec-
tiles on beryllium target) (3). For HSG cells at 10% survival level,
zneutron can be identified by an RBE of 2.0 (3):
Dðzneutron;10%HSGÞZD
RBEð10%HSGÞ
2:0
: ð2Þ
Here, DRBEð10%HSGÞ Z 4.0359 Gy (RBE) (according to
Kanai et al. (8): aZ0:3312 Gy#1, bphotonZ0:0593 Gy
#2) is the
constant RBE-weighted dose within the SOBP.
The clinically determined RBE for the therapeutic neutron
beam at NIRS was determined to 3.0 (3), and for a given
prescribed dose dHIMACpresc , this results in
D
!
zneutron;d
HIMAC
presc
"
ZdHIMACpresc =3:0 ð3Þ
at the neutron-equivalent position. Combining Eqs. 1, 2, and 3
leads to
lHIMACpresc Z2=3
dHIMACpresc
DRBEð10%HSGÞ: ð4Þ
In contrast to the passive HIMAC irradiation system, at GSI
a magnetic scanning system together with active energy variation
is used (9). Starting with a clinically prescribed RBE-weighted
dose, dLEMpresc, for the tumor volume, the treatment planning
system TRiP98 (TReatment planning for Particles) is used to
derive an individually optimized physical depth dose profile
(9e11). A detailed description of the radiobiological response of
the irradiated tissue is needed for this optimization and provided
to TRiP98 by an externally calculated data set (we use the term
“RBE table” in this article) containing RBE information for each
relevant ion type (carbon and possible fragments) and energy. An
RBE table is individually derived from photon response data of
the irradiated tissue by means of the Local Effect Model (LEM);
the TRiP98 optimization results thus strongly depend on the
particular choice of this input data set. This study is mainly based
on the extended LEM version recently proposed by Elsa¨sser et al.
(7), here termed LEM IV. In addition, because the clinical data
collected at GSI in the past decade was based on a previous
version (4), LEM I, we also show results based on this version.
The biological basis of LEM-based RBE tables can be charac-
terized by three parameters: aphoton and bphoton describing the linear
and quadratic part of the Linear Quadratic (LQ) model, respec-
tively, and Dt marking the high-dose transition from linear-
quadratic to purely linear dose response, in accordance with (12).
A LEM calculation additionally needs the effective radius of the
cell nucleus, but for all RBE tables discussed in this article, a fixed
radius of 5 mm was assumed.
Conversion between RBE-weighted dose
specifications used at NIRS and GSI
We based our conversion method on a reconstruction of the physical
dose distributions used at NIRS by the GSI treatment planning
system. Because of the different beam delivery systems, the physical
composition of the beams may be different even though the physical
dose is identical; however, it was shown that for comparable depth-
dose profiles, the biological effects are also comparable (13).
Following the requirements used to design the ridge filters at
NIRS, TRiP98 was used to optimize SOBPs from 20 mm to 120
mm (step size 20 mm) and for the three depths reported by Kanai
et al. (3) for a survival level of 10% for HSG cells (photon
parameters (7): aphotonZ0:3130 Gy
#1, bphotonZ0:0615 Gy
#2,
DtZ7:5). Although the relative shapes of the calculated depth
dose profiles were found to be in good agreement with the results
reported in Kanai et al. (3), the absolute dose values were slightly
higher than the measured values. Therefore, an additional scaling
factor mZ 0.88, determined by a least square fit, was applied. The
need for a scaling factor might be attributed to long-term variation
of cellular sensitivity of the HSG cells, as also discussed by
Inaniwa et al. (14), and the corresponding change in the photon
parameters a and b. However, because the main aspect of the work
Volume 84 $ Number 3 $ 2012 Mapping between HIMAC- and LEM-based treatment planning 855
presented here is to accurately reproduce the absorbed depth dose
profile, we preferred to use biological input parameters consistent
with our previous work and to optimally adapt the depth dose
profile by the scaling procedure. The solid curves in Fig. 1
compare the reconstructed dose distributions (including the
scaling factor m) with the measurement results (symbols). For the
120 mm SOBP in Fig. 1a also the unscaled result is displayed as
a dashed curve. The beam energies reported in Fig. 1 are taken
from Kanai et al. (3) and are connected to the HIMAC irradiation
system. At GSI, discrete numbers of pencil beams with different
energies are superimposed to form the SOBP. The reconstructed
SOBPs are therefore parameterized by the according SOBP depth
(position of the distal end) also reported in the figure: 160 mm for
panel a, 220 mm for panel b, and 275 mm for panel c.
Fig. 1. Comparison of LEM IV/TRiP98 reconstructed SOBPs (solid and dashed curves) for carbon ion irradiation to experimental results for
HIMAC (symbols) published by Kanai et al. (3) (their fig. 8ae8c). HIMAC data were available for six SOBP widths (20e120 mm) and three
depths expressed as primary beam energies (according to the HIMAC system): 290MeV/u (160 mm) in panel a, 350MeV/u (220 mm) in panel
b, and 400 MeV/u (275 mm) in panel c. The preoptimized LEM IV/TRiP98 results (panel a shows an example as dashed curve) were scaled by
a common factor of mZ0:88 (solid curves) to fit the HIMAC requirements (symbols) in a least square sense. The curves shown are used as
models for the SOBPs realized at HIMAC in our conversion method. HIMACZ Heavy-Ion Medical Accelerator facility, National Institute of
Radiological Science, Japan; LEMZ Local Effect Model; SOBPZ spread-out Bragg peak; TRiP98Z TReatment planning for Particles.
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For a given SOBP width w and depth h (distal end of the
SOBP), the reconstructed physical dose distribution
Dw;hðz; 10%HSGÞ can now be used to convert between HIMAC-
and LEM-based prescribed RBE-weighted doses, dHIMACpresc /d
LEM
presc,
by using TRiP98 and LEM to estimate the RBE-weighted dose
distribution DRBEw;h ðz; dHIMACpresc Þ connected with the physical dose
distribution Dw;hðz; dHIMACpresc ÞZlHIMACpresc Dw;hðz; 10%HSGÞ (see Eqs. 1
and 4). The TRiP98 calculation and therefore also the actual
mapping between dHIMACpresc and d
LEM
presc depends on the RBE table
provided by LEM, i.e., on the selected LEM version and more
fundamentally on the underlying tissue type and biological
endpoint.
DRBEw;h ðz; dHIMACpresc Þ is not necessarily flat within the SOBP. In
this study, we therefore calculated the median dLEMmedian of
DRBEw;h ðz; dHIMACpresc Þ across the SOBP as representative for dLEMpresc.
At GSI, an actual treatment plan parameterized by dLEMpresc tries to
realize a flat profile of the RBE-weighted dose inside the tumor.
The clinical comparability of the treatment plans connected with
dHIMACpresc and d
LEM
presc therefore depends on the homogeneity of
DRBEw;h ðz; dHIMACpresc Þ. In addition to dLEMpresc, we will therefore also report
DRBEw;h ðz; dHIMACpresc Þ at the proximal and distal end of the SOBP: dLEMprox ,
dLEMdist . To avoid instabilities due to slight oscillations at the prox-
imal part of the dose distributions resulting from the optimization
procedure, instead of the actual dLEMprox , in the Results section, we
report the value found for a linear approximation of
DRBEw;h ðz; dHIMACpresc Þ restricted to the first third of the SOBP.
Impact of tissue characteristics
The actual mapping depends on the RBE tables derived from the
measured photon responses by means of the LEM. We present
results based on two RBE tables, both representing tissues with
a=bZ2 Gy as characteristic for late effects in the central nervous
system. The first table was actually used during the clinical trials
at GSI and was based on LEM I and aphotonZ0:1 Gy
#1,
bphotonZ0:05 Gy
#2, and DtZ30 Gy. The second RBE table was
derived according to LEM IV with aphotonZ0:0030 Gy
#1,
bphotonZ0:0015 Gy
#2, and DtZ22 Gy. In addition to the LEM
version here, the photon based tissue parameters were also
updated to better reflect the differences in the order of magnitude
of the LQ parameters between in vitro and clinical endpoints as
discussed, for example, by Tai et al. (15).
Results
Shape of the RBE-weighted dose distributions
In Fig. 2, RBE-weighted dose profiles calculated by TRiP98 for
three prescribed doses and both LEM versions are shown. For an
improved visualization, only 120-mm SOBPs are displayed.
In Fig. 2a results for LEM I are shown. Around 6 Gy (RBE),
where the scaling factor lHIMACpresc is approximately 1, the profile is
nevertheless not flat but shows a slight depression at the distal end
of the SOBP. This depression increases with increasing dHIMACpresc ,
but even for 10 Gy (RBE), the deviation from the intended flat
profile can be considered moderate and the median should be
a representative quantity to relate prescribed doses between NIRS
and GSI: dLEMpresczd
LEM
median.
Figure 2b shows results based on LEM IV. The peak at the distal
end of the SOBP can be explained by the use of the refined Local
Effect Model, resulting in a more pronounced increase of the RBE-
weighted dose with depth compared with LEM I. This was desirable
because it was known that LEM I underestimates this gradient (5, 16).
Although the deviation from the flat distribution in the target is
larger in Fig. 2b than in Fig. 2a, the median is still a reliable
quantity for the description of the clinical effect of the irradiation.
This has also been analyzed by calculating the corresponding
equivalent uniform dose (EUD) (17). The deviation between EUD
and median were typically found to be <5%. Only for very high
dose levels and for LEM I, larger difference were observed (see
Table 1). We therefore again assume dLEMpresczd
LEM
median.
Conversion factors
The conversion factors dLEMpresc=d
HIMAC
presc are shown as solid black
curves in Fig. 3a and 3b for LEM I and LEM IV, respectively. They
are close to 1 around dHIMACpresc Z5 Gy (RBE) and can be significantly
higher at low doses and significantly lower at high doses. For both
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Fig. 2. RBE-weighted dose profiles for carbon ion irradiation
calculated by TRiP98/LEM for three scalings lHIMACpresc ðdHIMACpresc Þ of
the physical dose distribution of the 120-mm SOBP shown in
Fig. 1b: dHIMACpresc Z1 Gy (RBE), 6 Gy (RBE), and 10 Gy (RBE).
The conversion to LEMebased RBE-weighted doses depends on
the underlying RBE tables: in panel a, the calculations are based
on LEM I, and in panel b results for the same calculations based
on LEM IV are shown. HIMAC Z Heavy-Ion Medical Acceler-
ator facility, National Institute of Radiological Science, Japan;
LEMZ Local Effect Model (versions I and IV); RBEZ Relative
Biological Effectiveness; SOBP Z spread-out Bragg peak;
TRiP98 Z TReatment planning for Particles.
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LEM versions, the conversion factor was monotonically decreasing
with increasing dHIMACpresc . In Fig. 3c, LEM I and LEM IVare directly
compared, but in contrast to panels a and b, absolute values, dLEMpresc,
are shown here. For LEM I, slightly larger dLEMpresc were observed, but
in general, the differences were found to be small. In addition, both
curves appear as straight lines in the double-logarithmic plot.
Therefore, at least for the presented RBE tables, dHIMACpresc /d
LEM
presc
can be approximated by a power law, dLEMpresczA,ðdHIMACpresc ÞB, with
only two needed parameters, A and B.
Homogeneity of the RBE-weighted dose
distributions
Figures 3a and 3b additionally include the values found at the
proximal and distal ends of the SOBPs as relative values
(dLEMprox =d
HIMAC
presc , d
LEM
dist =d
HIMAC
presc ). Absolute values for these quantities
and numerical values for dLEMpresc=d
HIMAC
presc and d
LEM
presc are shown in
Table 2. Consistent with Fig. 2a and 2b, the values for the prox-
imal ends were found close to the median, whereas the deviations
to the distal ends were significantly larger. Figure 3b shows even
larger deviations from a homogeneous dose profile at the distal
end than Fig. 3a. Consistent with Fig. 2b, this indicates relative
high distal peaks found for lower dHIMACpresc . Differences between
LEM I and LEM IV are also found toward very high doses, where
the LEM IV curves converge, whereas LEM I curves run parallel.
However, the values at high doses must be taken with some
caution, because the LEM/TRiP98 predictions are based on an
approximation where the b values of the doseeresponse curve are
estimated from the effects of single particle traversals (10).
This approximation is expected to be sufficiently accurate at least
in the dose range below 10 Gy. A more detailed analysis of the
quality of this approximation at high doses is currently under
investigation (18). The courses of the LEM based RBE-weighted
dose for dHIMACpresc > 10 Gy (RBE) may therefore be less exact than
for the clinically more relevant lower doses.
Influence of the width of the SOBP
Figure 4 shows the conversion factor for different SOBP widths
from 20 to 120 mm. At least for small dose levels, dHIMACpresc , the
dependence on the SOBP width is significantly larger for LEM IV
compared with LEM I. Whereas in Fig. 4a the dependence on the
SOBP width slightly increases with increasing dHIMACpresc , we
Table 1 Comparison of median and EUD calculated for
LEM estimated RBE-weighted dose distributions in depen-
dence of prescribed HIMAC RBE-weighted doses, dHIMACpresc , for
60-mm SOBPs (depth according to Fig. 1b) and both RBE
tables (LEM I/LEM IV)
Prescribed
RBE-weighted
dose HIMAC,
Gy (RBE)
RBE-weighted
dose LEM, Gy (RBE)
LEM IV LEM I
Median EUD Median EUD
1 1.65 1.73 1.76 1.74
2 2.65 2.76 2.80 2.78
3 3.46 3.59 3.64 3.61
4 4.17 4.31 4.37 4.33
5 4.81 4.97 5.03 4.98
6 5.41 5.58 5.64 5.58
7 5.98 6.15 6.22 6.15
8 6.52 6.70 6.77 6.69
9 7.04 7.23 7.30 7.20
10 7.54 7.73 7.81 7.70
20 12.08 12.26 12.32 11.92
30 16.14 16.31 16.33 15.30
40 20.07 20.15 20.14 18.18
50 23.95 23.95 23.82 20.81
60 28.06 27.97 27.44 23.30
Abbreviations: EUDZ equivalent uniform dose; HIMACZ Heavy-
Ion Medical Accelerator facility, National Institute of Radiological
Science, Japan; LEMZ Local Effect Model (versions I and IV); RBE
Z Relative Biological Effectiveness; SOBPZ spread-out Bragg peak.
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Fig. 3. Course of the mapping dHIMACpresc /d
LEM
presc for an SOBP
width of 60 mm and a SOBP depth as in Fig. 1b for carbon ion
irradiation. In panels a and b, conversion factors (dLEMpresc =d
HIMAC
presc ) for
LEM I and LEM IV, respectively, are shown as solid curves.
Absolute values (dLEMpresc ) for LEM I and LEM IV are compared in
panel c. In addition to the abscissa, the ordinate is here logarithmic
as well. The nearly linear course of the curves therefore shows that
dHIMACpresc /d
LEM
presc can be approximated by a power law. In all figures,
the dLEMprescZd
HIMAC
presc relation is marked as dotted line. To visualize
the deviation from the demanded flatness of the RBE-weighted dose
distribution, the RBE-weighted doses found at the proximal (dashed
curve) and distal end (dashed-dotted curve) of the SOBP are also
shown (as relative values dLEMprox =d
HIMAC
presc and d
LEM
dist =d
HIMAC
presc ) in
panels a and b. HIMACZHeavy-Ion Medical Accelerator facility,
National Institute of Radiological Science, Japan; LEM Z Local
Effect Model (versions I and IV); RBE Z Relative Biological
Effectiveness; SOBPZ spread-out Bragg peak.
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observed a significant decrease of the dependence on the SOBP
width in Fig. 4b. Similar to the findings in Fig. 3b, in the latter
case, we found a minimum for the deviation between the curves at
a higher dHIMACpresc , here around 30 Gy (RBE), followed by a slow
increase. The dependence of the conversion factor from the SOBP
width can be explained by the inhomogeneity of the RBE-
weighted dose within the SOBP. Because the inhomogeneity is
mainly caused by the distal end of the SOBP and this part
is shared by all SOBP widths, the mainly inhomogeneous fraction
of the SOBP is included in each of the different SOBPs, but the
contribution of the more homogeneous fraction (found upstream)
increases with increasing width.
Influence of the depth of the SOBP
In Figs. 2e4, the depths of the SOBPs were selected according to
Fig. 1b. For the depths shown in Figs. 1a and c, the results are only
slightly different. For dHIMACpresc from 1 Gy (RBE) to 60 Gy (RBE)
and an SOBP width of 60 mm, we found a maximum difference
between the conversion factors with respect to the SOBP depths of
0.015 for LEM I and 0.075 for LEM IV, which is 6e8 times
smaller compared with the maximal deviations found in Fig. 4a
and 4b, respectively.
Discussion
In this article, we presented a method to convert clinically
prescribed RBE-weighted doses from the HIMAC/NIRS approach
to the LEM-based TRiP98 approach, which is in use in the pilot
project at GSI and at HIT, as well as in upcoming facilities in
Marburg, Kiel, Pavia, and Shanghai. For the interpretation and
comparison of clinical trials performed at HIMAC and GSI/HIT, it
turned out to be of extreme importance to consider the presented
conversion factors because, given the different methods to deter-
mine the RBE-weighted dose, similar dose values might not
necessarily result in similar clinical outcomes.
We presented data according to the clinical studies conducted at
GSI in the past decade (LEM I) aswell as data currently invalidation
for clinical studies (LEM IV). Because fixed depth-dose profiles are
used, the resulting RBE-weighted dose profiles in the target region
can deviate from the ideally flat profile (up to 60%deviation between
peak at distal end andmedian dose for low dose levels and LEM IV),
and details of the deviation depend on the dose level and the bio-
logical/clinical effect under consideration. Furthermore, the pre-
dicted deviation depends on the model version; because in general
the depth-dependent gradient ofRBEwasunderestimatedwithLEM
I, the deviations from the ideally flat RBE-weighted dose profile are
also less pronounced for this model version. Nevertheless, in the
scope of the EUD description, the inhomogeneities of the RBE-
weighted dose profiles were found to have no significant impact on
the resulting biological effects. Moreover, we could show that the
effect of the remaining inhomogeneities is mapped to the depen-
dence of the conversion factor on thewidth of the underlyingSOBPs.
The conversion factor reaches from 0.4 to 2.0 for prescribed
RBE-weighted doses (HIMAC) ranging from 1 to 60 Gy (RBE).
For both, LEM I and LEM IV, the conversion factor decreases
monotonically with increasing prescribed dose, but slightly
smaller values for the data set based on the LEM IV compared
with LEM I were observed. dLEMpresczd
HIMAC
presc could be found around
5 Gy (RBE). For lower doses, a conversion factor above, and for
higher doses below, 1.0 was found. In the pilot project, an RBE-
weighted dose of 3 Gy (RBE) per fraction (20 fractions) was
used, corresponding to a conversion factor of approximately 1.2.
However, because there is a clear trend toward lower fraction
numbers in the clinical trials at HIMAC, the conversion factors
will be considerably lower for hypofractionation studies using,
e.g., four fractions or even only a single fraction. For these cases,
conversions factors might be as low as 0.5.
Table 2 Numerical values according to Fig. 3
Prescribed
RBE-weighted
dose HIMAC,
Gy (RBE)
RBE-weighted dose LEM, Gy (RBE)
LEM IV LEM I
Proximal end
of SOBP
Distal end
of SOBP
Median across
SOPB
Conversion
factor
Proximal end
of SOBP
Distal end
of SOBP
Median across
SOP
Conversion
factor
1 1.4 2.7 1.7 1.65 1.8 1.6 1.8 1.76
2 2.3 4.1 2.7 1.33 2.8 2.6 2.8 1.40
3 3.1 5.2 3.5 1.15 3.7 3.4 3.6 1.21
4 3.8 6.1 4.2 1.04 4.4 4.0 4.4 1.09
5 4.4 6.9 4.8 0.96 5.1 4.6 5.0 1.01
6 5.0 7.7 5.4 0.90 5.8 5.2 5.6 0.94
7 5.5 8.4 6.0 0.85 6.4 5.7 6.2 0.89
8 6.1 9.1 6.5 0.81 6.9 6.1 6.8 0.85
9 6.6 9.7 7.0 0.78 7.5 6.6 7.3 0.81
10 7.1 10.3 7.5 0.75 8.0 7.0 7.8 0.78
20 11.8 15.1 12.1 0.60 12.9 10.6 12.3 0.62
30 16.3 18.9 16.1 0.54 17.3 13.7 16.3 0.54
40 20.6 22.2 20.1 0.50 21.5 16.4 20.1 0.50
50 25.0 25.5 23.9 0.48 25.7 19.0 23.8 0.48
60 29.6 28.9 28.1 0.47 29.7 21.5 27.4 0.46
Abbreviations: HIMAC Z Heavy-Ion Medical Accelerator facility, National Institute of Radiological Science, Japan; LEM Z Local Effect Model
(versions I and IV); RBE Z Relative Biological Effectiveness; SOBP Z spread-out Bragg peak.
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The conversion factor depends on tissue and endpoint. The
results shown here must therefore be considered specific to the
tissue parameters and corresponding RBE tables discussed in this
article. Similar analyses will thus be carried out for other LEM-
based RBE tables as soon as they are considered for clinical
implementation. It is expected that the curves shown in Figs. 3
and 4 shift to the left for tissues with a=b ratios <2, because
according to the general trend, the corresponding RBE predicted
by the LEM will be lower. However, the main trend that the
conversion factors are >1 at low doses per fraction and <1 at very
high doses per fraction will be unaffected.
It will then also be of interest in how far a simple power-law
representation, as given for the results in Fig. 4, will be applicable
for other endpoints. If this is found to be feasible, it will allow
easy implementation of this type of conversion factor and serve as
a guideline for comparability in treatment planning procedures
without the need to run elaborate alternative treatment planning
programs. Furthermore, the method can easily be extended to
other models, allowing calculating clinically applicable RBE
distributions in SOBPs such as, e.g., the MKM (Microdosimetric
Kinetic Model), which is currently being investigated for imple-
mentation in treatment planning (14). On this basis, a lookup
table-based system can be established to easily convert RBE-
weighted doses from one system to another and thus support
clinicians in comparison of clinical data obtained at different
institutions with different approaches for treatment planning. In
the same way, the impact of possible additional improvements of
the LEM can be assessed.
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Abstract
The relative biological effectiveness (RBE) is a central quantity in particle
radiobiology and depends on many physical and biological factors. The
local effect model (LEM) allows one to predict the RBE for radiobiologic
experiments and particle therapy. In this work the sensitivity of the RBE on its
determining factors is elucidated based on monitoring the RBE dependence on
the input parameters of the LEM. The relevance and meaning of all parameters
are discussed within the formalism of the LEM. While most of the parameters
are fixed by experimental constraints, one parameter, the threshold dose Dt , may
remain free and is then regarded as a fit parameter to the high LET dose response
curve. The influence of each parameter on the RBE is understood in terms
of theoretic considerations. The sensitivity analysis has been systematically
carried out for fictitious in vitro cell lines or tissues with α/β = 2 Gy and
10 Gy, either irradiated under track segment conditions with a monoenergetic
beam or within a spread out Bragg peak. For both irradiation conditions, a
change of each of the parameters typically causes an approximately equal or
smaller relative change of the predicted RBE values. These results may be used
for the assessment of treatment plans and for general uncertainty estimations
of the RBE.
(Some figures may appear in colour only in the online journal)
5 Now working at Siemens Healthcare.
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1. Introduction
The RBE is used to quantify the enhanced effect of ion beams in comparison to low LET
radiation such as x-rays or gamma rays. For applications in radiobiologic research as well as
in ion radiotherapy the precise characterization of RBE is of importance. Many experimental
and clinical studies have been carried out to reveal the RBE under various conditions (Ando
and Kase 2009, Gerweck and Kozin 1999, Friedrich et al 2013). However, as the RBE depends
on several factors whose versatile combinations cannot be investigated solely by experiments,
models for predicting the RBE have been developed. The LEM in its original version (LEM I)
(Scholz et al 1997) and the microdosimetric kinetic model (MKM) (Hawkins 1994, 1996) are
currently the only ones used for clinical treatment planning. Within the recent years, the LEM
has been gradually improved (Elsa¨sser and Scholz 2007, Elsa¨sser et al 2008). The latest version
LEM IV (Elsa¨sser et al 2010, Friedrich et al 2012b) comprises a mechanistic interpretation on
the level of double strand break (DSB) induction. This allowed one to significantly improve
the accuracy to model the RBE for all therapy relevant ions and energies with one unique
set of necessary parameters which have been fixed once for all model calculations. As their
values, as well as other experimental parameters (e.g. those specifying the tissue considered),
are associated with uncertainties the question arises how these translate into uncertainties of
the predicted RBE. Hence, for applications in radiobiology and in the clinics it is of interest to
quantify the consequence of a change of each input parameter for the RBE. The rates of RBE
change will reflect themselves in the robustness of treatment plans for ion beam therapy.
This paper is dedicated to the sensitivity analysis of RBE, obtained by a systematic
variation of parameters used within the LEM IV. The strategy is to carry out the analysis
in a very systematic way, where at first all parameters are inspected and classified, then
their relevance is quantitatively investigated for monoenergetic beams as well as for extended
irradiated volumes6. This strategy finally allows one to understand the parameter sensitivity
based on the physical or biological meaning of the parameter under consideration and to
compare the expectations for RBE uncertainty for the different ways of beam delivery. Our
approach is complementary to a recent publication (Bo¨hlen et al 2012), where the authors
investigated the parameter influence on RBE for extended targets and in detail discuss possible
implications for ion beam therapy.
The parameters needed for calculating RBE values with LEM may be subdivided
according to the model parts they are used in:
• specification of the physical aspects of track structure
• specification of the initial DNA damage distribution
• characterization of the cell and DNA conformation geometry
• characterization of the photon dose response curve.
In section 2 the basic principles of the LEM are revisited and the parameters needed for
RBE calculations are introduced. The relevant parameters for LEM calculations are classified
and discussed in section 3. The parameter sensitivity of the RBE values for monoenergetic
beams is presented in section 4. Section 5 is dedicated to the same analysis for a clinical
situation, where a SOBP is optimized in such a way that a homogenous distribution of the
RBE-weighted dose covers the target volume. Finally, the results are discussed and conclusions
are drawn in section 6.
6 Throughout the paper with monoenergetic beams we understand that the samples are irradiated under track segment
conditions, i.e. that energy and LET do not change along an ion track through a cell nucleus.
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2. Conceptual basis of the LEM
The LEM bases on the assumptions that the nuclear DNA is the unique sensitive part of the
cell to radiation, that DSB are the most relevant lesions, and that the radiation damage on a
molecular level is predominantly mediated by secondary electrons and hence only depends on
the local distribution of these secondaries. This includes the implicit assumption that for all
radiation qualities the spectra of the slowing down secondary electrons are similar. The main
idea is then to trace back the effect of ions to the effect of photons inducing locally a similar
pattern of initial damage.
In a first step, ions are assumed to pass through the cell nucleus, in which the DNA is
assumed to be distributed homogenously. Practically, for most applications we restrict here to
one single ion passing right through the centre of the cell nucleus. This allows one to assess
the effect of exactly one ion, from which the effect of a distribution of ions can be derived as
outlined in (Scholz et al 1997). A Monte Carlo simulation of the full spatial dose distribution
of a distribution of ions has also been implemented in LEM (Friedrich et al 2012b), but is not
used for this study for the sake of computation time. We checked that this so called single
particle approximation is valid up to several Gy and hence can be used for normal fractionated
radiotherapy. Furthermore track segment conditions are required, i.e. the particles show no
significant change of kinetic energy or LET along their way through the nucleus. According
to their track structure a local dose deposition is converted into a damage pattern of DSB
distributed within the nucleus. The local rate for the induction of initial DSB is proportional to
the local dose in each location within the track. The proportionality factor is the DSB yield as
measured in experiments with low LET radiation. In addition to these DSB, further DSB arise
due to neighbouring single strand breaks (SSB) on opposite DNA strands combining to a full
break of the DNA double strand (Elsa¨sser and Scholz 2007), resulting in an overall RBE for
DSB induction greater than one. In the implementation the simulation of the damage patterns
is performed by means of a Monte Carlo routine simulating many cells, each being affected
by one spatial DSB distribution. The procedure is stopped when the number of Monte Carlo
runs is sufficient to finally determine the effect of ions within a requested accuracy.
In a second step the initial damage distribution is converted into a distribution of isolated
or clustered DSBs, where the classification is defined based on the picture of a hierarchical
compartmented organization of chromatin into DNA giant loops (Yokota et al 1995) of some
Mbp size, corresponding to the micrometer length scale. The relevance of such a length scale is
known since a long time in radiobiology (Neary et al 1959, Rossi and Zaider 1996, Goodhead
2006) and thus supportive for this conception, though its interpretation in terms of DNA
conformation is under continuous debate. It is suggestive to assume that lesions can interact
if they were induced in the same DNA loop, while lesions in different chromatin domains are
processed independently. Consequently, the model distinguishes between domains without
any DSB, with exactly one DSB (called isolated DSB), or with more than one DSB (called
clustered DSB). Note that this term is not uniquely defined and used for different constellations
of lesions by different authors. All definitions, however, have in common that the term means
an accumulation of lesions (at least one of which is a DSB) in close neighbourhood. Indeed
it is known that isolated DSB can be repaired quite efficiently by the repair mechanism of a
cell, while complex damage is believed to have a higher impact on cell killing, supporting the
assumption used in LEM, that the fraction of complex damage is a determining factor for the
RBE.
In the third step a photon dose causing the same proportion of isolated to clustered DSBs is
evaluated. The effect corresponding to that photon equivalent dose is obtained from the photon
dose response curve. As for this case the local damage pattern of ion and photon irradiation
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Table 1. Overview over the parameters of the LEM, classified in groups corresponding to different
stages of a LEM model calculation. One can distinguish specific parameters which specify the
situation to be modelled, and general parameters which have been obtained by measurements,
fitted to reference data or estimated by theoretic considerations. For general parameters, the values
used are given, and their origin is indicated.
Parameter class Parameter Type Value Origin
Track structure γ General 0.062 Measureda
δ General 1.7 Measureda
rc General 6.5 nm Fit + theoretic argumentsb
σ General 4 nm Theoretic argumentsa
E Specific
LET Specific
Initial DNA damage αDSB General 30 Gy−1 Measureda
αSSB General 1250 Gy−1 Measureda
h General 25 bp Measureda
LGen Specific
Cell nuclear geometry Vn Specific
rn Specific
lDSB General 540 nm Fitb
Photon dose response curve α Specific
β Specific
Dt Specific
a See (Elsa¨sser and Scholz 2007) and references therein.
bSee (Elsa¨sser et al 2010) and references therein.
is comparable, the effect of ions can be calculated by a proper normalization from the photon
effect, and all related quantities such as the RBE are obtained easily. For a mathematical
precise formulation of the LEM we refer to (Friedrich et al 2012b).
Note that in this general formulation up to this point no specific endpoint is considered.
The LEM is appropriate for any endpoint as long as the effect is mediated primarily by the
induction of DSB to DNA loops or correlating strongly with it. The difference in RBE between
different endpoints originates from different associated photon dose response curves. The most
prominent endpoints to which the LEM was applied up to now are cell survival for cell culture
experiments and tumour control as well as normal tissue complication in carbon ion cancer
therapy or in vivo experiments (Elsa¨sser et al 2010, Scholz and Elsa¨sser 2007, Gru¨n et al 2012).
3. Parameters of the LEM
Calculating the effect of an ion impact from a photon equivalent situation requires knowledge
or modelling of (i) physical properties of the ions, (ii) factors determining the DNA damage
induction rates, (iii) geometric properties of the cellular nucleus and the chromatin, and
(iv) the photon dose response for the endpoint under consideration. The relevant parameters
are summarized in table 1 according to this classification, and their meaning will be discussed
below.
Some of the parameters have been fixed once, because there is no evidence for any
dependence on e.g. cell type or ion species. Their values are used for all simulations and have
been either extracted from experimental results, derived by theoretic arguments, or fixed by
fitting the LEM predictions to a reference set of experimentally obtained RBE data (Furusawa
et al 2000, Suzuki et al 2000). They are marked with general in table 1 and listed along
with their attributed values. All other parameters, marked as specific parameters, specify the
experiment or clinical situation to be modelled, i.e. they characterize the cell- or tissue type
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and their radiation response, define the particle species used and the energy. The distinction
of general and specific input parameters of the LEM is used throughout this publication.
Note that both general and specific parameters are associated with uncertainties. For some
parameters these are quite large (some ten per cents), e.g. for the radical diffusion length σ
or the yield parameters αDSB and αSSB. However, as two general parameters, the giant loop
domain size for DSB interaction lDSB and the maximum inner core radius rc, have been fixed
by a fit to RBE reference data sets, the fitted parameters calibrate the model and compensate
for uncertainties in the others, and therefore the uncertainties of the general parameters do not
propagate to the uncertainty of the RBE. This compensation is not mathematically strict, and
there might be combinations of all parameters where this procedure of calibrating the LEM
model might fail, leading to systematic errors in RBEs. However, some systematic errors in
the RBE predictions are only detected at low LET values, while mostly RBE predictions are
reasonably correct. This strongly suggests that the model set-up and the chosen parameters
are sufficiently accurate, which implies that the compensation of parameter errors works good
enough to predict RBEs correctly. Moreover this is supported by the values of the two fitted
parameters which are in agreement with theoretical expectations (nm range for rc and µm
range for lDSB). As a consequence of the compensation of parameters, for an uncertainty
analysis of RBE primarily the specific parameters characterizing an experiment or a clinical
case are of relevance.
Using the set of parameters as listed in table 1 in LEM IV allows one to simulate RBE
for a wide range of LET and for all therapy relevant ion species from protons to carbon
in reasonable agreement with experimentally or clinically evaluated RBE values (Gru¨n et al
2012). The different groups of relevant parameters needed for a LEM calculation are addressed
in the following point by point.
3.1. Physical parameters of beam and track structure
The incident particle is characterized by a kinetic energy per nucleon, E, and a corresponding
LET for a given particle species. Here energy and LET are determined within the cellular
nucleus. The LEM assumes that the LET does not change considerably along a passage of an
ion through the nucleus. If track segment conditions are violated, deviations between LEM
and experimental data may occur.
Microscopically the energy is transferred from the ion to the surrounding matter in point-
like ionization events. For many purposes it is sufficient to use the average dose distribution
pattern around the central axis of a passing ion. This parametrization of the energy loss of
particles in matter is commonly referred to as amorphous track structure (Cucinotta et al 1999).
Note that the concept of dose used here is a local dose, being proportional to a probability
density function for finding an ionization. In our implementation we follow the amorphous
track structure model according to (Elsa¨sser et al 2008), where the track structure consists of
an inner core with a constant dose up to an energy dependent radius which is parameterized by
rmin = βionrc with βion = v/c, particle velocity v and velocity of light c. Its maximum value,
rc = 6.5 nm was adequately chosen in (Elsa¨sser et al 2010) to fit experimental data and matches
the order of magnitude expected from theoretic considerations perfectly (Mozumder 2007).
Beyond rmin the local dose falls off quadratically up to a maximum radius rmax = γEδ ,
where rmax is given in microns and E in MeV per nucleon. The parameters γ and δ have
been derived by a fit to experimental data obtained in experiments using tissue equivalent
proportional counters (Kiefer and Straaten 1986). In this work there is no analysis of involved
uncertainties given, but it is evident that the uncertainties of γ and δ are smaller than their
values, but larger than on the per cent level. Below an energy of 2 MeV u−1 this parametrization
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does not resemble the measured doses with sufficient accuracy. Here, values different from
those in table 1 are used (γ = 0.124 and δ = 0.7). As the remaining range of particles of such
small energy is very limited and track segment conditions might be violated, the accuracy of
RBE predictions might be questionable, but for the same reason their importance within a
SOBP is low.
It is known that an essential fraction of lesions is induced by an indirect effect, i.e. by free
radicals which have been produced by secondary electrons. To account for this, the initial dose
distribution according to the parametrization discussed previously is convoluted with a radial
Gaussian of width σ = 4 nm, modelling an effective diffusion of free radicals. The value of
σ was fixed in (Elsa¨sser et al 2008) and is in agreement with diffusion lengths calculated by
Monte Carlo codes (Nikjoo et al 1997, Moiseenko et al 2001). Here it is important to note that
LEM follows an effective approach: as different radical species have different mean free path
lengths, its uncertainty on the nm scale is given by the corresponding wide spread of different
radical diffusion lengths.
3.2. Parameters for damage induction to the DNA
The crucial initial lesions of interest in the LEM are DSBs. Several experiments show that for
photons the initial DSB yield isαDSB ≈ 30 Gy−1 per cell for a DNA content LGen = 5.4×109 bp
as typical for rodents (Prise et al 2001, Stenerlo¨w et al 2003). This DSB yield refers to the
initial induction of DSB and is observed experimentally with low LET radiation. Likewise,
experiments showed that the yield SSB is αSSB ≈ 1250 Gy−1.
It is well accepted that SSB can be repaired effectively. However, for high LET radiation
two SSB in close vicinity on opposite strands may combine and form an additional DSB. Hence
the number of initial DSB calculated from αDSB is enhanced. This amplification is explicitly
modelled within the LEM. A fixed threshold of h = 25 bp for the maximum interaction length
of SSB is used in our implementation, in agreement with experimental results using plasmids
(Shao et al 1999), see (Elsa¨sser and Scholz 2007) for a more detailed discussion. While it is
negligible for photon irradiation, for high LET radiation qualities this effect can enhance the
DSB yield up to one order of magnitude, depending on particle species, LET and genomic
length (Elsa¨sser and Scholz 2007). Concerning the uncertainties of the parameters for damage
induction, in the literature typically values of 20–40 DSB and 1000–1500 SSB per cell and Gy
are discussed in the literature. For the distance threshold h a huge span of 3–60 bp is reported
in the literature. This motivates a reasonable fixation to 25 bp.
3.3. Parameters of the cell nucleus geometry
We assume that the DNA content of the cell is uniformly distributed in a cylindrical cell
nucleus, specified by parameters for the volume of the nucleus, Vn and its radius, rn. The
impinging particles are assumed to hit the nucleus in direction of the symmetry axis of the
nucleus. Note that the height of the nucleus is uniquely fixed by the two geometry parameters.
Distributions of nuclear sizes are discarded up to now.
To model chromatin loop domains a three-dimensional rectangular grid is superimposed
on the cell nucleus. The boxes of the grid resemble the domains in which DSBs are counted.
They have equal side lengths of lDSB = 540 nm. This length was determined by a fit to survival
data of Furusawa and coworkers (Furusawa et al 2000), and is in agreement with the typical
interaction length scale derived from microdosimetric considerations (Goodhead 2006). The
parameter lDSB thus determines the interaction lengths of distant DSB and fixes the proportion
of isolated and clustered DSB for a given dose and radiation quality.
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3.4. Photon dose response parameters
Within the LEM usually the linear-quadratic (LQ) model is used, in which the effect is given
by αD + βD2 with photon dose D and linear and quadratic coefficient parameters α and β.
The choice of the LQ model is somewhat arbitrary but convenient, as for almost all in vitro
and in vivo data as well as for most clinical reports on radiation effects are characterized in
terms of this model (Friedrich et al 2013, Ando and Kase 2009, Steel and Peacock 1989, Fertil
and Malaise 1985).
At high doses, however, it becomes more and more evident that the LQ model loses
validity, as the dose response tends towards a pure linear component. This is suggested by
theoretic considerations of the repair dynamics of the cell (Curtis 1986, Tobias 1985) as well
as by experimental findings from both in vitro (Astrahan 2008, Garcia et al 2007, Fertil et al
1994) and in vivo experiments (Guerrero and Li 2004, Carlone et al 2005). In the LEM
we model the different properties of the dose response curves at low and high doses by a
instantaneous transition from an LQ to a linear dose response at the transition dose Dt . Then
the main principle of the LEM is the mapping of the damage pattern caused by ions to a
damage pattern as induced by photons. For regions of high local doses, photon irradiation will
induce comparable damage patterns at doses above Dt , and hence Dt is an important parameter
for RBE calculations. There are three distinct ways of asserting a numerical value to it: One
can extract it from measurements, if the photon dose response curve is available to sufficient
high doses. Alternatively an empirical linear relationship between Dt and α/β exists, which
can serve to estimate Dt (Friedrich et al 2013). If one proceeds (and only if) along these
ways, the LEM is free of any specific fit parameters. However, if both of these procedures are
not applicable or affected with unacceptable accuracy (e.g. when the photon dose response
parameters are only known within a limited low dose range), the parameter must be fitted
individually to experimental high LET data from the cells or tissues under investigation.
4. Sensitivity analysis for irradiation with monoenergetic ion beams under track
segment conditions
In this section the change of RBE-LET relationships for cells or tissues irradiated with a
monoenergetic ion beam due to parameter variation is investigated. The results can be used to
estimate the influence of parameter uncertainties on the RBE for radiobiological experiments
mimicking aspects of carbon radiotherapy in the different situations with monoenergetic beams
in track segment conditions. They might also be useful to understand differences in RBE values
if calculated for or measured with different cell lines under comparable conditions.
Both the RBE at full survival (RBEα) and at 10% survival level (RBE10) are considered
as a function of the LET. The simulations have been performed for carbon ions and two
hypothetic cell- or tissue types, characterized by α/β = 2 Gy and α/β = 10 Gy. The general
strategy of the sensitivity analysis is to calculate for each parameter listed in table 1 (except
energy and LET) three RBE-LET relationships, one for a designed value of that parameter and
the other two obtained by increasing or decreasing this parameter by 25% of its initial value7.
In particular we chose α = 0.1 Gy−1, β = 0.05 Gy−2 and Dt = 8 Gy as design parameters
for α/β = 2 Gy and α = 0.5 Gy−1, β = 0.05 Gy−2 and Dt = 14 Gy for α/β = 10 Gy.
7 We chose here the reference change of 25% for all parameters to allow for an inter-comparison of the sensitivity
on the RBE determining parameters. Moreover, 25% resemble the order of magnitude of the uncertainties of the
input parameters, as none of the parameters is known to per cent accuracy, but also the uncertainties typically do not
exceed some ten per cents. A mathematical, more rigorous treatment would require one to consider the differential
expressions dRBE/dx for any parameter x.
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Figure 1. Relative change of RBEα (left) and RBE10 (right) over LET for carbon ions and cells or
tissues on the photon parameters for α/β = 2 Gy (blue) and α/β = 10 Gy (red). The horizontal
axis corresponds to the RBE at the design parameters (see text), and the dashed and dotted curve
emerge by decreasing or increasing the specific parameter about 25%, respectively. The vertical
lines indicate the LET values of 13 and 77 keV µm−1 used in table 2.
These parameter settings are typical for in vitro cell survival assays (Friedrich et al 2013).
The parameter Dt was adapted according to an empirical relation between α/β and Dt . This
linear relation was found when using the LEM over a huge set of experimental cell survival
data (Friedrich et al 2013), and is in agreement with experimental findings (Astrahan 2008).
The geometric specific parameters for both cases were chosen Vn = 500µm3 and rn = 5µm.
Again, these parameters approach typical values for mammalian cell lines.
For all combinations of effect levels for which the RBE is evaluated (RBEα or RBE10)
and for both α/β ratios (2 Gy or 10 Gy), we obtained for each parameter a band in the RBE-
LET characteristics which describes the variability of RBE under variation of ±25 % of this
parameter8. In all cases but one, sensitivity was investigated by varying one single parameter.
As an exception, for a change of the parameter Vn we also changed lDSB as a second parameter
in order to keep the number of chromatin loops within the cell nuclei constant. Figure 1 shows
the dependence of the RBE variation on the photon LQ parameters α, β and Dt . In figure 2 the
influence of the nuclear volume Vn, nuclear radius rn, the DNA loop domain size lDSB and the
DSB yield αDSB on RBE is presented.
8 Note that a change of one of the LQ parameters α or β immediately implies a modification of their ratio α/β. Here
the assumed α/β ratios of 2 and 10 Gy refer to the designed (unchanged) parameter values.
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Figure 2. Relative change of RBE as presented in figure 1 for the nuclear volume, the nuclear
radius, the DNA loop domain size and the DSB yield.
Generally from the figures it can be seen that in most cases there is less or at most equal
sensitivity on parameter variations for α/β = 10 Gy compared to α/β = 2 Gy. Similarly, the
RBE at 10% survival is typically less sensitive to parameter variations compared to RBEα .
Moreover it becomes evident that the increase of some parameters leads to either a decrease or
an increase of RBE. Based on some simple mechanistic interpretations within the framework
of the LEM the different sensitivity patterns can be interpreted, as shall be demonstrated at
some examples in the following.
To β, Dt , and αDSB the RBE is primarily sensitive for intermediate LET values. These
parameters show a bulb-like pattern in the plots. For very low LET they are of minor importance
(as all parameters), as the nature of the radiation field converges to that of photons, and hence
RBE will get close to one. At high LET the overkill effect will take place, i.e. in the limit of high
LET a cell will only survive if it is not hit, and will be inactivated as consequence of any hit. Due
to this simplistic picture these biologic parameters lack of importance in the high LET regime.
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The parameters α and rn in contrast show pronounced importance for high LET, which
can be explained by the same argument: The probability for a cell to be hit and with that the
effect increases with the nuclear radius and thus with the geometrical cross section rn. The
photon parameter α has, in contrast to β and Dt , for high LET almost no influence on the ion
dose response curve within LEM. Nevertheless there is a prominent dependence of RBE on α
because it directly affects the dose at which the reference effect level is reached on the photon
dose response curve.
The parameter lDSB shows two pronounced sensitivity regions, while there is almost no
sensitivity between 100 and 200 keV µm−1. The reason is an interference of the length scales
involved: Generally an increase of lDSB allows for more DSB clustering within the photon
radiation field, while this effect is not so prominent for ions, which results in a decrease of
RBE. But in the intermediate LET regime the track diameter is of the order of the loop domain
size. In this case an increase of the domain size will lead to an effective increase of clustering
almost as much as for photons, because for increased loop domains all DSB caused in the
whole track structure may contribute to DSB clusters. As there is not much differential effect
between photons and ions in this case, the RBE sensitivity to changes of lDSB is low. For very
high LET finally a further increase of lDSB will not lead to more clustered lesions caused by
the ion track, hence the sensitivity recovers.
In a similar way the direction of RBE change with respect to the direction of change of
the input parameter can be interpreted: An increase of the photon parameter α, e.g. implies a
steeper photon dose response curve and consequently a lower dose needed to reach a desired
effect level. A higher α will also correlate to a steeper ion dose response curve. But as the
enhanced effect of the ion dose response is primarily caused by the inhomogeneity of the local
dose deposition pattern in combination with the nonlinear response to local doses, which is
parameterized by β and Dt , the steepening due to an increase in α is less pronounced than for
photons. As a result the RBE will decrease, if α is increased. All parameters show a unique
directional RBE change except Vn for which at low LET a parameter decrease and at high LET
a parameter increase leads to RBE increase.
The analysis presented here has also been performed for other particle species (protons,
helium and neon). However, the results generally follow a similar systematics, and thus
no detailed discussion is presented here. The most relevant difference is that as the whole
RBE-LET characteristics is shifted towards higher LET for heavier ions, they provide a
lower sensitivity on the parameters for low LET, while lighter particles are more sensitive
there.
To project out the findings of this sensitivity analysis with monoenergetic beams for
particle therapy, the most important results of the sensitivity analysis for carbon ions are
summarized for therapy relevant LET values in tables 2 and 3 for α/β = 2 Gy and 10 Gy,
respectively. In a treatment like situation a good conformity to a tumour in the target region is
desirable and the therapy benefits from the high RBE of carbon ions just before stopping as it
allows one to keep the doses applied to normal tissue low. Hence in the target region typically a
high average LET and a high dose are expected, leading to low survival of tumour cells, while
in the entrance channel doses should remain low, and the LET of the high energetic carbon
ions is small. In the tables these situations are represented by results for RBE10 at a high LET
and for RBEα at a rather small LET, respectively. But also the complementary cases occur:
At the margins of the spread out Bragg peak (SOBP), depending on the field geometry and
the irradiation angles, some parts of the tissues might be covered by radiation with rather high
doses of rather low LET radiation or vice versa. These interfaces between peak and plateau
regions are of particular interest in therapy as all tumour cells must be inactivated, while in
the same way normal tissue shall be spared as much as possible. As tumour and healthy tissue
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Table 2. Parameter dependence of RBE for monoenergetic carbon ions in therapy comparable
situations for α/β = 2 Gy. The header part of the table contains the RBEα and RBE10 for LET
values typically found in the entrance channel and the Bragg peak region in carbon ion therapy,
respectively. Here the design parameter settings were used. Below the header part the relative
changes in RBE in per cent after change of one parameter about −25% or +25% (bottom or top
numbers) are given. The second column contains the correlation direction, labelled as 0, + or − if
RBE does not change, goes typically up or down with increasing parameter, respectively. Note that
this information is valid below the overkill regime—for high LET the correlation might change
(see text).
Entrance Bragg peak
(13 keV µm−1) (77 keV µm−1)
RBEα RBE10 RBEα RBE10
1.44 1.04 9.08 2.31
corr. #RBEαRBEα (%)
#RBE10
RBE10
(%) #RBEαRBEα (%)
#RBE10
RBE10
(%)
Vn −/+ −4.977.66 −0.771.06 −1.981.98 −2.161.73
rn +
+0.46
+0.64
+0.12
−0.04
+2.23
−5.44
+2.24
−5.44
lDSB − −9.44+19.41 −1.29+2.76 −9.13+7.27 −8.84+7.27
α − −6.19+10.30 +0.04−0.05 −17.56+29.25 −0.63+0.55
β + +7.68−7.68
+0.74
−0.83
+19.74
−20.41
+8.77
−10.15
Dt 0/+ ±0 +0.48−0.80 +14.47−17.05 +14.47−17.05
γ − −2.39+2.92 −0.33+0.40 −1.78+2.42 −1.78+2.43
δ − −8.79+13.79 −1.20+1.95 −10.42+12.46 −9.90+12.46
rc − −0.51+3.26 −0.07+0.45 −4.78+6.14 −4.77+6.14
σ − +1.96+0.46 +0.27+0.06 −6.16+8.39 −6.15+8.39
αDSB − −0.74+1.71 −0.10+0.23 −6.44+10.01 −6.44+10.01
αSSB +
+2.27
−0.77
+0.31
−0.11
+14.86
−12.62
+14.86
−11.69
h + +0.03−0.22
+0.00
−0.03
+6.46
−6.85
+6.46
−6.86
LGen − +0.43+1.31 +0.06+0.18 −5.59+8.53 −5.59+8.53
show often different radiosensitivities, beneath dose and LET also the α/β ratio plays a role
here, which reflects the complexity of RBE.
In the tables the design RBE values as well as the RBE values after parameter change
are given for typical situations in the entrance channel (LET = 13 keV µm−1) as well as in
the SOBP (LET = 77 keV µm−1). The representative values for the LETs have been adopted
from (Suzuki et al 2000). In the tables, also the direction of change of the RBE is given: when
a parameter is increased, the RBE may either typically go up as well (as marked with a ‘+’
sign to indicate that positive correlation) or down (as marked with a ‘−’ sign). In the case of
Dt there is for small LET no dependence for RBEα , which is labelled by ‘0’. Exceptions of
a unique correlation occur only for the parameter Vn where the direction of RBE change gets
reverted at an LET of 150 keV µm−1 (thus labelled with ‘+/−’ and for very small parameter
sensitivities where an increase and a decrease may hardly change RBE, while nevertheless
small changes are seen in the simulations in the same direction due to fluctuations in the Monte
Carlo calculation. The dependence on energy or LET is not listed in the tables, as LET is the
dependent variable in the figures presented, and for a given particle species energy is uniquely
defined for a given LET in the Bethe–Bloch regime.
Note that the RBE depends on each of the quantities typically less than proportional, i.e.
when a parameter is changed about 25% the RBE usually changes less than 25%. Up to few
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Table 3. As table 2, for α/β = 10 Gy.
Entrance Bragg peak
(13 keV µm−1) (77 keV µm−1)
RBEα RBE10 RBEα RBE10
1.09 1.04 3.27 2.44
corr. #RBEαRBEα (%)
#RBE10
RBE10
(%) #RBEαRBEα (%)
#RBE10
RBE10
(%)
Vn +/− −0.741.10 −0.480.58 −3.063.36 −3.283.28
rn +
+0.42
−0.54
+0.34
−0.55
+4.58
−9.94
+4.61
−9.96
lDSB − −2.49+5.12 −1.39+2.89 −13.52+10.49 −12.71+10.46
α − −1.80+2.90 −0.42+0.37 −14.21+23.44 −6.96+8.18
β + +2.03−2.02
+0.73
−0.81
+13.80
−14.49
+8.55
−9.71
Dt 0/+ ±0 +0.13−0.22 +6.08−9.50 +6.44−9.52
γ − −0.96+0.37 −0.53+0.21 −2.12+2.87 −2.01+2.85
δ − −2.76+3.77 −1.54+2.12 −12.96+14.30 −12.19+14.28
rc − −0.21+0.77 −0.12+0.43 −5.33+6.73 −5.04+6.70
σ − +0.27+0.33 +0.15+0.18 −6.66+8.89 −6.30+8.87
αDSB − −0.75+0.47 −0.42+0.27 −7.09+10.78 −6.70+10.75
αSSB +
+0.74
−0.61
+0.42
−0.34
+15.60
−13.85
+15.57
−13.02
h + +0.38−0.06
+0.21
−0.03
+6.92
−7.40
+6.90
−6.99
LGen − +0.10+0.64 +0.06+0.36 −6.06+9.06 −5.73+9.04
exceptions RBE does not change by more than 25%. From figures 1 and 2 it is evident that
for a 10% survival level only the nuclear radii rn exceed the 25% level for RBE changes. At
77 keV µm−1 as representative for the target region the RBE is very sensitive on the photon
dose response parameters, the track structure parameter δ and the yield of SSB.
5. Sensitivity analysis for a clinical situation
The application of carbon ions for cancer treatment in the clinics requires treatment planning
which accounts for the RBE in such a way, that the target volume is covered uniformly by
a described RBE-weighted dose, while the doses in the normal tissues and in particular in
organs at risk remain low. This strategy is followed in the particle treatment facilities in Japan
(Tsujii and Kamada 2012) as well as in Europe (Combs et al 2010, Schulz-Ertner et al 2007),
although their beam characteristics and the methods in accounting for RBE differ.
The RBE in a voxel based treatment plan corresponds to a mixed radiation field, because
several particle species, each having an individual energy distribution, may contribute to the
overall dose deposited due to fragmentation, straggling and scattering. Because of this mixing
the large sensitivities detected in the last section are balanced out, and hence the irradiation of
extended targets will show a damped sensitivity of RBE to its input parameters.
In this section the same sensitivity analysis is presented for SOBPs, as before for
monoenergetic beams and cells or tissues under track segment conditions. Thus, each of
the specific parameters of the LEM listed in table 1 was again modified by ±25% and the
induced change in RBE was monitored. To facilitate the analysis a sphere as idealized target
geometry with 60 mm depth extension placed in a depth of 150 mm (isocentre) was regarded9.
9 Note that this choice corresponds to rather large, deep seated tumours.
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Figure 3. Dependence of RBE over water equivalent depth for carbon ions and cells or tissues
with α/β = 2 Gy and α/β = 10 Gy on the LQ parameters. The corresponding RBE-weighted
dose distributions were all optimized to 3 Gy in the target region. The solid curve corresponds to
design parameters (see text), and the dashed and dotted curves emerge by decreasing or increasing
the specific parameters about 25%, respectively.
The treatment planning software TRiP98 (Kra¨mer et al 2000, Kra¨mer and Scholz 2000) was
used to optimize a physical dose leading to a homogeneous RBE-weighted dose throughout
the SOBP. In general the RBE varies with the depth in tissue because the LET distribution
changes. For this reason we here discuss depth distributions of the RBE, instead of its LET
dependencies.
The strategy closest to the clinical routine is an optimization of two directly opposing
fields to give a flat RBE-weighted dose of 3 Gy within the target, in line with the fraction
dose used in the GSI clinical trial (Schulz-Ertner et al 2007). Note that for each parameter
setting of the sensitivity analysis an individual optimization must be performed. As before, all
calculations were performed for tissues with α/β = 2 Gy and α/β = 10 Gy with the same
absolute values as in the previous section. The results are visualized in figures 3 and 4 where
the depth distributions of the RBE values along an axis right through the isocentre (beam’s eye
view) are presented. We chose here to present the absolute RBEs instead of relative changes
after parameter variation as in the previous figures, because for a SOBP the RBE profile is
very instructive. Note that the mixed radiation field provides a variation of the average LET
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Figure 4. As figure 3, for the nuclear radius and the size of the chromatin loops.
with depth. Hence here the depth is the appropriate quantity to replace the dependence on
LET, which was discussed in the last section.
At this point it is important to note that often for in vivo systems and clinical endpoints the
LQ parameters happen to be much smaller (Brenner 1993). In order to establish comparability
to the results in the previous section, here the absolute values were kept the same. However,
it is known that RBE values for small and large absolute values are comparable for the same
α/β ratios, with the only difference that overkill effects appear more pronounced for higher
absolute values. Hence for small absolute values less sensitivity on parameters which affect
overkill is expected, and we checked that conjecture at some examples (data not shown).
Generally, the curves in figures 3 and 4 show a low RBE in the entrance channels and
a considerably higher RBE in the target, where particles are stopping and have a higher
LET consequently. This is one of the superiorities of carbon ions compared to protons in
radiotherapy. For a single field treatment plan the RBE distribution across the SOBP shows
pronounced maxima towards the distal boundary of the target volume. There exclusively
stopping particles (except some fragments) are present, causing a high LET, while at the
proximal regions and within the SOBP broader mixtures of LETs exists. In a treatment plan
consisting of two or more fields the statement holds in general, i.e. at the whole boundary
of the target region. There the fraction of stopping particles is higher compared to within the
target. Consequently the high LET components, causing a high RBE, are most prominent at
the boundary. A relative uncertainty will therefore translate into a higher uncertainty of RBE-
weighted dose at the margins of a SOBP. In contrast, in the figures the RBE distributions appear
to be almost parallel for different parameter adjustments, leading to a reduced sensitivity at
the margins of the target volume. This is due to the usage of two opposing fields, where at the
margins high LET and comparably low LET components are mixed. Strategies for optimizing
treatment plans such that the high LET components in the radiation field are more uniform
distributed across the SOBP are currently discussed (Bassler et al 2010) and might help to
diminish uncertainties of RBE (Bo¨hlen et al 2012).
When varying one of the input parameters, the RBE values are shifted into the same
direction as was detected in the previous section. That means that the direction of the correlation
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between RBE and any specific parameter remains the same for both monoenergetic beams and
SOBPs.
Regarding the quantity of the deviations a damping is observed compared to the maximum
variations detected in the previous section. This is due to the mixture of LETs which is caused
by the spread of pristine Bragg peaks forming the SOBP and due to fragments, which have to
be taken into account properly (Lu¨hr et al 2012, Gunzert-Marx et al 2008). The mixed radiation
quality also implies a smaller overall RBE, also giving rise to smaller sensitivities. The feature
of damping is of interest for the robustness of treatment plans. Furthermore, as before, the
deviations typically do not exceed 25% and are therefore less than direct proportional to the
change of the specific parameters.
A RBE-weighted dose of 3 Gy approximately corresponds to about 50% and 15% cell
survival for the original set of specific parameters for α/β = 2 Gy and 10 Gy, respectively. But
in contrast to the last section, where the survival levels were fixed in advance by considering
RBEα or RBE10, here the dose remains fixed at 3 Gy, when parameters are varied. Thus an
optimization to 3 Gy when one of the LQ parameters is changed leads to slightly different
survival levels for each parameter adjustment.
Figure 4 presents the results of the sensitivity analysis of the geometric parameters rn and
lDSB. When changing the nuclear radius a variation in RBE is primarily visible in the target
region and suppressed in the entrance channel. This behaviour can be again understood by
looking at the case of monoenergetic ions, where there is only a marginal dependence on rn
in the low LET region. The difference in RBE after a change of the chromatin loop size lDSB
is, in particular for α/β = 2 Gy, comparably large and in contrast to all other parameters
also very prominent in the entrance channels. Again, the reason can be understood by looking
at figure 2 and tables 2 and 3: while the Bragg peak typically covers LETs between 50 and
100 keV µm−1, in the entrance channels lower LET values occur. For RBEα a quite high
sensitivity to lDSB has been found with monoenergetic beams at low LET values. Remnants of
this finding cause the sensitivity in an extended treatment plan.
6. Discussion
6.1. Justification of the approach
The sensitivity analysis presented in this work is based on an approach using single parameter
variations. The question arises if such a ‘factorized’ approach is appropriate and overall
RBE changes could be calculated by a linear superposition of the RBE changes of each
individual parameter. Instead, one also could expect that shifts in any two parameters act on
RBE dependent on each other in a correlated way. We will argue in the following that these
correlations between parameters with respect to RBE change play only a second order role.
Formally, the RBE can be regarded as a mathematical function dependent on a set of
parameters {pi}, i.e. RBE = RBE({pi}). If parameters are changed from {pi} to {pi + δpi}, the
RBE can be expanded in a Taylor series, where the first order term contains a sum of terms
dRBE
dpi δpi, and the second order term of type
d2RBE
dpidp j δpiδp j. Hence the ‘factorization’ approach is
resembled by first order terms, and correlated RBE change by second and higher order terms.
So, if the values of changes are not too large, the second order contributions will be smaller than
the first order contributions and thus can be neglected. For a proper uncertainty analysis this has
to be fulfilled anyway: only if the uncertainties associated with the parameters are smaller than
the parameter values (which is typically the case), the principles of error calculus will apply,
and under this conditions the argument given is valid. We also checked that numerically for
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some examples by calculating the RBE after a coexisting parameter detuning and comparing
it with the RBE calculated with a linear superposition of RBE changes.
6.2. Importance of parameters for RBE uncertainty
The sensitivity analysis presented in the two previous sections reflects how RBE changes, when
one of the input parameters is varied. This allows one to assess the variability of RBE based
on the variability of one of the input parameters. While some of the general parameters such
as δ are obtained with a quite good accuracy from experimental results, others have relatively
large error bars. In this case we followed the strategy to use average values from the literature.
For instance, values in the typical range between 20 and 40 DSB per Gy are reported for αDSB.
Recent works also indicate that the yield could be much higher, but is underestimated due to
systematic experimental errors (Neumaier et al 2012). So, according to the state of research
these parameters may be subject to change in future. However, it is important to note that the
sensitivity on input parameters does not directly provide information about RBE uncertainty,
as shall be explained in the following.
Despite remarkable uncertainties in the input parameters, in combination all general
parameters form a consistent input parameter set, as two of them, lDSB and rc (cf table 1),
were fitted once to experimental data (Furusawa et al 2000, Suzuki et al 2000) to calibrate
the model. By this procedure they compensate for possible misadjustments of the measured
general parameters and minimize the model inherent systematic uncertainties of RBE. Indeed,
a large contribution of the general parameters to the overall uncertainty of RBE values has not
been observed, which indicates that the systematic errors of the LEM are small. For in vitro
cell survival experiments (Elsa¨sser et al 2010) and clinical cases (Gru¨n et al 2012) we showed
in several publications that the LEM predicts RBEs with reasonable accuracy for different
LET values or depths, dose levels and cell types.
The specific parameters characterize the experiment or clinical situation and have to be
evaluated in order to use the LEM. Among them, the genomic length and the geometric
parameters are usually known or can be obtained without too much effort. Thus the interesting
consequence is that the predominant source of uncertainty of RBE, which is a quantity for high
LET radiation is due to the uncertainty of the photon parameters α, β, and Dt , i.e. the response
parameters of the low LET radiation. Thus in the following we focus on these parameters only.
Moreover for RBE simulations it is usually sufficient to fix the ratio α/β, because the RBE
does only marginally depend on a common scaling factor of the absolute values of α and β, for
small and intermediate LET. A plausible reasoning for this is, that the nonlinear dose response
curve leads to a high RBE foremost by means of high local doses. A measure for the excess
effect due to the nonlinearity, normalized to the linear component is just the inverse of the α/β
ratio. Indeed, RBE seems to scale linearly with (α/β)−1 (Friedrich et al 2013). The α/β ratio
can also be used to find an estimate for Dt by means of an empirical relationship. Another
strategy could be to replace the linear quadratic linear model used within the current LEM
implementation by a different photon dose response model which provides the saturation of
effect increments without an explicit threshold parameter. Investigations towards this direction
are on the way, and one possible option is to use the GLOBLE model (Friedrich et al 2012a)
which fulfills these requirements.
6.3. RBE uncertainty for monoenergetic beams and SOBPs
In this section we want to make use of the presented sensitivity analysis and provide examples
for an uncertainty analysis. To understand the influence of the composition of a radiation field
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Table 4. Parameter dependence of RBE for monoenergetic carbon ions in therapy comparable
situations at 3 Gy and for a SOBP composed of two opposing fields and optimized to 3 Gy (RBE)
formed by carbon ions for α/β = 2 and 10 Gy. The upper part contains the LET or dose averaged
LET and the reference RBE values. In the middle section of the table the relative changes in RBE
after change of one parameter about−25% or +25% (bottom or top numbers) are given in per cent.
In the bottom line the overall uncertainty of the RBE value is given, provided the uncertainties of
α, β and Dt are 10%, 20% and 30%, respectively.
α/β = 2 Gy α/β = 10 Gy
Monoenergetic SOBP Monoenergetic SOBP
LET or LETD 77 keV µm−1 54 keV µm−1 77 keV µm−1 52 keV µm−1
RBE 3.63 1.98 2.52 1.48
#RBE
RBE (%) #RBERBE (%) #RBERBE (%) #RBERBE (%)
α −6.3+7.7
−4.5
+5.7
−10.1
+32.8
−5.9
+8.5
β +4.1−6.4
+1.9
−3.0
+7.7
−9.3
+3.4
−4.3
Dt +14.5−17.1
+7.6
−9.0
+6.4
−9.5
+2.5
−3.7
#(%) 20.2 10.7 18.1 7.0
on the parameter sensitivity of RBE in more detail, the centre of a carbon SOBP composed
from two opposing beams and representing a mixed radiation field, was compared with a
monoenergetic beam of high LET, mimicking the distal end of a one-sided SOBP. While in the
former case the radiation field is composed of an overlay of low and high LET components, in
the latter only one high LET component is contributing. Table 4 contains the relative change of
the RBE after an initial change of one of the specific parameters α, β and Dt of±25% for both
cases, where the restriction to the photon parameters is justified by arguments given in the last
subsection. The SOBP has been chosen as in section 5 with two opposing fields optimized to
a RBE-weighted dose of 3 Gy and extended to 60 mm in a depth of 150 mm in the isocentre.
There, the dose averaged LET is 54 keV µm−1 and 52 keV µm−1 for α/β = 2 Gy and α/β =
10 Gy, respectively, where there is a small difference as the dose optimization respects the
α/β ratio and hence results in different LET compositions of the fields. For the monoenergetic
beam an LET of 77 keV µm−1 was chosen as in section 4, but to allow comparison on the same
dose level the RBE was here evaluated at 3 Gy RBE-weighted dose instead of considering
RBEα or RBE10 as before.
For any varied parameter, the relative change of the RBE in the SOBP is damped compared
to the change detected for the monoenergetic beam. The damping can still be observed for a
comparison of the SOBP with a monoenergetic beam of comparable LET (about 50 keVµm−1,
data not shown). Thus it is obviously a consequence of the broader LET distribution within a
SOBP. But the damping of RBE sensitivity goes along with a smaller RBE. Hence for clinical
applications a compromise between the RBE and its uncertainties has to be found. If the RBE
is large, so will be its relative uncertainty, and vice versa.
When a photon dose response curve is known, often one of the parameters α and β can be
determined quite well, while the other has a higher uncertainty. The most crucial part, however,
is to determine an appropriate value for Dt , which is hardly accessible in experiments or clinical
data. As a good estimate one can apply an empirical relationship between Dt and the α/β
ratio, or determine Dt by a fit to high LET data, if available. Exemplarily we here assume that
α, β and Dt are known with uncertainties of 10%, 20% and 30%, respectively, which seem to
be typical estimates. We calculated the corresponding partial uncertainties of RBE by scaling
the numbers given in table 4 from a 25% variation to these uncertainty levels. By calculating
the propagation of the errors one can now evaluate an overall uncertainty in the following way:
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bearing in mind that there is an anti-correlation between α and β induced by the common
LQ fit procedures we simply added their relative errors, which is a rather pessimistic way of
propagating errors, as it does not allow for mutual uncertainty compensation. From this sum
and the uncertainty of Dt then a total uncertainty was calculated by means of Gaussian error
propagation, allowing for such partial compensation of uncertainties. As a result, the overall
relative uncertainties # given in the bottom line of table 4 are obtained.
These numbers are on the one hand typical and indicate the order of magnitude of
uncertainty which is usually expected for RBE simulations with the LEM. They clearly
demonstrate the damping of RBE uncertainties within a SOBP compared to monoenergetic
irradiations. In particular the detected deviations for the irradiation within a SOBP is about
10%, which is in the order of magnitude acceptable for clinical applications. But this calculation
is an example and specific for the choice of the parameters and uncertainty levels of the specific
parameters as well as on the irradiation geometry. The numbers given should hence not be
understood as a general uncertainty analysis. They rather indicate the order of magnitude of
RBE uncertainty to be expected, while for any particular case such an analysis should be
considered individually.
6.4. Sensitivity on photon and ion dose response
As RBE is a relative quantity comparing the doses needed with photons and ions for the
same effect, the question arises if the RBE sensitivity on an input parameter is caused by
the sensitivity of either the ion or the photon dose response curve. This was approached by
monitoring the relative change of doses for ion and photon radiation at the same effect under
parameter variation.
Generally, a change of α will result in larger dose changes for photons as compared to
ions. Hence the RBE sensitivity on α is not due to the high LET dose response, but rather
reflects the uncertainty of the photon dose response itself. In contrast, a change of β term will,
for moderate effects, change the ion dose response curve more severely than the photon dose
response curve. This is because the initial slope of ion survival curves strongly depends on
the photon β parameter which quantifies the nonlinear dose response and hence scales the
enhanced effects of high local doses as delivered to the tissues by individual charged particles
along their tracks.
Thus, concerning α, there is a smaller level of uncertainty in ion therapy as compared to
conventional photon therapies, while for β it is just the opposite. Hence a good fraction (cf
table 4) of the overall uncertainty calculated in the last subsection, corresponding to α will
also be present in a treatment with photon radiation.
6.5. Sensitivity for fixed α/β ratio
From clinical studies there are several ways of obtaining information of the photon dose
response parameters. Quite often the α/β ratio can be fixed quite well (e.g. when found from
fractionation studies) while the derived absolute parameter values α and β can be challenged.
Hence it is also of interest to investigate the RBE dependence on photon parameter change
when the α/β ratio stays fixed, i.e. when α and β are changed jointly by the same factor
of 25%. This was checked, and we found for the therapeutic relevant LET range that there
is almost no dependence of RBEα on parameter change, and that there is about 10% or 5%
maximum change of RBE10 for α/β = 2 and 10 Gy, respectively. This can be interpreted by
the principles of LEM: The action of individual ions is expressed by the linear coefficient αI
of ion dose response curves, which directly determines RBEα . In LEM, it is obtained as an
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extrapolation from photon effects, which are linear in both α and β. If they both are scaled by a
common factor, so will αI , and hence RBEα remains constant. As for the quadratic component
βI nonlinear terms arise, describing the interaction of lesions from different ions, this argument
does not hold and thus a sensitivity of RBE10 on parameter change is detected.
In clinical practice, however, as both α and β are affected by uncertainties (e.g. due to a
limited patient number but also due to inter-individual differences), the α/β will also show an
uncertainty. Thus always a sensitivity analysis for different α/β ratios should be carried out
in prospective treatment planning.
6.6. Sensitivity on distributions of input parameters
In a population of cells the input parameters for estimating the RBE might not assume a single
value but rather be subject to a distribution. For instance the geometrical cross section of cell
nuclei shows a broad distribution for most cell lines. Then in a first approach the strategy is
to rely on the mean of the parameter values, resulting in a RBE which approximates the mean
RBE to first order. Associated uncertainties can be estimated using the sensitivity analysis
presented here.
A full consideration of distribution effects would require to determine the contribution of
each subpopulation of the distribution to the corresponding RBE distribution. However, for
a more pragmatic handling the parameter distribution is replaced by an effective parameter,
reproducing the mean RBE. For the nuclear geometrical cross sections at high LET where the
RBE is sensitive on the nuclear cross section due to overkill, for a given distribution of cross
sections an effective cross section of typically less than the mean (about 80%) will reproduce
the mean RBE (Elsa¨sser et al 2008).
Another example where uncertainties due to parameter distributions play a role is the
variability in dose response within a patient population in therapy. It is common procedure to
apply non-individualized regimens, where recommended doses are found by dose escalation
studies over sufficient large patient numbers. The distribution of radiosensitivity parameters
leads to a flattening of the dose response curve of tumour control (Dasu et al 2003). This
phenomenon can be quite crucial and eventually has to be taken into account for analysis
of clinical outcomes (Kanai et al 2006). However, as seen for the α term in this study the
population heterogeneity has higher impact on dose response to photon than to ion radiation
(Scholz et al 2006). A more personalized determination of input parameters, e.g. by means of
biomarkers, could help to further reduce uncertainties.
6.7. Strategies for sensitivity minimization
The general goal of any kind of radiation therapy modality is to deliver dose in the target region
and to avoid dose delivery as good as possible within the surrounding healthy tissue. Further
constraints as sparing out organs at risk may apply. But regarding charged particle therapy
recent work (Bassler et al 2010, Grassberger et al 2011) questions if a homogeneous dose
distribution across the target should be the only objective in treatment planning. Additionally,
LET homogeneity could be another promising objective. In addition to dose homogeneity,
LET homogeneity promises to reduce RBE uncertainties. Other studies investigated practical
applicability, e.g. by ramp fields (Kra¨mer and Ja¨kel 2005) or by modifying the LET distribution
by active scanning (Grassberger et al 2011) and quantified implications for the RBE uncertainty
(Bo¨hlen et al 2012). In a previous work (Gru¨n et al 2012) we demonstrated that the delivery
of dose in two opposing fields, both contributing equally to the overall dose, reduces the
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uncertainties very effectively. Table 4 gives evidence for the reduced RBE uncertainty
(damping), but also demonstrates the reduction of RBE going along.
Unavoidably, an uncertainty-free RBE model cannot exist, as the biological determinants
of RBE, i.e. the radiosensitivity parameters, are subject to variability. Hence a reduction of RBE
uncertainty as much as possible as a consequence of a more homogeneous LET distribution
might be desirable, and could be realized by combining different fields irradiated in different
angles in the target volume, or even inhomogeneous dose fields adding up to a homogeneous
dose across the target volume. Finally, depending on particular aspects of the treatment plans,
a compromise between a high RBE in the target (without caring about LET distribution) and
a lower, but less uncertain RBE (applying a rather homogeneous LET distribution) has to
be found.
6.8. Relation to other RBE models and to experimental RBE data
Throughout this paper, many aspects of RBE uncertainty have been discussed at hand of the
LEM. But most of the implications of this study are also revealed by other high LET models. In
the MKM, which is the only model apart from LEM used in clinical practice in recent versions
(Inaniwa et al 2010, Sato and Furusawa 2012), the prediction of the RBE is based on the dose
response to photon radiation, too, and hence their uncertainties are propagated to RBE in a
similar way. The model of Carabe and Jones (Carabe-Fernandez et al 2007, Jones et al 2012)
is a reformulation of the LQ model and thus input data of both radiation qualities are needed
for which the RBE is to be predicted. It uses only few assumptions and also demonstrates the
direct dependence of RBE on photon dose response parameters.
Finally, by investigating experimental RBE data (Friedrich et al 2013, Paganetti et al
2002), a scatter of measured RBE values of in vitro cell survival experiments reflects the
order of magnitude of RBE uncertainty corresponding to the model predictions (calculated
from typical uncertainties of the photon parameters as in table 4), except for low LET where
some remaining systematic deviations of LEM predictions in comparison to experimental
RBE values are present. To give an order of magnitude, for monoenergetic carbon ions with
an LET of 77 keV µm−1 at 3 Gy the typical RBE uncertainty is 20% and almost independent
on the α/β ratio. As outlined before, this number will be damped within an SOBP.
This agreement between RBE uncertainties observed in experiments and the uncertainties
predicted by RBE modelling is a further strong support that LEM is able to predict essential
characteristics of RBE. This also implies that the results presented in this study are not model
specific, but are rather general properties of RBE.
7. Conclusions
This work provides a detailed and systematic discussion of the sensitivity of RBE to its
determining parameters. It demonstrates that radiobiologic models such as LEM are suitable
to predict RBE along with the RBE uncertainty for applications in radiobiologic experiments
and particle therapy. In particular two findings which have been presented in the previous
sections are important for the discussion of simulated RBE values. First, the RBE values
depend typically less than proportional on the determining parameters, with few exceptions
only. Second, going over from cells or tissues irradiated with monoenergetic beams to extended
volumes irradiated with a SOBP, the influence of uncertainties on RBE values are damped
due to the mix of radiation qualities at each position in the SOBP. The results and methods
presented may thus be helpful for optimizing the precision of RBE predictions.
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Purpose: Proton radiotherapy is rapidly becoming a standard treatment option for cancer. However,
even though experimental data show an increase of the relative biological effectiveness (RBE) with
depth, particularly at the distal end of the treatment field, a generic RBE of 1.1 is currently used in
proton radiotherapy. This discrepancy might affect the effective penetration depth of the proton beam
and thus the dose to the surrounding tissue and organs at risk. The purpose of this study was thus to
analyze the impact of a tissue and dose dependent RBE of protons on the effective range of the proton
beam in comparison to the range based on a generic RBE of 1.1.
Methods: Factors influencing the biologically effective proton range were systematically analyzed
by means of treatment planning studies using the Local Effect Model (LEM IV) and the treatment
planning software TRiP98. Special emphasis was put on the comparison of passive and active range
modulation techniques.
Results: Beam energy, tissue type, and dose level significantly affected the biological extension of
the treatment field at the distal edge. Up to 4 mm increased penetration depth as compared to the
depth based on a constant RBE of 1.1. The extension of the biologically effective range strongly
depends on the initial proton energy used for the most distal layer of the field and correlates with the
width of the distal penumbra. Thus, the range extension, in general, was more pronounced for passive
as compared to active range modulation systems, whereas the maximum RBE was higher for active
systems.
Conclusions: The analysis showed that the physical characteristics of the proton beam in terms of the
width of the distal penumbra have a great impact on the RBE gradient and thus also the biologically
effective penetration depth of the beam. © 2013 American Association of Physicists in Medicine.
[http://dx.doi.org/10.1118/1.4824321]
Key words: proton radiotherapy, biologically effective range, RBE, LEM, treatment planning, distal
penumbra
1. INTRODUCTION
Proton beam therapy is becoming a clinical standard treat-
ment procedure in radiotherapy for specific types of cancer
which are difficult to treat with surgery or conventional
radiotherapy with photons. Protons are known for their
superior depth dose profile compared to x-rays, and their
tissue sparing effects make them particularly suitable for
tumors located close to critical structures. The biological
effectiveness of protons in tissue has been shown to be on av-
erage very similar to that of x-rays for in vivo endpoints1 and
most of their path which is why a constant relative biological
effectiveness (RBE) of 1.1 is used in clinical practice.2
Nevertheless, in vitro studies show that even protons have
an increased RBE at the end of their range, which significantly
exceeds 1.1 depending on the tissue type.3 There are only
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few experiments which determined a RBE at the distal end of
the extended Bragg peak, but nearly all showed an increase,
which clearly exceeds 1.1.4–10 This increase of the RBE can
be explained by the sharply increasing linear energy transfer
(LET) at the distal edge of the spread-out Bragg peak (SOBP),
which consequently leads to an extension of the effective pro-
ton range as described, e.g., by Larsson and Kihlman,11 Sweet
et al.,12 and Robertson et al.4 The major deviation from a
constant RBE of 1.1 thus occurs at the distal field end and
strongest in the distal edge of the Bragg peak. The resulting
biological extension can be of special concern for organs at
risk (OAR) located close to treated tumors, especially if the
beam is directed toward the critical structure. Moreover, as in
general for high-LET radiation, the tissue type and dose level
are expected to have significant impact on the RBE and thus
also on the extension of the effective range as also shown by
Carabe et al.13
The Local Effect Model (LEM) in its recently published
version (LEM IV) (Refs. 14 and 15) has shown to be suitable
to predict tissue and energy dependent RBE values not only
for carbon ions but also for protons and other clinically rele-
vant ions. In the present work, we thus use the LEM IV for
a systematic analysis of the factors influencing the biological
range extension. We first analyze the impact of the biological
characteristic of a given tissue and physical parameters such
as dose, dimension, and depth of the SOBP on the extension
of the effective range. Special attention is then turned to the
influence of the physical beam characteristics on the biolog-
ical extension and the subsequent systematics by comparing
different beam delivery methods, i.e., active and passive beam
delivery. We finally discuss the potential impact of these fac-
tors in clinical cases, where the range extension might be of
concern for the dose delivered to the surrounding tissue.
2. MATERIALS AND METHODS
2.A. Treatment planning
To investigate the biologically effective range of pro-
tons, idealized target geometries (cubes) placed in a simu-
lated water phantom were used to facilitate the systematic
analysis. The cubic volume has a fixed lateral dimension of
50 × 50 mm2 but varies in its dimension along the beam
axis. Treatment plans consisted of only one field to most
clearly illustrate the range extension. The treatment plan-
ning system TRiP98 was used to optimize the physical dose
distribution.16–18
As proton treatments can utilize active or passive range
modulation, both modalities were simulated. For active range
modulation,19 the primary beam energy was varied in order to
shift the Bragg peaks in depth, for example, used at the Hei-
delberg Ion-Beam Therapy Center (HIT). For passive range
modulation, a range shifter was simulated. With the range
shifter modality, only single primary proton energies are used
and polymethyl methacrylate (PMMA) plates are positioned
in between the beam exit window and target area to degrade
the beam energy and shift the Bragg peak in depth.20 Note
that with active range modulation the energies used depend
on the location and dimension of the target volume whereas
the passive range modulation uses one fixed energy. We
thus simulated typical energies used in proton beam therapy
with the passive modality, i.e., 160 and 235 MeV as well as
monoenergetic beams from 71 to 220 MeV. However, the
details of the beam characteristic at different institutions are
expected to be accelerator and beam line dependent, and thus
the analysis presented here mainly focuses on the general as-
pects of the range modulation technique rather than a detailed
facility-dependent beam description.
Note that within this paper the terms “active” and
“passive” only refer to the range modulation technique. Con-
cerning the lateral extension of the treatment field for both
range modulation modalities, a spot scanning technique via
horizontal and vertical deflection of the beam was simulated.
The dose levels were chosen from 1 to 10 Gy absorbed dose to
cover the whole clinically relevant range of dose prescriptions
including hypofractionation.
2.B. RBE data
Biological optimization with TRiP98 requests RBE input
data, which are calculated with the LEM. The basic princi-
ple of the LEM is to derive the biological effectiveness of
ion beam radiation from a combination of the known dose
response curve for photon radiation with the description of
the microscopic dose deposition pattern of individual particle
tracks.14, 21–23 For the prediction of the RBE, the latest ver-
sion of the LEM (LEM IV) was used, which has been shown
in a previous publication14 to predict the RBE over a wide
range of particles from protons to carbon ions with sufficient
accuracy. The LEM can be used to precalculate RBE values
for all projectiles from protons to neon in the energy range
from 0.1 to 1000 MeV/u, which characterize the RBE for the
initial slope of the dose response curves and are stored in a
so-called “RBE-table”. These precalculated values are used
as input for the TRiP98 treatment planning system, which de-
termines actual RBE values based on the mixed composition
of the radiation field and the dose in each voxel of the treat-
ment volume.17, 24
The biological input parameters of the LEM are the pa-
rameters αγ , βγ , and Dt describing the photon dose-response
curves according to a modified linear-quadratic model. This
modification is characterized by a transition to a linear shape
for doses larger than Dt,21 which is consistent with the linear-
quadratic-linear model as proposed by Astrahan25 with
S(D) =
{
e−(αγD+βγD2) for D < Dt
e−(αγDt+βγD2t +smax(D−Dt )) for D ≥ Dt
, (1)
where smax = αγ + 2βγ Dt is the maximum slope of the pho-
ton dose response curve for doses larger than Dt. All other
parameters of the LEM are kept constant and were chosen as
described in Elsässer et al.14
In a first step, it was demonstrated that the combination
of LEM and TRiP98 actually allows to accurately predict the
variation of RBE along the SOBP for proton beams. There-
fore, the model predictions were validated by comparison
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TABLE I. Input parameters for the RBE tables.
RBE table αγ (Gy−1) βγ (Gy−2) αγ /βγ (Gy) Dt (Gy)
AB6.5a 0.16 0.0246 6.5 13
AB47.5 0.57 0.012 47.5 15
AB2 0.1 0.05 2 8
AB10 0.5 0.05 10 14
aAB is the abbreviation for the photon αγ /βγ -ratio with the number representing
its value.
with two sets of experimental RBE data obtained for differ-
ent cell lines with significantly different sensitivities. Tang
et al.7 measured the RBE for survival of Chinese hamster
ovary (CHO) cells exposed to doses of 1, 2, 4, 6, and 8 Gy
and at different depth positions of 2, 10, 18, and 23 mm, us-
ing a 65 MeV proton beam to produce a SOBP with about
17.5 mm extension located between approximately 10 and
27.5 mm depth. As input parameters for the model calcula-
tions, the photon parameters obtained with Cs-137 gamma
rays given in Tang et al.7 together with a Dt of 13 Gy for
the RBE table AB6.5 (Table I) were used.
Bettega et al.8 determined the RBE for the survival of
SCC25 cells derived from human squamous cell carcinoma of
the tongue in a 65 MeV modulated proton beam of 15 mm ex-
tension. The corresponding photon input parameters, as given
in Bettega et al.8 for Co-60 gamma rays, together with a Dt of
15 Gy, were used for the RBE table AB47.5 (Table I). For the
two simulated SOBP, a bolus of 5.9 mm was used to adapt the
position of the Bragg peak in depth; this accounts for facility-
and beam line specific details not taken into account in this
simulation study.
For the systematic studies regarding the biological range
extension, two different RBE tables were used (Table I). The
RBE tables describe two hypothetical cell or tissue types with
an αγ /βγ -ratio of 2 Gy (AB2), characteristic for rather ra-
dioresistant late responding cell or tissue types, and with an
αγ /βγ -ratio of 10 Gy (AB10), characteristic for rather ra-
diosensitive early responding cell or tissue types.26 The pa-
rameter settings are typical for in vitro cell survival assays,
where a change of the αγ /βγ -ratio usually goes along with a
change of αγ rather than of βγ . The parameter Dt was adapted
according to an empirical approximated linear relation be-
tween αγ /βγ -ratio and Dt. This relation was found empiri-
cally when using the LEM over a huge set of experimental
cell survival data.27
2.C. Determination of the biologically effective range
The biological range extension was quantified by taking
into account the RBE predicted by the LEM IV for differ-
ent dose-levels and biological endpoints described by the
αγ /βγ -ratio. As a reference dose distribution, we optimized
a physical absorbed dose and calculated the corresponding
RBE-weighted dose with constant RBE of 1.1; the depth
where the RBE-weighted dose decreased to 80% of the pre-
scribed RBE-weighted dose, i.e., dcRBE80 = 0.8 · dcRBEprescr was
used to determine the corresponding biologically effective
(a)
(b)
FIG. 1. (a) Schematic example for the difference Rdiff80 between bio-
logical range for constant RBE = 1.1 and variable RBE. The black
dashed line corresponds to the dcRBE80 . (b) Schematic comparison of the
range extension for two initial proton energies of 80 and 160 MeV. For
160 MeV, a water equivalent absorber was simulated in order to shift the
distal end of the SOBP to the same position as for 80 MeV.
range RcRBE80 . The 80% isodose d80 was chosen according to
considerations of Gottschalk28 where it was stated that the
distal d80 is a well suited value to describe the range of the
proton beam since it is independent of the energy spread of
a certain beam and reflects the mean projected range of the
protons.28,13 Figure 1(a) schematically shows the biological
range extension due to a variable RBE with depth indicated
by the green line segment.
In analogy to the reference value, the biologically effec-
tive range in the case of a variable RBE, RvarRBE80 , was also
determined from the position where the RBE-weighted dose
decreases to the reference value of dvarRBE = dcRBE80 = 0.8 ·
dcRBEprescr as defined above for the case of constant RBE. The bi-
ological extension, i.e., the difference in biological range pre-
dicted by the LEM IV as compared to the case of a constant
RBE is then calculated as Rdiff80 = RvarRBE80 − RcRBE80 .
The biological extensions were determined for the RBE
tables AB2 and AB10 (Table I) together with all the previ-
ously described settings and field arrangements. Moreover,
the biological extension was determined for monoenergetic
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Bragg peaks ranging from 71 to 220 MeV optimized to differ-
ent dose levels and covering penetration depths from approx-
imately 50 to 300 mm. For the monoenergetic Bragg peaks,
the peak defines the dose level and the Rdiff80 is determined as
described above.
Furthermore, the influence of the width of the 80/20 distal
penumbra of the Bragg peak on the biological extension was
investigated. The width is defined as the difference in pene-
tration depth from the 80% isodose (percentage of the pre-
scribed dose) to the 20% isodose.2 Note that the symbols in
Figs. 3–6 correspond to simulated data points and the corre-
sponding lines are empirical best fit-curves to the data points
with the aim to guide the eye. Figure 1(b) demonstrates the
difference in the width of the distal edge of the Bragg peak
using different energies to modulate the SOBP. Due to mo-
mentum spread and range straggling effects (scattering and
range modulation components in the nozzle), which are more
prominent for higher energies, the 80/20 distal penumbra in-
creases with increasing energy.29
Finally, the RBE at the position of the maximum RBE-
weighted dose was evaluated to investigate the correlation
with the width of the 80/20 distal penumbra. The RBE at max-
imum RBE-weighted dose was chosen because it is a measure
for the highest effect in the tissue. To choose the maximum
RBE would be not suitable since the RBE further increases
throughout the distal penumbra and is highest for infinitesi-
mal doses which go along with high uncertainties. The ranges
RcRBE80 and RvarRBE80 were determined along the central axis of
the beam using TRiP98.
3. RESULTS
3.A. Comparison with experimental RBE
measurements along depth
Figure 2(a) shows the RBE measurements reported by
Tang et al.7 with CHO cells in different depths for 1, 2, 4,
6, and 8 Gy, respectively. The model predictions based on the
RBE table AB6.5 are in accordance with the experimentally
observed RBE within the SOBP; the RBE is slightly underes-
timated by the model in the entrance region.
Figure 2(b) shows the RBE measurements reported by Bet-
tega et al.8 with the SCC25 cell line in different depth posi-
tions including the declining edge for 2, 5, and 7 Gy, respec-
tively. The RBE prediction is based on the RBE-table AB47.5
for a 65 MeV modulated proton beam. Only a minor dose de-
pendence, but still a strong increase of RBE at the declining
edge, is observed.
Since in both cases a good agreement of the model pre-
dictions and experimental data was observed, the accuracy of
the model was considered to be sufficient for the systematic
analysis described in Secs. 3.B and 3.C.
3.B. The biologically effective range
We systematically analyzed the impact of the increased
RBE of low energetic protons on the extension of the effective
range considering various physical and biological parameters:
(a)
(b)
FIG. 2. (a) RBE predicted by the LEM for CHO cells based on RBE table
AB6.5 (Table I) (lines). The symbols correspond to the RBE values measured
by Tang et al. (Ref. 7) for CHO cells at different positions of a passively mod-
ulated 17.5 mm SOBP with a pristine energy of 65 MeV for different physical
dose levels in the SOBP of 1, 2, 4, 6, and 8 Gy. (b) RBE predictions by the
LEM for SCC25 cells based on RBE table AB47.5 (lines). The symbols cor-
respond to the RBE values measured by Bettega et al. (Ref. 8) at different
positions of a passively modulated 15 mm SOBP with a pristine energy of
65 MeV for different physical dose levels of 2, 5, and 7 Gy in the SOBP. The
vertical dashed line in both plots indicates the depth at which the dose drops
to dcRBE80 in the case of a constant RBE.
! The dose level! The extension and position in depth of the target volume! The range modulation technique (active and passive)! The tissue type as characterized by the αγ /βγ -ratio for
photon irradiation.
Figure 3 shows the biological range extension dependent
on the dose for target volumes all having the same proximal
end (a) and target volumes all having the same distal end but
differing in their depth dimension (b). The calculation was
performed using the active range modulation method with dif-
ferent energies to cover the target volume. Independent from
the dimension of the SOBP, only minor differences are ob-
served when the distal end of the spread out Bragg peak is
positioned at the same depth. In contrast, target geometries of
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(a)
(b)
FIG. 3. Dose dependent biological range difference Rdiff80 for different target
depth dimensions from 20 to 100 mm for active beam modulation with same
proximal end at 50 mm but different RcRBE80 (a) and same RcRBE80 at 152 mm
but different proximal end (b). The solid symbols correspond to an αγ /βγ -
ratio of 2 Gy and the open symbols to an αγ /βγ -ratio of 10 Gy, in (b) the
curves lie on top of each other. Note that here and in subsequent figures the
symbols represent the simulated data points and the lines are empirical best
fit-curves to the data points with the aim to guide the eye.
the same dimension with the distal end positioned in differ-
ent depth (same proximal end) show large variations in the
biologically effective range extension.
For passive range modulation, a bolus was simulated to
shift the proximal end of the SOBP to the same position in
depth when using different energies. As shown in Fig. 4, the
biological extension is largely different when comparing the
different initial energies of 160 and 235 MeV, respectively.
This demonstrates that the biological extension is not ex-
plicitly depth dependent, but the primary energy determines
the effect. The difference between the active and the passive
modulation results from the difference to vary the penetra-
tion depth of the primary beam. In the first case, the penetra-
tion depth of the primary beam is varied using different initial
energies (Fig. 3) whereas in the second case the penetration
depth is varied placing material behind the beam exit window
(Fig. 4), leading to more pronounced range straggling.
(a)
(b)
FIG. 4. Dose dependent biological range difference for different target depth
dimensions in depth from 20 to 60 mm using the passive range modulation
with the same proximal end at 50 mm but different distal ends RcRBE80 for
initial energies of 160 (a) and 235 MeV (b). The solid symbols correspond
to an αγ /βγ -ratio of 2 Gy and the open symbols to an αγ /βγ -ratio of 10 Gy.
Note that the curves for the different dimensions lie on top of each other.
The fact that the biological extension of the beam does not
depend on the extension of the target volume, but seems to
primarily depend on the initial energy indicates that the bio-
logical range extension is mainly determined by the width of
the 80/20 distal penumbra. We thus analyzed the correlation
of the biological extension with the width of the 80/20 dis-
tal penumbra using monoenergetic Bragg peaks with different
initial energies ranging from 71 to 220 MeV.
Figure 5(a) illustrates the biological range extension de-
pendent on the 80/20 distal penumbra. Variation of the distal
penumbra is achieved by variation of the energy from 71 to
220 MeV, and with increasing energy an increase of the dis-
tal penumbra is observed due to a more pronounced range
straggling. The increasing distal penumbra is connected to an
increased extension of the biologically effective range, which
is most pronounced for low doses, low αγ /βγ -ratios, and high
energies as used for deep seated tumors, i.e., 235 MeV, where
range differences exceeding 4 mm are observed [Fig. 4(b)].
The extension of the biologically effective range emerges due
to a competition between the decreasing dose and increasing
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(a)
(b)
FIG. 5. Biological range difference (a) and RBE at maximum RBE weighted
dose (b) vs the distal penumbra for different physical dose levels of 1, 3, 6,
and 10 Gy. The data points represent the distal penumbra for energies from
71 to 220 MeV. The solid symbols correspond to an αγ /βγ -ratio of 2 Gy and
the open symbols to an αγ /βγ -ratio of 10 Gy.
RBE. Decreasing initial energy accompanies a steeper dose
penumbra and leads to a higher LET and thus maximum RBE
at the distal part of the SOBP [Fig. 5(b)]. Simultaneously, the
LET gradient in the distal penumbra of the dose distribution
becomes steeper and covers a smaller region in depth, and
correspondingly the biological range extension becomes less
pronounced [Fig. 5(a)]. Figure 5 thus demonstrates that the
RBE at maximum RBE-weighted dose is anticorrelated with
the width of the 80/20 distal penumbra, whereas the biological
range extension correlates with the 80/20 distal penumbra.
3.C. Influence of the reference isodose
The range of the proton beam is a matter of definition. In
the clinical routine, the range of the proton beam in water is
defined at the distal 90% isodose.2, 30 In this study, the 80%
isodose is used as reference for the biological range exten-
sion. The 80% isodose is a good compromise to describe the
biological spread of the beam since it reflects the extension of
the high dose region at the distal end as well as for the phys-
ical properties.28 Figure 6 shows the influence of the isodose
FIG. 6. Difference in biological range extension of the proton beam for
range definitions based on various isodoses from 90% to 20%. The differ-
ences are shown for a target volume of 100 mm depth dimension with the
RcRBE80 at 152 mm which corresponds to an energy of ∼150 MeV. The as-
sumed αγ /βγ -ratio is 2 Gy.
level used for the proton range definition on the biological
range extension with different reference isodoses from 90%
to 20%. The choice of the reference isodose matters mainly
for small doses where the largest deviations are observed
in the predicted biological range difference between the
reference isodoses.
4. DISCUSSION
4.A. Relevance of a variable RBE
With the increasing interest in protons as a promising treat-
ment modality for cancer radiotherapy, an accurate prediction
of the increased biological effectiveness and assessment of
the associated uncertainties becomes important. Two aspects
especially have to be considered here:! The increased RBE-weighted dose observed at the distal
end of the SOBP! The extension of the RBE-weighted depth-dose profile
due to the rise of RBE in the distal penumbra.
Due to the competition between increasing RBE with
depth and decreasing dose, the position of the maximum
RBE-weighted dose and maximum RBE typically do not co-
incide; the maximum RBE-weighted dose is reached close to
the end of the SOBP, whereas the maximum RBE is found
beyond that position at low doses in the penumbra region of
the dose distribution.8, 31
Experiments which focus on the measurement of RBE
along the proton SOBP typically aim at the determination of
the maximum RBE-weighted dose, since this is of particular
interest with respect to constraints concerning the tolerance
of normal tissues located close to the distal end of the treat-
ment field. Many in vitro experiments indicate a rise of RBE
at the distal end significantly above the clinically used value
of 1.1.4–10 However, the experimentally determined RBE in
the distal edge is associated with large uncertainties since the
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measurement is very difficult due to the steep dose and LET
gradient.
Because of uncertainties in the systematic description of
this increased RBE, e.g., in terms of dose level and tissue
characteristics, a detailed depth dependence is currently not
taken into account in clinical practice.3,1 Instead, situations
are avoided where an increased RBE could lead to unaccept-
able high normal tissue doses, and consequently the poten-
tial advantages of proton beams cannot be fully exploited
yet. Therefore, there is a clear need to make progress in
the detailed analysis of the factors influencing the RBE in
proton beams and to take them into account in treatment
planning.32–35 Biophysical models are valuable in that respect
because they allow extrapolation to situations that are difficult
to exploit experimentally. However, thorough validation of a
model by means of available experimental data is of course
required before it can be used for this extrapolation.
4.B. Validation of the LEM for proton irradiation
For the analysis presented here, we used the LEM IV
that has been demonstrated to accurately predict the biolog-
ical effectiveness of protons for a typical clinical treatment
scenario.14 However, a more detailed analysis is desirable to
further validate the model with respect to the dependencies
of RBE on the depth position in the SOBP, the dose level
and the cell or tissue type under consideration. We have thus
compared the model prediction along the SOBP to two data
sets reported by Tang et al.7 and Bettega et al.8 for CHO and
SCC25 cells, respectively.
For both cellular systems, in general a very good agree-
ment between model prediction and experimental data has
been achieved for different dose levels and different posi-
tions within the SOBP. In the entrance region, the LEM some-
what underestimates the RBE in the case of CHO cells. This
might be traced back to the contribution of secondary recoil
protons induced in the target material, which are not taken
into account in the current version of the treatment planning
system. Other studies36, 37 have shown that this contribution
could lead to about 8% higher RBE values in the entrance re-
gion. In contrast to CHO cells, for SCC25 good agreement
is also observed in the entrance region. However, because of
the generally lower RBE values for SCC25 as compared to
CHO cells, this cell system might not be sufficiently sensitive
to detect this subtle difference. Anyhow, the observed under-
estimation of the RBE in the entrance channel has no influ-
ence on the agreement of the RBE prediction in the distal end
and penumbra and thus is not of concern for the estimated
biological range extension.
4.C. Impact of dose and tissue type on the biological
range extension
Because of its good agreement with measured RBE values,
the LEM is suitable to analyze in detail the extension of the
biologically effective range that results from a variable RBE
as compared to a constant RBE value of 1.1. In general, ac-
cording to the LEM prediction the extension is expected to be
more pronounced for tissues characterized by a low αγ /βγ -
ratio as compared to tissues with a high αγ /βγ -ratio. The dif-
ference is most significant at low doses and gets smaller with
increasing dose. We did not focus on the sensitivity of the
threshold dose Dt since we adapted the parameter according
to an empirical relation between the αγ /βγ -ratio and Dt found
by Friedrich et al.27 Apparently, a variation of Dt accompanies
a RBE variation which also influences the biological range ex-
tension. However, in the case of protons, the RBE is rather ro-
bust for a Dt variation and the main determinant for the RBE
remains the αγ /βγ -ratio.
These general trends are in line with the results recently
published by Carabe et al.13 They also analyzed the biolog-
ical range extension, but used another empirical model for
the calculation of RBE values38 and a different evaluation
method for the biological range difference based on the dif-
ferences becoming apparent in the dose-volume histogram
(DVH). However, this evaluation method is not too differ-
ent from the central axis approach we used due to the fact
that we as well as Carabe et al.13 consider idealized target
geometries (cubes) in our analysis. We thus expect no differ-
ences since deviations in the DVH are only due to the biolog-
ical range extension at the distal end. Their results also indi-
cate a dose dependence of the range extension, although this
dose dependence seems significantly less pronounced as in
our case. Similarly, Carabe et al.13 also demonstrate a tissue
dependence of the range extension, where for small αγ /βγ -
ratios the range extension is much more pronounced than
for high αγ /βγ -ratios. However, in this case, the results re-
ported by Carabe et al.13 differ not only quantitatively but also
qualitatively from our results. Whereas in our analysis for all
situations an increased extension as compared to the assump-
tion of a constant RBE is found, in the analysis of Carabe
et al.13 in general negative extensions are found for higher
αγ /βγ -ratios, indicating that the corresponding RBE values
in the distal penumbra are smaller than the reference value of
1.1. This is in contrast to our case, where RBE values always
higher than 1.1 are predicted for all combinations of dose
levels and αγ /βγ -ratios that were analyzed.
Since the predicted extension obviously significantly de-
pends on the model that is used for the RBE calculations, a
detailed conceptual comparison of the different models and
their underlying assumptions would be highly desirable. Al-
though this detailed discussion would be beyond the scope
of the present paper, we would like to address the main as-
pects that are likely to contribute most to the differences ob-
served between the two models. For the LEM, according to
the track structure properties, the minimum RBE value pre-
dicted for low LET protons is 1 [the slightly lower value of
0.97 observed in Fig. 2(b) for the very sensitive SCC25 cells
is considered to be insignificant with respect to the magni-
tude and range of RBE values discussed here]. In contrast,
the parameterization used by Carabe et al.13 allows for RBE
values substantially below 1 at low LET and in particular for
higher αγ /βγ -ratios; the limiting value for LET → 0 is re-
ported to be 0.843. This difference is likely due to the fact that
actually the RBE-LET relationship is not exactly linear in the
LET range up to 20 keV/µm. The LEM predicts a vanishing
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slope for the RBE-LET dependence in the limit of LET→ 0,
but then shows an overproportional increase toward the high
LET values. A linear fit to such a bended curve would typ-
ically show an underestimation of the RBE at very low and
high LET values, but an overestimation at intermediate LET
values. A more thorough comparison to experimental data
would however be required to analyze this aspect in detail.
Furthermore, if for a given proton energy the LEM predicts
RBE values greater than 1, the RBE values in general decrease
with increasing dose. In contrast, although details depend on
the LET and αγ /βγ -ratios, according to the parameterization
used by Carabe et al.13 the maximum RBE values observed at
low doses (RBEmax) can be smaller than the minimum RBE
values (RBEmin) that represent the RBE values for D→∞.
This corresponds to an inverted dose dependence of RBE as
compared to the LEM prediction. Taken together, although
the general trends like increase of RBE with increasing LET
and decreasing αγ /βγ -ratio are similarly predicted by both
approaches, the RBE values along a SOBP might be system-
atically shifted in the model used by Carabe et al.13 as a con-
sequence of the above mentioned quantitative differences, and
might show an inverted dose dependence of RBE for low LET
values.
4.D. Impact of the dose gradient at the distal
penumbra on the biological range extension
In our analysis, we showed that for different range modu-
lation techniques significantly different range extensions are
expected, and that these variations can be traced back to the
gradient in the distal penumbra of the dose distribution. To
our knowledge, this aspect has not been addressed in detail
by other studies so far; they mainly focus on the maximum
RBE-weighted dose in the distal edge and the consequential
overdosage, which are of concern for the nearby OARs.3, 39
Nevertheless, the impact, e.g., of the full-width at half max-
imum (FWHM) of the proton peak on RBE effects in general
has been recognized, but not been specifically analyzed
in terms of the dose gradient at the distal penumbra. For
example, Paganetti et al.31 reported about the anticorrelation
between the RBEα (ratio of initial slopes, αI/αγ ) at the maxi-
mum dose of pristine Bragg peaks for different beam energies
and their corresponding FWHM. Surprisingly, although no
supporting details are presented in this paper, the authors con-
clude that the biological extension “increases with decreasing
initial proton energy,” which is in contrast to our results.
Furthermore, Paganetti and Schmitz40 discuss the influence
of beam modulation techniques on dose and RBE in proton
radiation therapy. They show that the RBE gradient becomes
less pronounced with increasing initial proton energy, but
the aspect of range extension is not addressed in their
paper.
In that respect, it might be important to emphasize that
lower overall RBE values do not necessarily lead to a less
pronounced biological extension of the SOBP. Instead, the
range extension critically depends on the balance between
increase of RBE and the dose gradient at the distal penumbra,
as schematically illustrated in Fig. 7. If the dose gradient
Depth
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FIG. 7. Schematic example for the influence of the dose gradient at the distal
penumbra on the biological range extension.
and with that the LET gradient is high, this results in com-
parably large RBE values. However, even a correspondingly
large vertical shift of the depth-dose curve resulting from
the high RBE values will not lead to a large longitudinal
shift because of the high dose gradient. In contrast, for a
shallower distal penumbra, the corresponding RBE values
might be lower, but due to the inclination of the distal
penumbra even a comparably small vertical shift can lead
to a more pronounced longitudinal shift. This effect is,
moreover, independent on the model used to predict the
RBE.
Consequently, the biological range extension is also af-
fected by the beam delivery method. In active range modu-
lation techniques, in general, lower initial energies are used,
leading to a higher gradient of the distal penumbra. This
results in a high maximum RBE at the distal edge, but a
smaller biological range extension. In contrast, passive range
modulation techniques use higher initial energies, leading to
a shallower gradient of the distal penumbra. In this case,
smaller maximum RBE values but a more significant bio-
logical extension is expected. Nevertheless, it is primarily
the resulting gradient that determines the biological exten-
sion, but not the exact technique that is used to generate the
SOBP.
According to these considerations, the increased RBE of
protons at the distal end shows up in any case, either as a com-
parably high RBE at the distal end of the SOBP or a large bio-
logical extension. Appropriate choice of the radiation modal-
ity allows shifting between these two options, but there seems
to be no possibility to completely avoid the impact of RBE
effects.
Moreover, the extension is expected to affect not only the
distal penumbra, but also the lateral penumbra. However, it
is expected that in the lateral direction the dose dependence
of RBE is more important, whereas the contribution of the
increase of LET is less pronounced, although the detailed
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balance between these effects will also depend on the posi-
tion in depth.
4.E. Clinical impact of the biological range extension
Range uncertainties represent a major reason to avoid field
configurations that point in the direction of a critical organ
behind the target volume, although particularly in this con-
figuration the specific advantages of particle beams could be
exploited.41 In order to account for these uncertainties, at
present in many proton facilities 3.5% of the proton range
plus extra additional 1–3 mm is used as an extra margin.42, 43
In case of prostate treatments with proton ranges of approx-
imately 15 cm, this corresponds to more than 5 mm extra
range and for anterior-oriented fields would deliver high dose
to the anterior rectal wall.41 Up to now, mainly physical as-
pects are considered in the estimation of these range uncer-
tainties. According to the analysis presented here, extensions
of up to about 4 mm have to be taken into account result-
ing from the increased RBE at the distal part of the SOBP,
depending on the dose level and tissue characteristic under
consideration.
Johansson44 showed for the irradiation of hypopharyngeal
carcinoma where they positioned the distal penumbra just be-
fore the spinal cord that the effective dose to the spinal cord
with a variable RBE increased by a factor of 1.5 compared
to the case where a constant RBE of 1.1 was chosen or only
the physical dose was regarded. Even though the critical dose
level was not exceeded, one should be aware that not only a
larger part of the surrounding tissue is affected but also the
integral dose to this volume is much higher than expected
as discussed also by Jones et al.45, 46 Special caution is thus
needed for pediatric patients where the same dose affects an
even larger relative fraction of the surrounding tissue com-
pared to adult patients.47, 48
The impact of range uncertainties and extensions has been
also addressed by Gensheimer et al.;49 using MRI measure-
ments, they were able to directly determine the biologically
effective range in patients treated with proton beams. They re-
ported an average overshoot of the proton beam in the lumbar
spine of 1.9 mm (0.8–3.1 mm). They attributed a small part
of the overshoot to the increased RBE in the distal edge but
assumed that the overshoot should be less than 1 mm based
on the study of Paganetti et al.50 “because the higher beam
energy causes a more gradual dose falloff.”
However, according to the discussion above, we come to
the opposite conclusion, namely, that the overshoot should in-
crease with increasing energy precisely because of the more
gradual penumbra. The biological extension predicted by the
LEM IV is dependent on the pristine energy used and would
be between 1.6–3 mm for 235 MeV and 1.1–1.8 mm for
160 MeV and a RBE-weighted dose (RBE = 1.1) of 2 Gy
(RBE) at the 50% isodose, depending on the radiosensitivity
of the tissue type. These values are significantly larger than
the maximum value of 1 mm as estimated by Gensheimer
et al.;49 they could thus explain the discrepancy between the
overshoot that according to the authors could be attributed to
misregistration of the MRI and CT images and the overshoot
actually measured in the patients.
5. CONCLUSION
The RBE predictions of the LEM for protons together with
the treatment planning software TRiP98 showed to be con-
sistent with experimental data and thus represent a useful
tool to describe the variable RBE along the treated volume.
It was demonstrated in this study that the biologically effec-
tive range of proton beams is strongly dependent on physical
properties of the beam as well as on dose and the biologi-
cal properties of the tissue irradiated and can lead to up to
4 mm extension of the SOBP in extreme situations. In general,
the extension is more pronounced for shallow as compared to
steep gradients of the dose in the distal penumbra for a given
dose level and tissue type.
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